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Abstract 
 
Prevention of disease is a key strategy in the NHS, contributing to cost-effective health care 
and lower morbidity and mortality through early identification and management of risk factors 
in large populations. However, effects of increased prescribing, in the form of a growing burden 
of treatment for patients and challenges associated with polypharmacy, have prompted criticism 
from medical practitioners as well as scholars from the biomedical and social scientific fields. 
Whilst a growing evidence base guides prescribing, factors in the social world also influence 
how medicines are used. Patients’ views on medicines are recognised as important for a good 
outcome of treatment, but they are not very well known with regards to risk management 
prescribing and polypharmacy. The research presented in this thesis draws on critical 
examinations of societal influences on large-scale prescribing, and focuses on cardiovascular 
(CVD) risk management in primary care. This approach allowed me to explore the use of 
medicines in a setting where prescribing is common but also involves challenges in terms of 
the balancing of beneficial and harmful effects for populations and individuals. 
General influences on patients’ expectations of prescribed medicines were addressed in a 
review and synthesis of medical and social scientific literature describing beliefs, views and 
experiences. An update of the national clinical guidance on CVD risk assessment and 
modification of blood lipids offered an opportunity to review how CVD risk and the benefit 
and harm from statins were represented in a lay context; UK newspapers. In the empirical part 
of the research, I explored patients’ understanding of their own use of medicines in CVD risk 
management. My findings produced a thematic structure describing how patients conceptualise 
a diagnosed CVD risk and make sense of the recommended risk management treatments. 
Central influences on patients’ views are a simplified representation of CVD risk as a distinct 
condition with particular consequences for the individual, anticipation of defined effects from 
medicines, and a personalised understanding of health information which leads to individual 
responsibility for engaging with risk management. To propose implications of my findings, I 
discuss them in relation to three current policy reports on disease prevention and prescribing. 
My study adds knowledge about a central part of modern primary care, based on suggestions 
of how the currently dominating approach in CVD prevention might shape people’s perspective 
of medicines. 
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I say one must not travel during the holy month. 
Then I start out, and wonderful things happen. 
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Chapter 1 
Introduction to the research problem and this study 
 
1.1 Chapter overview: Introducing my research 
In this thesis, I present my research into patients’ understanding of the use of medicines in 
cardiovascular (CVD) risk management. It starts with an introduction of the research problem 
that I will address: polypharmacy as a result of increasing prescribing in primary care, which 
has the potential to cause both positive and negative effects. 
The research presented here is informed by a critique against the expansion of biomedical 
interventions into more and more areas of human life. It also draws on research into patients’ 
practical and emotional engagement with medicine-taking. Although exploring a research 
question that is formed in response to current medical practices and issues, it has its theoretical 
background in medical sociology. Therefore, this thesis contributes new knowledge that 
complements the biomedical model of CVD risk management, while also testing a recently 
suggested theoretical framework for describing the present driving forces behind increased 
prescribing of medicines. 
In this first chapter, I explain the background reasoning for the research and how I decided on 
a setting to conduct my study. The chapter introduces the research question that is address in 
the thesis, and the aims and objectives which defines how I set out to answer it. Finally, I give 
an overview of the remaining chapters, showing the structure of the thesis. 
 
1.2 The research problem: Polypharmacy is a challenging part of today’s health care 
Polypharmacy is the use of multiple medicines daily by a singular patient.[1] Derived from the 
Greek and meaning ‘many medicines’, there is no universally agreed number of how many 
medicines are required for the term to be used. Neither is it specified if the term applies only 
to items prescribed for long-term use, or also includes medicines that are used for shorter 
periods; either prescribed or available over the counter.[2,3] Around four or five daily 
medicines is commonly used as the cut-off in the recent literature.[1,4] As an introduction to 
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my research field, I will start by giving an overview over the complex phenomenon of 
polypharmacy. 
1.2.1 Prevalence and effects of polypharmacy 
Although the number of concomitant medicines that is regarded as polypharmacy differs 
between countries and research teams,[5-7] the trend seems to be towards increased 
prevalence.[8,9] A Scottish study of prescriptions dispensed in the community between 1995 
and 2010 showed that the proportion of adults using more than five medicines daily doubled, 
and the proportion using ten or more medicines tripled.[10] Similar development has been 
reported from Sweden.[11] 
With increased prevalence there has been increased interest in the effects of polypharmacy. Its 
benefits are recognised in management of conditions where combinations of medicines help to 
achieve control over short- and long-term outcomes, for example in type 2 diabetes, HIV and 
coronary heart disease.[12-14] However, the number of medicines prescribed to an individual 
is associated with an increased risk for adverse drug reactions and drug interactions for 
patients,[8,10,15-19] leading to morbidity, hospitalisation and mortality.[9,17,20] 
Polypharmacy also creates a potential burden of treatment carried by patients, requiring efforts 
to manage complex treatments and infringing on daily life.[21,22] The challenge that 
polypharmacy presents to the delivery of health care [3] has led academic and professional 
organisations to call for improvement of the current situation.[1,23,24] 
1.2.2 Efforts to improve the situation 
From a medical perspective, challenges related to polypharmacy include the definition of the 
problem and identification of factors that contribute to it. Moreover, there is a need to 
understand the nature of the difficulties that polypharmacy bring about – whether they are 
practical matters of managing increasingly complex regimes or if they also involve questioning 
the appropriateness of medicines in various situations. 
Awareness of the problems related to polypharmacy has spurred efforts to improve the 
situation, especially for key patient groups such as the elderly and people with 
multimorbidity.[4,25] Medical and pharmaceutical research has investigated polypharmacy 
from the angle of it being a threat to adherence (due to complex regimens), and therefore 
focuses on devising systems and tools to help doctors and patients manage multiple medicines 
in a safe way. Examples of such efforts are different sets of criteria for evaluation of clinical 
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benefit,[26-28] technologies to aid prescribing, [29] medication reviews [2,3,30] and tools like 
reminder charts for patients.[31,32] Aspects of the context around prescribing have also been 
investigated: influence of the format of guidelines [33] and style of medical practice [34] have 
been targeted in efforts to ensure quality in prescribing within health care systems prone to 
increasing polypharmacy. 
Quality in prescribing is a central concept in medical approaches to manage polypharmacy. 
One report – Polypharmacy and medicines optimisation; making it safe and sound [1] – which 
is directed to health care professionals, suggests the need to differentiate between appropriate 
and problematic cases. Appropriate polypharmacy is defined from a clinical perspective, where 
multiple medicines are prescribed in line with best evidence and the patient has support to 
ensure that they are taken correctly. Correspondingly, problematic polypharmacy is the 
prescribing of multiple medicines where the intended benefit is not realised. 
1.2.3 Remaining gaps 
However, polypharmacy is an issue that involves many perspectives and actors, and therefore 
it is a complex issue to research. As discussed above, it has the potential to cause benefit as 
well as harm for patients.[1] There is a growing body of knowledge about specific aspects of 
polypharmacy, for example its prevalence, association with certain conditions and 
consequences in terms of adverse events. However, the research to date focuses on improving 
the medical management of medicines use and thus retains a professional and biomedical 
perspective. In addition to the biomedical aspects of polypharmacy, health care and medicines 
are also important institutions of today’s society, which adds influences from the social world 
to the possible understandings of the phenomenon. A significant gap lies in understanding the 
use of multiple medicines from a patient perspective – including practical strategies applied by 
individuals in daily life and the influence from lay views of health, illness and medicines. With 
the research presented in this thesis, I seek to add to the knowledge about the complex issue of 
polypharmacy by exploring it from the perspective of patients. 
 
1.3 Theoretical background 
Indications of iatrogenic problems caused by polypharmacy, in the form of harm from excess 
medicines and a growing burden of treatment [35] are signs that the efforts within medicine 
and pharmacy to improve the situation are not effective enough. From the inception of the 
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research project that is presented in this thesis, my approach was that it would critically 
examine polypharmacy from a different perspective than the biomedical, and thereby 
potentially suggest why prescribing continues to increase despite the awareness of a growing 
burden of treatment. For a theoretical background against which such as study could be 
planned, I turned to medical sociology. It has a long tradition of examining the social structures 
surrounding and interacting with concepts of health and illness, and the interaction between 
people and medicines. 
1.3.1 Patients’ reasoning and decisions about medicines 
Patients’ usage of medicines can be seen as taking place at an intersection of medical science 
and daily lives. The biomedical evidence-base that underpins prescribing is introduced via 
health care professionals’ choice of diagnosis and medication, and also in instructions about 
how to use the pharmaceuticals. Patients’ following (or not) of such instructions has received 
much attention as an important factor for the outcome of treatment.[36,37] However, the 
notions of ‘compliance’ or ‘adherence’ (patients following prescribers’ orders about how to 
take medicines) are also criticised for its inherent acceptance of the medical view as 
superior.[38] Sociological considerations of the phenomenon include such aspects as the 
meaning patients attach to medicines and how non-compliance can be seen as a result of a 
different process of reasoning, rather than failure to understand the medical rationale behind 
prescribing.[39,40] 
This reasoning informs patients’ decisions about whether or not to incorporate the medicine-
taking into daily activities, where advice given by health care professionals may get combined 
with patients’ personal understanding of practical, social and moral aspects of using 
medicines.[39,41,42] Issues like class, race, gender and age may also influence the role 
medicines play in health and illness.[43,44] Recent additions examine the impact of systems-
factors such as health care organisation and governance, regulatory mechanisms and the 
influence from media and pharmaceutical industry, which are discussed below.[45-48] 
Important background for my study of polypharmacy from a perspective that also includes 
social influences (see section 1.2.3) also stems from Britten’s work on the role and meaning of 
medicines in society.[41] For my examination of CVD risk management from a patient 
perspective, with the aim of finding explanations for how medicines are used, the starting point 
was the concept of medicalisation. 
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1.3.2 Medicalisation 
Medicalisation emerged as a term in the 1970’s, drawing on examinations of the application of 
medical scientific practices to social life and experts’ dominance over lay people as a form of 
social control.[46,49] It developed in response to an expansion of medical definitions of various 
aspects of life, most notably behaviours that were deemed deviant and thereby a threat to 
society.[50] Conrad [51] suggests the following definition: “defining a problem in medical 
terms, usually as an illness or disorder, or using a medical intervention to treat it”. 
Medicalisation recognizes the power exercised by medical professionals by means of 
surveillance, diagnosis and prescribing. The expansion of that power into more and more areas 
of life while defining the experiences of health and illness and diminishing people’s own 
abilities to handle such matters, following the contributions from Zola [52] and Illich [53] are 
central themes to the concept. 
1.3.3 Pharmaceuticalisation 
Recent development of the understanding of medicalisation in today’s society points to the 
altered driving forces behind expansion of medicine, the practice and consumption of health 
care and the role of medicines. Parallel to globalisation of markets and the introduction of 
market forces into the health care sector (among other areas), attention is given to the influence 
of the pharmaceutical industry over how medicines are developed and used.[49,54,55] This 
development of the concept, termed pharmaceuticalisation, [54,56] takes into account the 
changes in society towards more focus on the individual, with correspondingly less importance 
of the state or traditional social structures.[46] In doing so, pharmaceuticalisation includes 
other areas than medicine as influential, and explorations of the concept include both micro- 
and macro levels. Examples of the former is the permeation of medicines into areas of daily 
life and their role in the shaping of identities and consumption related to matters perceived as 
health-related.[57,58] On the larger scale examples include the role of legal systems for the 
distribution of medicines within society [45,59] and investigations of the 
‘pharmaceuticalisation of public health’ discuss the role played by the pharmaceutical sector, 
governments, non-governmental organisations and local communities.[46] 
Williams and colleagues [56] have suggested a framework of six dimensions for examining 
how pharmaceuticalisation takes place, showing possible links between the use of medicines 
and non-medical aspects of the world; things like expectations, identities, communication and 
legislation: 
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- Selling sickness? The redefinition and reconstruction of health problems as having a 
pharmaceutical solution. One reason for the increase in prescribing is that more 
conditions are defined as related to disease, and thus become indications for 
prescribing. This expansion of the market for medicines is driven by pharmaceutical 
companies that simultaneously promote conditions and the treatment for them. Efforts 
to increase sales of pharmaceuticals are directed towards individuals as well as health 
care professionals, and presented as education and research.[60] 
- Changing forms of governance: globalisation and the new role of regulatory agencies 
in promoting innovation. It is recognised that political processes contribute to how 
pharmaceutical industry has gained influence over the way that medicines are 
developed and approved. One effect is that drug manufacturers dominate the large trials 
that influence clinical guidelines for diagnosis and prescribing.[45,61-63] 
- Mediation: the (re)framing of health problems in the media and popular culture as 
having a pharmaceutical solution. Public understanding of the need for, and value of, 
medicines is shaped by how disease and treatment are presented in the media. Aspects 
such as self-diagnosis, celebrity endorsement and representation of personal accounts 
from both patients and professionals contribute to how diseases are perceived, and the 
media are powerful communication tools for the pharmaceutical industry and other 
organisations. In addition, social media offers platforms for individuals to share stories 
that include medicines, which might contribute to others’ understanding of the products 
and their place in health and illness.[64] 
- Patients, consumers and the life world: the creation of new social identities and the 
mobilisation of patient or consumer groups around drugs. Extensive marketing of 
medicines via popular media and patient advocacy groups has contributed to the role of 
the patient as knowledgeable and powerful actors in health care, but also places 
responsibility on individuals to manage their health with medicines. People are 
encouraged to take greater part in their treatments by becoming ‘expert patients’. 
- From treatment to enhancement? The use of drugs for non-medical purposes and the 
creation of new consumer markets. Medicines are being used to normalise, repair and 
augment [55] aspects of life, health and bodies in a process where the boundary between 
medical and social arguments for using pharmaceuticals is re-negotiated. 
- Pharmaceutical futures in the making: drug innovation and the colonisation of health 
futures. This dimension deals with how the future is shaping the present; how 
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expectations of pharmaceutical products for intervention influence the actual flow of 
resources and thereby drive drug development and inform policy. 
 
1.4 Choosing a setting for researching polypharmacy in UK primary care 
In my effort to research the complex phenomenon of polypharmacy in UK primary care, I have 
chosen to focus on one particular way of using medicines and set out to offer a thorough 
investigation of it, namely the use of medicines in cardiovascular risk management. Below, I 
give an overview of the epidemiology of CVD in the UK, and the strategies applied in 
prevention. This serves as a background for outlining the reasons for my choice of research 
‘setting’; why CVD risk management is a useful topic to research in order to learn about a 
complex way of using medicines and therefore in understanding polypharmacy. 
1.4.1 Epidemiology of CVD in the UK 
CVD is a leading cause of death in the UK among people both under and over 75 years [65-
67], and mortality and morbidity rates resulting from CVD are higher in deprived areas.[65,66] 
Risk factors for CVD consists of fixed ones; age, gender and family history of CVD, and 
preventable ones that relate to an individual’s lifestyle; smoking, lack of physical exercise, 
harmful consumption of alcohol, low intake of fruit and vegetables and obesity. Physiological 
risk factors that contribute to a person’s CVD risk are high blood pressure, elevated blood 
cholesterol, diabetes and chronic kidney disease.[66] The association between lifestyle 
behaviours and CVD mortality and morbidity may explain the distribution of cases between 
social classes; those that are deprived have a higher risk of dying and experiencing illness from 
CVD.[66] 
Management of CVD and CVD risk is also a major reason for prescribing medicines in the 
UK, with various types of anti-hypertensives (medications that control the blood pressure) and 
statins (which lower blood cholesterol) being among the most prescribed products in England, 
Scotland, Wales and Northern Ireland.[68-71] 
1.4.2. Prevention strategies 
Since many deaths and cases of morbidity from CVD are preventable,[66,67] preventive efforts 
are prioritised in the NHS.[23] Historically, the implementation of evidence based risk 
management strategies has contributed to a significant decrease of CVD mortality.[67] 
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Cardiovascular prevention can be divided into two types; primary and secondary. Primary 
prevention of CVD aims to reduce risk factors in people without heart disease, with the goal to 
prevent events altogether,[72,73] whereas secondary prevention is interventions that reduce the 
risk of recurring events in people that have established CVD.[73,74] 
The principles behind primary prevention of CVD were outlined by Rose in 1981.[75] He 
described how the rationale for preventive interventions depends on the prevalence and 
distribution of risk factors in a population,[76] and contrasted ‘high risk’ strategies directed 
towards individuals with ‘low risk’ strategies that encompass the population as a whole. The 
high risk strategy entails prescribing of medications and lifestyle changes to a relatively small 
group of people at considerable risk for CVD. These patients need to actively engage with the 
intervention (take medicines and change habits) for it to be effective. In return, they would be 
likely to benefit from the changes, since reduction of a high risk is strongly associated with 
fewer acute events. Low risk strategies instead aim to decrease the overall prevalence of risk 
factors in the population. They thereby achieve a smaller reduction of CVD risk in each 
individual but decrease the number of events in the population as a whole. Rose used reduction 
of salt in food as an example of a low risk strategy and pointed out the advantages of social 
pressure to decrease people’s use of tobacco. In terms of number of lives saved by CVD 
prevention, Rose concluded that the low risk strategies would produce a better outcome since 
the number of people at low risk is so much larger than the number of people at high risk. 
However, low risk strategies depend on people’s acceptance of broad-ranging interventions 
from which individual gain is difficult to demonstrate. 
1.4.3 The NHS Health Check 
A tangible example of preventive efforts in primary care is the NHS Health Check, which aims 
to reach all English citizens between 40 and 74 years of age.[77] This national programme for 
risk assessment and management entails measurement of blood pressure, cholesterol and body 
mass index and records age, ethnicity, smoking status, physical activity and medical family 
history. In addition to assessing the risk for CVD, it also screens for diabetes, kidney disease 
and dementia, and is described on the NHS public website as a ‘midlife MOT’.[78] The 
programme is presented as focus on promoting lifestyle changes and primary prevention, 
thereby reducing the need for medications in CVD risk management.[72] 
Questions remain regarding the value of general screening programmes for common health 
conditions, like the NHS Health Checks.[79,80] A Cochrane review found no evidence that 
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such checks are effective in improving health in terms of for example mortality, hospitalisation, 
disability or absence from work. However, there was an indication of general health checks 
leading to more diagnosing and more prescribing.[80] In the case of CVD, the programme’s 
predictions build on risk assessment and calculations,[81] and thus cannot predict individuals’ 
risk for events which has raised questions about the sensitivity and specificity of the 
strategy.[79] Moreover, the limited coverage of the health checks particularly in some of the 
groups that might have an elevated risk (smokers, some ethnic minorities) jeopardises its value 
as a preventive strategy.[79,81] Critics of the NHS Health Checks have found it expensive with 
regard to its effects on mortality,[79] and ineffective in terms of its capacity for leading to 
sustained changes in behaviour among people at risk.[81] The policy has also been criticised 
for not evaluating the limitations or possible negative effects of the programme [82] and for 
medicalising CVD risk.[79] 
1.4.4 Changing approaches in primary care 
The broad introduction of NHS Health Check is representative of a changing approach to CVD 
risk management in UK primary care. Traditionally, the UK has used a high risk strategy for 
CVD prevention, and focused services on secondary prevention and specific target 
groups.[72,83] However, a shift towards more primary prevention has occurred in the last 
decade, with the Department of Health, the NHS and Public Health England stating that 
prevention of disease needs to be prioritised over treatment.[23,65] Individuals are encouraged 
to eat well, be physically active and avoid tobacco and alcohol.[72,84] Improved population 
health by means of prevention of disease is also put forward as a cost-effective way to use the 
resources within the NHS.[23,65] 
Some aspects of the current strategy for CVD prevention are linked to the knowledge gaps 
regarding polypharmacy (see section 1.2.3) and also highlight issues associated with 
pharmaceuticalisation (see section 1.3.3). More specifically, these relate to the biomedical 
discourse of CVD as a driving force behind increased prescribing, and the challenge of 
balancing possible benefit and harm from medicines when considering not only populations 
but also a patient perspective on prescribing. These aspects set the scene for my research, and 
are described below. 
1.4.5 Increased prevention leading to increased prescribing 
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Many CVD risk management regimens include multiple medicines,[1] and thus have the 
potential to introduce polypharmacy to a large number of people. While increased 
polypharmacy is often attributed to an aging population (which is presumed to have more 
diseases),[2,11,85] the pattern of how conditions are diagnosed has also changed.[35,80] In 
parallel to the emphasis from policy-makers on primary prevention, more data has been made 
available that supports the lowering of biomarkers with medicines also in people at low risk 
for CVD.[61,86] Widened diagnostic criteria have been criticised as a driver of prescribing, 
since they classify people that were previously considered healthy as needing medicines.[35] 
After the initial success of medicines against high blood pressure and cholesterol, lowered 
treatment targets and thresholds for intervention have been introduced as more data has been 
made available rather than in response to clinical demand.[61] 
As mentioned above, current research about polypharmacy is largely focused on biomedical 
and professional aspects of the use of medicines. For example, the suggestion to define 
appropriate polypharmacy from problematic polypharmacy uses clinical benefit as the criterion 
for justifying the need for medicines.[1] However, what is considered appropriate can be 
subject to how the assessment of effect is done: pharmaceutical intervention may be deemed 
beneficial due to its net effects on the population level while the situation for individuals within 
the cohort can encompass both benefit and harm from medicines. In CVD risk management, 
the preventive effect will be tangible for some patients (who avoid a heart attack or stroke) 
whereas other patients experience no difference or suffer from side effects. 
Regarding the balancing of benefit and harm, which is central to any pharmaceutical 
intervention, it has been suggested that the biomedical tradition for defining, producing and 
reviewing data about medicines promotes a dominance of positive effects discernible on the 
population level over individual perspectives on health and medicines.[87] An effect of this 
focus in drug development is that the priorities may differ from those of patients. Applied to 
CVD risk management, the dominance of a biomedical discourse will mean that the potential 
benefit from medicines is given close attention, whereas potential harm (such as side effects 
and treatment burden) is less carefully considered. This may influence the balancing of positive 
and negative outcomes in the decisions about prevention policies in a way that favours more 
pharmaceutical intervention. Fontana and colleagues, who addressed UK patients’ acceptance 
of medicines for primary prevention of CVD, show the limitations of a biomedical model in 
explaining the actual use of medicines.[88] In contrast to the low level of harm from medicines 
that is assumed in clinical guidelines, they found patients to turn down a hypothetical risk 
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management treatment on the basis of not finding the potential for gained longevity making it 
worthwhile to take a medicine for the rest of their lives. 
The changed diagnostic criteria in CVD expand pharmaceutical markets and introduce more 
medicines to more people [61] – many of which have not experienced any cardiovascular 
problems. Since one of the original aims in my research was to explore polypharmacy from the 
view of patients, the particular features of CVD prevention for individuals also guided the 
development of my research question. These are summarised below. 
1.4.6 Researching patients’ perspectives on CVD risk management prescribing 
As mentioned above, the population approach to CVD risk management depends on 
individuals’ acceptance of a preventive strategy. When prevention entails prescribing of 
medicines, it therefore requires the active participation – taking medicines daily – of people 
that become diagnosed as patients at risk for CVD. The extension of prescribing for the purpose 
of CVD risk management to include people without symptoms of illness introduces medicine-
taking to an increasing number of people that are unlikely to benefit from them.[35,79,89] The 
low risk strategy (described in section 1.4.2) also means that benefit from treatment is realised 
on the population level, but not discernible for individual patients. 
In CVD prevention, a lower level of initial risk makes it less likely for a person to benefit from 
risk reduction.[75] The absence of symptoms in people at low risk might also make medicine-
taking seem questionable, as there is no illness to “try and get rid of”. On the other hand, the 
potential for side effects is the same regardless of CVD risk level.[75] The balance between 
potential future benefit and current harm from medicines therefore becomes contentious when 
people at lower risk are considered for pharmaceutical intervention.[35] Researching CVD risk 
management in primary care offers an opportunity to explore how patients perceive, value and 
balance possible beneficial and harmful effects from medicines in situations where symptoms 
of illness are not necessarily framing their experience. 
 
1.5 Research approach 
In this project, I set out to expand the knowledge on polypharmacy and patients’ views of 
medicines, while also contributing to the development of the concept of pharmaceuticalisation 
by critically reviewing it in a particular setting. Moreover, inspired by the concrete challenge 
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that CVD risk management prescribing and polypharmacy presents to both patients and health 
care professionals, I wanted to create new knowledge that had the potential to be useful in 
primary care practice. For this purpose, I used a combination of approaches which are discussed 
below. 
The reasoning about what knowledge that needed to be created in order to suggest a more useful 
“patients’ perspective” of polypharmacy and CVD risk management, which guided my 
planning of the study, drew on Maxwell’s descriptions of critical realism.[90,91] Such a 
position combines a realist ontology with a constructionist epistemology. This means that it 
acknowledges the existence of a world that exists regardless of our knowledge about it, while 
also recognising that any type of understanding of the world depends on perspectives and 
viewpoints, and therefore is constructed in relation to things like experiences and 
interpretations. It challenges the notion that only observable, measurable phenomena and 
relations can be known and used in claims about reality.[92,93] In addition to a physical world 
that can be predicted and controlled, it acknowledges the influence of social structures in which 
individuals form their understanding and perform actions.[94] Here, my approach was also 
informed by elements of social constructionism – notably, the suggestions that the “idea” of 
CVD risk management takes shape in reciprocal interaction with the institutions, practices and 
individuals that engage with it in some way.[95] This perspective influenced my 
methodological position, insofar as pointing to the value of researching medicines use with a 
view that was open to such multi-directional relations. 
In terms of examining the use of medicines in CVD risk management, the realist ontology 
accepts the presence of risk factors in people’s bodies and physiological effects of medicines 
– these phenomena have real qualities that exist independently of whether they are 
characterised; they are not merely social constructs that depend on particular situations. 
However, the constructionist epistemology adds that there is no independent knowledge about 
this real world. Therefore, the biomedical description of CVD risk and medicines is one, but 
not the only, possible and valid knowledge about it. 
Drawing on the critical realist reasoning meant I set out to explore patients’ views on CVD risk 
management medicines with the understanding that also such things that emerges from 
people’s own accounts can add valuable knowledge about the researched phenomenon.[91] 
Since I aim to explore patients’ understanding of medicines while recognising that medicine-
taking takes place in the context of people’s daily lives and under possible influences from 
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society, power relations and personal experiences of health and illness, I adopted an 
epistemology that recognizes that ‘truth’ about the world is related to the one that knows, and 
changeable due to shifting perspectives. In contrast, a study performed within the biomedical 
tradition, with a strictly empiricist view on knowledge about CVD risk management, would 
apply the condition that new knowledge about medicines use needs to be expressed in terms 
that derive from a biomedical description of the world. The biomedical definitions of medicines 
have their origin in a positivist paradigm where one ‘truth’ about the world is recognised and 
where new knowledge is sought in empirical experiments designed to confirm or reject 
hypotheses.[96] Examples of this approach to polypharmacy are seen in the efforts to define 
appropriate polypharmacy from problematic on the grounds of clinical definitions – 
descriptions of benefit stemming from medical science itself are used to assess its effects, while 
aspects that are not situated within medicine are not considered. As argued by Maxwell and 
Mittapalli,[90] such a view could be seen as restricting the type and scope of questions which 
can be asked, thereby restricting the ways of expanding knowledge. 
Drawing together the background for my study – the questions prompted by increased 
prescribing alongside the awareness of effects from ‘too much medicines’,[97] the theoretical 
suggestions regarding pharmaceuticalisation [54,56] and the decision to examine 
polypharmacy from a perspective guided by critical realism [90,91] – the following 
considerations helped me formulate a research question: 
- Prevention of CVD morbidity and mortality in the population requires large 
numbers of people to take medicines before any sign of ill health. With the 
apparent discrepancy between experienced and diagnosed health, I wanted to 
find out how patients respond to the ‘role’ assigned for them by a prescribing 
practice that is directed by population-level outcome targets. 
- The beneficial effect from risk management medicines decreases at lower 
levels of risk, whereas the potential for side effects from medicines remains the 
same. As medicines are suggested to people at lower risk, I wanted to 
understand what patients expect the medicines to do for them. 
- From an individual perspective, the use of medicines includes more aspects 
than the biomedical. By focusing the research on patients’ views and drawing 
on a combination of theoretical and methodological perspectives, I wanted to 
form conclusions and suggest explanations about the implications of 
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prescribing practice for individual patients that are useful and viable in clinical 
and other contexts. 
Initially, this study was designed to compare GPs’ and patients’ perspectives on polypharmacy 
in CVD risk management. As the study developed, I instead chose to explore different aspects 
of patients’ views. This was due to the realisation that an investigation that focused on patients 
would be enough to contribute new knowledge regarding the use of medicines. Since my early 
reading and ideas for research questions were all centred on patients’ role in medicines use, I 
deepened this perspective throughout the project, rather than changing it to include 
practitioners. Four interviews with GPs that I held at the start of this project are not formally 
analysed and included as data in the study, but as they provided some suggestions about 
professional views on CVD risk management they were useful as background material. A 
summary of the interviews is available in appendix A1. 
 
1.6 Aims and objectives 
The aim of this study is to understand the experience and role of patients in large-scale primary 
care prescribing for prevention of disease. My research question is “What are the influences on 
patients’ understanding of the use of medicines in cardiovascular risk management?” The 
research question translates into the following objectives: 
 To understand the existing known influences on patients’ overall expectations 
of medicines, through a review of the scientific literature. 
 To examine societal influence on peoples’ concept of CVD risk management, 
through a critical review of a current case study (the debate about the extended 
prescribing of statins) as presented in newspaper articles. 
 To understand individual experience and translations of expectations and 
knowledge regarding medicines for CVD risk management, through interviews 
with patients. 
 To integrate the findings from the three studies mentioned above, and present 
an account of implications for prescribing for CVD risk management from an 
individual patient perspective. 
 To suggest the implications of my findings for health care practitioners, 
policymakers and scholars working on pharmaceuticalisation. 
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1.7 Outline of the thesis 
In the present chapter, I have introduced the research topic of polypharmacy and the setting in 
which I intend to explore it, which is CVD risk management in UK primary care. Moreover, I 
have described the theoretical background for my study; the critique against increased 
prescribing formalised as pharmaceuticalisation, and how I will draw on a critical realist 
perspective in researching patients’ understanding of medicines. 
Chapters 2 and 3 consist of two literature reviews; one of scientific publications and one of 
newspaper articles. The first review explores patients’ expectations of medicines. It concludes 
that they are influenced by more aspects than those that are represented in a biomedical model 
of medicines use, and that individual experience plays a major part in patients’ understanding 
of medicines. It also identifies a lack of knowledge regarding patients’ concepts of CVD risk 
management, and concludes that this will be addressed in the empirical part of this thesis. The 
second review considers one of many non-medical sources that inform lay understanding of 
health and medicines. Here, I use the timely revision of the NICE clinical guidelines for 
cardiovascular risk assessment and lipid modification to explore how policy-makers’ and 
medical professionals’ statements are transferred into a lay context. It explores the tension 
between individual and population aspects of risk management medicines, and looks at how 
CVD risk and its containment are described in a popular context. 
Chapter 4 describes the methods in my empirical study. After outlining the methodological 
approach for creating new knowledge about my research topic, I describe the process of 
recruitment and sampling of participants and how data were collected in interviews. The 
chapter also contains a detailed account of how I organised and analysed data in order to present 
my account of patients’ understanding of medicines in CVD risk management. Finally, I show 
how I will assess the validity of my findings by discussing their applicability to this particular 
field and their transferability to other areas of medicine. 
Chapters 5 and 6 present the findings in the empirical study, with one major theme in each 
chapter. The themes, sub-themes and categories are displayed alongside quotes showing how 
participants shared experiences and stories about medicines during the research interviews. 
Personalised representation of causes and consequences, individual responsibility following 
diagnosis, the necessity of taking action, experience-based reasoning and stability as 
confirmation of benefit are the major points that form patients’ understanding of CVD risk 
management medicines. 
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In chapter 7, I combine the findings from the two literature studies and the empirical research 
to consider how they contribute towards a new account of patients’ views of CVD risk 
management medicines which is based on individuals’ experiences and understanding. The 
main themes throughout the study are presented, and I discuss what the new knowledge adds 
in terms of how to approach CVD risk management prescribing and polypharmacy in primary 
care. 
Finally, in chapter 8 I critically review the trustworthiness of my findings in relation to the 
research problem, strengths and weaknesses of the methods I used and my positionality as a 
researcher. Some interesting aspects of risk management and prescribing that have been present 
in this study without becoming part of the main research process are pointed out as suggestions 
for further research. To conclude, I revisit the starting point for this thesis – how knowledge 
about patients’ views of medicines might contribute to better understanding of the complex 
phenomenon of polypharmacy. 
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Chapter 2 
Patients’ expectations of medicines – a review and qualitative synthesis 
 
2.1 Chapter overview: turning to the literature 
One thought that informed the direction of the research underpinning this thesis was “what 
makes people accept risk management medicines, despite the small individual risk reduction 
and the lack of tangible benefit?” To start investigating what might be taken into account in 
patients’ balancing of risks and benefits in decisions about whether to use medicines, I 
undertook a review of the literature on factors that influence patients’ expectations. It draws on 
two comprehensive descriptions of the formation of expectations on health care matters and 
includes primary research into the use of prescribed medicines for a number of symptomatic 
conditions. The review is presented and discussed in this chapter. A version of this text was 
published as a review article in Health Expectations in January 2015, see appendix A2. 
This review and synthesis of the literature informed my further work by outlining the 
mechanisms at play in patients’ understanding of effects from medicines. The findings also 
gave rise to questions about how future benefits from medicines prescribed to manage risk 
conditions are conceptualised, which informed my empirical study. 
 
2.2 Patients’ expectations 
Treatment for the purpose of management of risk for future disease often targets asymptomatic 
conditions. Benefit from this type of prescribing is established on the population level, but not 
necessarily demonstrable for individuals. In addition, beneficial effects require long-term 
commitment to therapy by large numbers of people. Considering the absence of illness 
symptoms and subsequent remedy from this type of prescribing, I wondered what may make 
patients accept medicines for the purpose of risk management. As shown by the medical 
sociology literature, a health care professional’s instruction based on a biomedical model of 
risk and benefit might not be enough of a rationale for patients to engage with treatment.[41] 
The concept of pharmaceuticalisation suggests that expectations of effect and benefit from 
pharmaceuticals are an important driving force for increased use of medicines.[56] As risk 
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management prescribing considers actions related to future events, I therefore decided to use 
patients’ expectations as a central point in the examination of their understanding of this 
phenomenon. Given my critical realist perspective, my review of patients’ expectations focused 
on what might influence such expectations, acknowledging that personal and social 
circumstances might be part of how people understand, and engage with, medicines. 
In a meta-ethnography of lay experiences of medicine-taking for a number of symptomatic 
conditions, Pound and colleagues present the expectations patients have in relation to treatment 
of a number of long-term conditions.[98] Hopes and expectations of benefit are named as an 
important factor in the evaluation of medicines: they relieve or control symptoms, avoid relapse 
or hospitalisation, slow or halt disease progression, prevent future illness or bring normality. 
In a theoretical description of the influences on patients’ expectations on medicines, Thompson 
and Suñol emphasise the combination of cognitive and affective components and outline a 
range of personal and social factors that interplay with the information provided in a health 
care context.[99] These include needs, values, experiences and emotions, as well as social 
norms, conditions and restrictions. Four types of expectations are identified: Ideal, predicted, 
normative and unformed (see figure 2.a). 
Type of expectations Characteristics 
Ideal expectations Desired or preferred outcome based on idealistic beliefs regarding 
what a medicine can provide 
Predicted expectations Anticipated, realistic outcome based on personal or vicarious 
experience and other sources of knowledge 
Normative expectations What the patient thinks should or ought to happen, based on 
evaluation of what is deserved or socially endorsed 
Unformed expectations Inability or unwillingness to formulate what is expected due to fear, 
social norms or lack of knowledge 
Health care context-specific features that influence expectations  
Long-term relation between patient and doctor 
Patient’s emotional state may be shaped by illness experience and coping strategies 
Patient’s knowledge about the condition and the effects of medicines may be very limited at the 
outset of a treatment, but increases over time 
Patients tend to use a subjective rather than objective set of notions when evaluating effects and 
services 
 
Figure 2.a Classification of patients’ expectations suggested by Thompson and Suñol [99] 
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Using these two models as a theoretical framework for how expectations are formed, 
formulated and related to experiences, I set out to review the literature on patients’ expectations 
with the aim to produce an account of mechanisms and influences. The two research questions 
in this particular part of the study were “What are the influences on patients’ expectations 
regarding prescribed medicines?” and “What benefits do patients expect from medicines 
prescribed for long-term prevention of disease?” 
 
2.3 Methods 
2.3.1 Search strategy 
The database searches were set up to explore possible influences on patients’ expectations of 
medicines. By using broad search terms I aimed to capture multiple aspects on the research 
questions so that a comprehensive account could be formed. 
Searches were done in two stages. In the first step, I explored influences on patients’ general 
expectations related to prescribed medicines. To find out specifically about treatments for the 
management of risk for future disease, the second step focused on patients’ ideas about 
benefits with medicines prescribed for preventive purposes. Search terms are outlined in table 
2.1. Searches were performed in Medline and Scopus during August and September 2013 for 
publications from all available years. 
Table 2.1 Search terms 
Research question Search terms Hits 
 
What are the influences 
on patients’ 
expectations regarding 
prescribed medicines? 
expect*AND influence* AND patient* AND prescribing OR 
prescription 
614 
expect*AND patient* AND primary care AND prescribing OR 
prescription 
135 
influence* AND qualitative research AND prescribing OR 
prescription 
427 
What benefits do 
patients expect from 
medicines prescribed 
for long-term 
prevention of disease? 
benefit* AND expect*AND qualitative research AND prescribing 
OR prescription 
225 
benefit*AND expect* AND medicine* AND patient* AND 
prevent* 
122 
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2.3.2 Selection of publications 
The first step in the selection was scanning of article titles. Abstracts and full-text articles were 
then checked for descriptions of patients’ accounts of using medicines and descriptions of 
influences on expectations. Due to the exploratory nature of this review, quality of the reported 
study was not used as a criterion for inclusion or exclusion. Instead, a careful examination of 
the applicability of the reported findings to the area of long-term prescribing was undertaken 
at the selection and synthesis stages.  
Articles were included in the review if they explicitly addressed qualitative aspects of patients’ 
expectations, beliefs, views or thoughts about medicines prescribed for treatment or prevention 
of long-term conditions and were written in English. Publications retrieved in the searches but 
excluded during the review process described practices or behaviours rather than views, 
professionals’ expectations rather than patients’, evaluations of specific interventions or solely 
quantitative aspects of patients’ expectations. Articles about end-of-life care or medicines used 
for lifestyle or aesthetic purposes (obesity, facial acne, hair loss) were also excluded, on the 
basis that expectations related to these types of treatments are likely to be influenced by 
emotional factors that lie outside the scope of this research. 
2.3.3 Extraction and synthesis of data 
Data extraction and synthesis of findings was done by open coding of reported influences on 
patients’ expectations in the selected literature followed by a constant comparative thematic 
analysis [100] and synthesis.[101] The open coding was informed by, but not limited to, the 
aspects of patients’ expectations on medicines discussed by Thompson and Suñol and Pound 
and colleagues.[98,99] 
As recommended by Thomas and Harden for the rigour of a thematic synthesis,[101] context-
specific information was recorded alongside the extracts in the first round of descriptive 
coding. Preserving links to the context in which data originate makes the aligning and synthesis 
of findings from various types of studies describing different illnesses more robust.  
While examining each included article line-by-line for reports of any influence on expectations, 
I listed all such extracts in a spreadsheet together with study characteristics. The full list was 
then reviewed and extracts were assigned descriptive labels such as ‘own immediate/practical 
need’, ‘testing’, ‘other people’s views’, ‘belief’ and ‘medical information’. Extracts with 
similar descriptive labels could then be combined across studies and categorised thematically. 
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Here, the contextual information helped clarify how data extracts might describe aspects of the 
same phenomenon (and so be appropriate to combine) or only seemingly similar things (and 
so needing another look at where to put them). As an example, the list of descriptive labels 
contained many examples of specified outcomes that patients expected from medicines, but 
some of these originated from accounts of experiences and others were given as replies to 
hypothetical questions. Once the coded extracts had been collected under descriptive themes, 
they were compared on the basis of features that were less context-specific and more generic 
so that analytical categories reflecting features shared between separate studies could be 
assigned. 
Data within the emerging analytical categories were compared for similarities, differences and 
contradictions so that as many aspects as possible of each type of influence was captured. 
Content was moved around to produce distinct and internally coherent characterisations of each 
type of influence on expectations. Finally, the categories were aggregated into themes that 
reflected their whole content. Thematic synthesis allows for themes to be formulated at a level 
‘beyond’ description of the different types of data in separate studies so that new interpretations 
and explanations can be suggested. 
Throughout the process of selection of publications, data extraction and synthesis I discussed 
the work and the emerging findings with Prof Walley and Dr Reeve. This served as guidance 
as it was my first attempt at qualitative analysis and synthesis of data, and also strengthened 
the interpretive validity of the findings. At the point of starting to formulate comprehensive 
themes, I began to write a descriptive account of the findings that was also shared with Prof 
Walley and Dr Reeve. This helped test the emerging story and identify dissonance and 
uncertainty that needed further exploration. In addition, the criteria for trustworthiness 
proposed by Lincoln and Guba were used as a framework for the critical assessment of the 
emerging analysis.[96] 
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2.4 Findings 
Combinations of the search terms in titles or abstracts yielded 1428 unique records. After 
scanning article titles, 92 abstracts were reviewed which led to 27 full-text articles being 
assessed for inclusion. Reference lists in the reviewed papers were scanned for useful sources, 
which returned 23 more publications. The final synthesis included 20 publications, 12 of which 
were identified via databases and eight from the scanning of references. The selection process 
is shown in figure 2.b and data and contextual characteristics from the included articles are 
summarised in table 2.3 (see the end of this chapter). 
 
 
Figure 2.b Search results and selection process for articles. 
 
Four themes were identified from my synthesis of the literature (see table 2.2). Influences on 
patients’ expectations of medicines range from being highly specific and related to short-term 
targets that medicines are hoped to help achieve to general views on whether medicines are 
useful at all. Practical experiences, personal beliefs and other people’s opinions are influential 
as expectations are formed and develop over time. 
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Table 2.2 Codes and themes 
Theme Examples of codes 
A need to achieve a 
specific outcome 
Medicines relieve symptoms, help avoid hospitalisation, control disease 
or improve the conditions of daily life [39,102-104] 
Confirmation of effects is sought, and lack of identifiable effects can lead 
to the medicine being seen as not useful [39,103,105,106] 
Medicines offer something beyond what is achieved by diet and exercise 
[104,107] 
A medicine prescribed for prevention “stops a heart attack”, “cures the 
bones” or “does the job the doctor says need to be done” [103,108] 
Benefits with preventive treatments are overestimated [109,110] 
Patients wish for guarantees of survival [109-112] 
Experiences and 
evaluation developing 
over time 
Duration of illness influences understanding of disease and treatment 
effects [105,113] 
Past bad experiences of side effects triggers a conscious evaluation of 
risks and benefits when new treatments are suggested [105] 
Patients are seeking to confirm and adjust expectations [105,107] 
One’s own experiences and those of other people are used in decisions 
about medicines [103,104,107,108,113-115] 
Risks and benefits are balanced by patients in a different way than by 
doctors [105,108-111] 
Negative values – 
dependency, criticism 
and social stigma 
Fear of getting addicted, associations with illicit substance use [102,116] 
Hesitancy to be dependent on medicines for a normal life [39,116] 
The number of medicines used by one person can be seen as too high 
[105,106] 
A personalised meaning 
of medicines; their 
necessity and usefulness 
Medicines for different conditions are seen as being of different value 
[117]  
Patients with the same condition express diametrically different views 
about the treatment: necessary or of very limited value; as something that 
helps them to live normally or the only way to avoid death; as a choice 
based on experience or a resignation in lack of other options 
[102,104,116] 
Core health beliefs and notions of responsibility and morality influence 
decisions [103-105,118] 
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2.4.1 A need to achieve a specific outcome 
The first theme shows how patients’ expectations are influenced by a perceived need to bring 
about change. Medicines are described as an instrumental way to relieve both specific and 
wide-ranging aspects of symptomatic illness by patients with depression needing to get better 
quickly after “hitting rock bottom”,[102] and epilepsy, where the medicines control seizures as 
well as reduce worry.[39] Preventive medications are also seen as providing very specific 
benefits such as “stopping a heart attack” or “curing the bones”.[103,108] Here, the change is 
not in the form of alleviation of experienced illness symptoms. Instead, medicines are expected 
to produce general benefits related to a condition that is defined by a medical professional. 
Even more general descriptions of medicines as effective tools to care for oneself beyond that 
which can be achieved with diet and exercise are shared in interviews with patients suffering 
from heart failure and osteoporosis.[104,106] These anticipations resemble a combination of 
the ideal and predicted expectations described by Thompson and Suñol.[99] In terms of 
expressing expectations, it has been suggested that this is predominantly done by patients 
looking for specific outcomes, especially in relation to a condition that greatly impacts on their 
daily lives.[103] 
Another indication that specific changes are important influences is the need for confirmation 
of a medicine’s effect by symptom relief or some other immediately observable benefit. 
Correspondingly, a lack of salient effect from the medicines may lead to loss of perceived 
meaning with the therapy in patients’ views. This phenomenon points to the link between 
medicine-taking and relief of symptoms as an important motivator for patients.[39,98,105,106] 
Patients’ expectation that medicines will obtain certain effects also seem to apply to outcomes 
defined by someone other than the patient; both as a general ‘they should do what the doctor 
says need to be done’ [103] and more specifically mentioned by people with schizophrenia 
saying that medicines are used by doctors to control patients’ behaviour and make it acceptable 
to society.[114] 
An element of specificity also applies to the anticipated amount of effect. In relation to 
expectations on medicines for risk reduction several studies report that patients overestimate 
the possible benefits with preventive treatments: the anticipated reduction of risk for 
cardiovascular events and stroke in return for the effort of taking medicines every day is much 
higher than clinically possible and when provided with information about the likely level of 
benefit patients tend to decline treatment referring to potential side effects.[109,110] 
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In interviews with elderly patients about their willingness to use anticoagulants to prevent 
stroke, patients discussed the decision in terms of gambling and trade-offs and expressed 
wishes for a guaranteed number of disease-free survival years.[111] The format of risk and 
benefit information when suggesting treatment for the management of risk seems influential 
on patients’ decisions about treatment: relative risk reduction yields much higher acceptance 
than number needed to treat (NNT) and disease-free survival stratified between groups of 
patients gave more positive responses than when presented in a summarised way.[112] The 
representation of benefits by absolute or relative risk reduction might be interpreted by patients 
as giving everyone a reduced risk, whereas with NNT one single person gets the whole benefit 
of survival, making it less appealing. An expressed desire for a guaranteed number of years 
and the gambling and trade-off language used by patients in discussions of the decision to 
accept or decline treatment also suggest that benefit is being conceptualised as a specific effect 
or event that is delivered by medicines. 
2.4.2 Experiences and evaluation develop over time 
The expectations placed on medicines seem to be influenced by previous experiences of illness 
and medicine usage.[39,105] Predicted expectations [99] dominate. These are weighted 
together in a continuous evaluation of whether and how to use the prescribed medicines and 
longer duration of illness seems to open up for a more nuanced description of expectations. A 
cyclical trial and evaluation, where patients balance their view on long-term medicine-taking 
with important experiences of improvement and worsening of their condition, make patients 
experts on their own treatment.[102] This evaluation includes factors from the medical realm 
such as information about the condition, possible consequences and prescribed medicines as 
well as factors from other parts of life. In comparison to medical professionals’ evaluation of 
medicines’ appropriateness, patients use a shorter time-scale when determining if a medicine 
has beneficial effects. Their acceptance of risks or symptoms in relation to possible side effects, 
and the number of aspects weighted into such decisions, also make patients’ decision-making 
different from that stipulated by a biomedical model of health and illness.[108,113] 
Aside from patients’ own experiences, information from surrounding people is reported by 
several authors as influential on expectations. Doctors’ advice [109,114] is balanced with 
personal and vicarious experiences, [104] whereas academics and pharmaceutical industry are 
seen as less reliable sources.[115] Development of trust in a prescriber seems to influence 
patients’ decision to accept treatment, suggesting that it leads to expectations of beneficial 
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effects,[107,115] while patients that retain a more critical stance compare prescribing to 
experimentation and question the doctor’s knowledge about how a specific patient’s body 
works.[108] Consulting peers seems to be associated with patients being reluctant to accept 
treatment.[107,108] 
Patients’ balancing of perceived beneficial and harmful effects changes over time.[105,107] 
Even patients that want their doctors to make decisions about treatments state a desire to be 
informed about the anticipated effects in order to participate actively in evaluation of the 
effects. Information for this purpose is also sought from public sources and the health care 
system to confirm and adapt expectations.[103] 
2.4.3 Negative values – dependency, criticism and social stigma 
The third theme encompasses negative aspects of medicines that are not derived from personal 
experience but instead related to general, societal views. It contains aspects of normative and 
unformed expectations.[99] Certain types of medicines are described by patients as associated 
with addiction, dependency and illicit substance usage. Asthma patients describe negative 
associations evoked by illegitimate use of steroids by bodybuilders and depressed patients hold 
initial reservations about treatment due to fear of addiction and social stigma. Patients describe 
both their own views, those of family members and reports available in the public realm as 
negatively influencing the usage of medicines.[102,116] 
The number of medicines used by one person is also reported as something that may be valued 
negatively and evoke criticism from others. Patients question the helpfulness of taking a large 
number of medicines every day [106] and may decline new suggested therapies on the basis 
that they are already using too many medicines.[105] 
2.4.4 A personalised meaning of medicines; views on their necessity and usefulness 
The fourth theme is built up by codes related to the perceived utility of medicines in patients’ 
lives, beyond that of providing immediate effects. This encompasses longer periods of time 
and wider aspects of living with illness. A recurring feature in the dataset was the widely 
contrasting views patients share in relation to medicines’ usefulness and necessity. This theme 
displays a combination of the four types of expectations described in figure 2.a. 
When diagnosed with a chronic condition such as asthma or epilepsy, medicines can play the 
role of either aids to obtain normality, by giving the patient control over symptoms, or obstacles 
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cutting one off from normality by their association with social stigma and having an illness. 
However, such negative notions can be overcome by acquiring knowledge about a condition: 
steroids form an essential part of the management of asthma, and medication against depression 
or epilepsy becomes accepted as a way to get on with life.[39,102,116] 
A number of authors address the question about whether medicines are seen as necessary for 
life, health etc. or if usage is optional, subject to personal inclination and should be balanced 
with lifestyle changes to help manage the condition. Patients with multiple conditions may 
regard some medications more necessary than others, or some as being essential and other 
optional.[117] In interviews with elderly women about osteoporosis medication some 
participants stated that the medication was an inevitable, normative way to treat a condition 
associated with old age and therefore it would be effective, whereas others claimed that the 
natural ageing of the bones would limit the effectiveness of medication. In more general terms, 
prescription medication was described both as a way to obtain something beyond what diet and 
exercise could bring and as a “last resort” that would only be used if those failed.[104] 
In several studies medicines are described as a commitment and ‘part of life’ by patients with 
chronic conditions. However, this can have both positive and negative connotations. Heart 
failure patients interviewed about their associations with medicines report taking them without 
knowing what benefits they will bring but “because I don’t ever get better” or “otherwise I will 
die”. On the other hand, the medicines also allow patients to “complete things during the day” 
and “enjoy doing more things”.[106] Similarly, depressed patients described the decision to 
use medicines in the long term as a conclusion based on experience, or as resigning to them 
being the only way to get by.[102] 
One way to reconcile the opposing views expressed by patients living with the same chronic 
condition is the conclusion that expectations on medicines are influenced by deeply held 
personal views. This is described in terms of core beliefs about health and illness and feelings 
of responsibility or obligation to use medicines when diagnosed with a condition.[105,107,118] 
Links between acceptance of treatment and demographic characteristics such as level of 
education or social class have been addressed and discussed by a few authors, but with 
inconclusive results.[110,118] 
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2.5 Discussion 
This analysis identified four themes regarding influences on patients’ expectations of 
medicines: a need to achieve a specific outcome; the development of experiences and 
evaluation over time; fear of dependency and social stigma; and personalised meaning of the 
usefulness and necessity of medicines. 
2.5.1 Influences on patients’ expectations 
The desire for observable short-term effects, usage of experiences and knowledge in a process 
of evaluation and notions of meaning linked to personal and societal values show that 
expectations on medicines are multi-dimensional and dynamic. A low acceptance for side 
effects, fear of dependency on medicines that do not have addictive properties and criticism 
against using a high number of medicines every day are influential factors that fall outside the 
biomedical model of health and illness. 
In the specific case of expectations of benefit from medicines that are prescribed to manage 
asymptomatic risk conditions, my findings highlight a number of issues for consideration. 
Patients’ desire for tangible benefits and specific outcomes in the first theme and the role of 
experiencing ill health and medication effects in the second theme highlight a potential lack of 
meaningful ways to relate to and engage with medicine-taking when the reason for treatment 
is a risk identified by one’s doctor. An implication of this may be that patients interpret a 
decision about using such medicines as a dichotomous choice rather than as a way to influence 
the likelihood of outcomes. Another aspect is the perceived need for and acceptance of 
treatments for a growing number of conditions related to risk for future disease. The third and 
fourth themes point to possible issues regarding patients’ acceptance of the concept of risk 
reduction by means of treating cohorts in order to decrease the number of acute events in a 
population. Prescribing of several medications, for example in order to get a patients’ blood 
pressure within a target range, may be considered medically appropriate if there is evidence for 
possible benefit from all of them. However, patients’ views that it renders a number of daily 
tablets that is “too high” or that higher blood pressure is part of aging challenges the notion of 
benefit. In a wider sense, the increased availability and prescribing of medicines that target risk 
for future disease might influence personal and societal values held about using medicines for 
preventive purposes. 
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Influences identified in my analysis mirror the ideal, predicted, normative and unformed 
expectations described by Thompson and Suñol [99] (see figure 2.a) and show how patients 
engage in practical evaluation of medicines as described by Pound and colleagues.[98] The 
synthesised data comes from one literature review and 17 primary data collections, representing 
several clinical fields and a range of qualitative aspects of medicine-taking.  My synthesis 
therefore broadens the description of influences on patients’ expectations on medicines. It helps 
progress the understanding of patients’ expectations by highlighting the importance of 
evaluation of medicines from an individual perspective. This finding is important for the further 
development of a theoretical description of medicines used for the purpose of risk management. 
2.5.2 Critical review 
Codes and themes also resonate with an investigation of the impact of long-term medicine-
taking on quality of life published by Krska and colleagues just after the searches for this 
analysis were undertaken.[22] There, the authors identify wishes for tangible effects, usage of 
different sources of information to confirm expectations, trusting or challenging 
recommendations from one’s doctor, fear of dependency and complex decision-making 
regarding the usage of a necessary but disliked medicine. As my review identified these themes 
across a range of publications describing different types of data, it adds weight to the research 
by Krska and colleagues. The identification of similar themes between the two studies also 
provides an indication of the transferability of the findings. 
A methodological limitation of the presented synthesis is that although I had support from my 
supervisors in the decisions about searches and extraction as well as the coding and formulation 
of themes, the practical work was done by only myself. During the database searches it became 
clear that “expectations” is used liberally in the literature and it was difficult to specify narrow 
search terms that captured exactly what I was looking for. For this reason, searching reference 
lists of the included articles became an important way to identify publications. Another 
limitation, which is related to the difficulty of defining a comprehensive search strategy, is that 
only two databases were searched. Repeating the searches in PsycINFO and CINAHL, and 
using the same search terms and criteria for inclusion and exclusion, returned some of the 
already included articles but did not identify any more publications to include. 
Other limitations are due to the diverse nature of the primary data in the included publications, 
which is derived from narratives, interview material and data collected via questionnaires and 
describe both personal experiences and statements about hypothetical scenarios. Although the 
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connection between using medicines and living with a long-term medical condition has been 
highlighted,[39,116] only a few of the included publications discuss this issue in relation to 
their findings. This makes it difficult to determine whether the data represent specific 
expectations of medicines or thoughts about health, illness and care in general. An example of 
this is the discussion of a relation between readiness to make a decision about starting treatment 
and acceptance of it in a couple of the included publications, where the decision-making 
process may be hampered by a patient’s ambivalence vis-à-vis the diagnosis or the prescriber 
in clinical cases, and by difficulty to relate to the task in a hypothetical situation. 
Assessment of truth value, applicability, consistency and neutrality helps determine the validity 
of findings in qualitative research.[96] The recursion of codes and themes between this 
synthesis and other investigations of qualitative aspects of patients’ views on medicines is an 
indication of truth value and consistency of the results. However, the neutrality may be 
compromised by the fact that most of the included publications, although researching 
qualitative aspects of expectations, adopt a medical model where the aim to increase adherence 
to treatment becomes evident in the conclusions. Applicability of findings may differ between 
clinical fields. With regards to long-term management of risk, the reviewed literature contains 
descriptions of some elements that relate to patients’ decisions to accept or decline medicines. 
However, gaps remain in the theoretical understanding of how benefits with such medications 
are conceptualised, and how this may interrelate to prescribing for such purposes. This gap will 
be addressed in the empirical part of my research. 
 
2.6 Conclusions 
Unwanted effects of the increasing prescribing of medicines in the UK are the growing burdens 
of medication-related problems, waste and costs for patients and the NHS. In addition to 
interventions framed as medicines management, addressing the social aspects of health, illness 
and medicines could offer a way to understand and address more aspects of the increasing 
levels of prescribing in primary care in the UK. 
The stochastic nature of usage of medicines for the purpose of risk management, where time 
to beneficial outcome and distribution of benefit in a group of treated individuals are impossible 
to predict, makes patients’ conceptualisation of benefits an interesting and important but also 
under-researched element of prescribing. Whereas medical and economic arguments for risk 
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management medications can be gathered on a population level, findings in this qualitative 
synthesis suggest that individual patients are influenced by many more types of knowledge and 
values in a continuous, personal evaluation of whether to start and continue using medicines. 
A deeper exploration of how patients conceptualise benefits with medicines prescribed to 
manage risk is the objective of the empirical part of my research, involving interviews with 
patients at different levels of risk for cardiovascular disease. Building on this review, the aim 
will then be to develop a fuller theoretical understanding of how this topic can contribute to 
improved usage of medicines. 
 
Table 2.3 The dataset 
 
Authors, year Content 
Schofield et al 
(2011) 
Context Semi-structured interviews with 61 patients recruited from GP practices in 
three areas in the UK. Eligible patients invited via a letter from their GP. 
All participants had been prescribed antidepressants against depression 
and/or anxiety for at least a year. Purposive sampling is used to reflect the 
population of users of antidepressants in terms of age, sex, ethnicity and 
socioeconomic background. Most participants had experienced several 
episodes of depression at the time of the interview. 
 Findings - At the time of initiation of treatment, medicines were seen as a short-
term measure to get better at a time when they really needed it. 
- Many participants had reservations against antidepressants when first 
consulting their GP, due to concerns about using medicines in the long 
term, fear of addiction and negative views held by themselves or others. 
- Using and experimenting with medicines over time makes patients 
experts on their own conditions and treatments. This expertise gives the 
patient more control over decisions regarding management of their 
illness. 
(table continues overleaf) 
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Conrad 
(1985) 
Context In-depth interviews with 80 people with epilepsy about the meanings of 
medications in everyday life and why medicines are taken or not, carried 
out as a part of a larger project about living with epilepsy. All participants 
were or had been using medications against the condition. Recruitment 
was done via community channels. Participants are described as between 
14 and 54 years old, mostly lower middle class and coming from urban 
areas in the US. Interviews were held independent of medical and 
institutional settings. 
 Findings - Peoples’ practices regarding medicines are related to aspects of control 
in two directions: taking control over symptoms or worries about the 
disease, or being controlled by a disease that forces usage of medicines. 
- A continuous evaluation of the medicines is undertaken, and patients 
may stop taking them if no specific effect is perceived. 
- The author refers to a general view in society that it is better to try to 
achieve health goals without medicines, and reports reflections of this 
view in the participants’ accounts. 
Dolovich  
et al 
(2008) 
Context The study aims to investigate expectations and influences thereon to find 
out if expectations have an impact on how medicines are used. Purposive 
sampling and recruitment through community and health care channels in 
Canada was used. The 18 participants represent different ages, living 
conditions and types of medicines used. Semi-structured interviews were 
conducted around the medicines the participant considered most 
important, and analysed using grounded theory. 
 Findings - Expectations are most clearly expressed by patients who want a clearly 
defined outcome in a condition that affects their daily life 
- Participants are realistic in what they want medicines to achieve and use 
different sources of information to adapt and confirm their expectations. 
- The number of medications used every day was described as an issue; 
either as burdensome for an individual or in general terms. 
Unson et al 
(2003) 
Context With a stated aim to increase adherence, patients’ beliefs about 
osteoporosis (OP) medication and medicines in general are assessed. 
Focus groups based on ethnicity was recruited via senior centres and 
housing estates in deprived areas in the US. A convenience sample of 55 
women aged 60 years or older participated. Most participants were on 
prescribed medication, but not for OP. Authors suggest that what is 
handled as a dichotomous question (treatment or not) in medicine is a more 
complex decision for patients, where heuristics, moral aspects and power 
relations are at play. 
 Findings - Side effects are considered serious and on a short term basis; “they can 
be worse than the disease itself” and “25% protection without side 
effects is better than 50% with”. 
- Participants use both their own experiences and those shared by others 
in decisions about medication. 
- Scepticism about prescribers’ knowledge about how medicines affect 
specific patients; prescribing partly seen as doctors’ experimentation. 
(table continues overleaf) 
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Granger et al 
(2012) 
Context Mixed methods study aiming at exploring theoretical linkages between 
symptom experience over time and the meaning of medication adherence. 
Ten patients with chronic heart failure completed questionnaires 
measuring beliefs, behaviours, symptoms and satisfaction and were 
interviewed about the meaning associated with medicines. Patients were 
recruited by research nurses during an admission to a US university 
hospital with exacerbation of their condition. 
 Findings - Experience of symptoms influences the meaning attributed to medicines. 
- Medicines are described in positive ways as tools to care for oneself, but 
also with negative notions of being inevitable if wanting to avoid death. 
- Patients questioning how a large number of medicines everyday can be 
helpful. 
Mazor et al 
(2010) 
Context Telephone interviews with women ≥65 years that fulfilled WHO criteria 
for osteoporosis, recruited from a multispecialty practice in 
Massachusetts, US. History of dispensed prescriptions was used to classify 
participants into three groups of equal sizes: not using medication, started 
but discontinued medication and currently on medication. The study links 
core beliefs about medicines to patients’ views on perceived need, safety 
and efficacy of a medication. 
 Findings - The need and usefulness of medication is described as related to age, but 
with different conclusions: old age and brittle bones make medicines 
necessary, or offset the efficacy of medicines. 
- Patients that make use of peers’ knowledge or experience of the 
medication are sceptical to treatment. 
- Connects participants’ views on medicines with their core beliefs about 
health and illness. 
Nair et al 
(2007) 
Context Semi-structured interviews seeking to investigate patients’ experiences 
with risk-benefit assessment when making decisions about treatment for 
type II diabetes. The 18 Canadian patients used different types of treatment 
and were recruited through community and health care channels. Both 
purposeful and theoretical sampling was used to ensure inclusion of 
patients that found treatment easy as well as difficult. The interpretation 
of the interviews was validated in a focus group session towards the end 
of the analysis process. 
 Findings - Avoidance of medication may be based on the impression that one is 
already taking too many medicines. 
- Duration of illness and experimentation with medicines influences the 
understanding of the effects of disease and the treatment. 
- Patients develop a personalised understanding of the value of a 
treatment, and this forms a basis for the decision whether to use a 
medicine. 
(table continues overleaf) 
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Smith et al 
(2000) 
Context Experiences, concerns and willingness to participate in decision-making 
about medicines was explored and compared between patients with the 
three conditions. Group interviews were arranged via voluntary 
organisations for each condition in the UK. 
 Findings - Patients with schizophrenia had experienced medicines as a way for 
doctors to modify their behaviour in order to be acceptable in society. 
- Patients wishing to leave decisions about medicines to doctors still 
wanted to be informed about positive and negative effects so that they 
could monitor their treatment. 
- Information about medicines is used to participate in decisions and 
challenge doctors. 
Cranney  
et al 
(1998) 
Context In an investigation of barriers to implementation of guidelines for 
hypertension treatment, UK healthy elderly patients’ and GPs’ perceptions 
of risks and benefits was addressed. Participants recruited via a GP 
practice (75 patients) and on a training course (121 GPs). Attitudes to risk 
with untreated hypertension and ideas about benefit from prescribed 
medicine were assessed with questionnaires accompanied by visual aids 
during semi-structured interviews. 
 Findings - Most patients overestimate both the risk with untreated hypertension and 
the benefit from preventive treatment, and accepted treatment based on 
trusting their doctor. 
- When provided with information about the clinically proven relative risk 
reduction, fewer patients accept treatment and more patients mention the 
risk of side effects. 
- Communicated ideas about benefit with treatment are rather vague, and 
based on conceptions of prevention being necessary or helpful in 
general. 
Leaman and 
Jackson 
(2002) 
Context Questionnaire completed by 216 patients from a single GP practice in the 
UK. A random sample of patients, stratified for age and gender, were 
asked to state the level of benefit requested for acceptance of a first, second 
and third medicine for treatment of hypertension. Benefit was represented 
with fixed levels of NNT(5). Hypothetical scenarios explaining the 
consequences of a myocardial infarction and some practical aspects of the 
treatment accompanied the questionnaire, and respondents were asked to 
answer with only these aspects in mind. 
 Findings - Patients request a much higher level of benefit than what has been 
clinically proven. 
- Authors mention patients’ lack of rationality in making decisions about 
medicines, leaving decisions to doctors and altered circumstances when 
facing a real rather than a hypothetical situation as explanations for why 
so many patients are on treatment for hypertension despite the results in 
the study. 
(table continues overleaf) 
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Fuller et al 
(2004) 
Context Older people’s attitudes to stroke prevention were examined by presenting 
probabilities of risks and benefits with warfarin treatment. People aged 66-
97 years answered questionnaires about hypothetical scenarios of risk 
reduction and practical aspects of treatment. The 81 participants were 
recruited via an elderly medicine outpatient clinic at a large university 
hospital in the UK. 
 Findings - Participants expressed wishes for a guaranteed number of years of 
disease-free survival in order to engage with medicine-taking. 
- Experiences of disease in the family and personal health beliefs are 
influential on the acceptance of treatment. 
Hux and 
Naylor 
(1995) 
Context Data on benefit of lipid-lowering medication from a large clinical study 
was presented in different formats (relative and absolute risk reduction, 
NNT, average and stratified survival) to 100 participants aged 35-65 
recruited from an outpatient setting in Canada. Treatments were presented 
as free of charge, without side effects and suggested by a doctor in 
hypothetical scenarios. Participants’ preferences and their stated certainty 
about the decision were recorded in order to investigate how the format of 
benefit data influences decisions about treatment. 
 Findings - Relative risk reduction generated the highest acceptance for treatment, 
followed by absolute risk reduction. 
- Stratified survival data was preferred over average numbers. 
Arkell et al 
(2013) 
Context Experiences, attitudes and expectations about information given prior to 
starting anti-TNF therapy were assessed in focus group interviews with 
ten rheumatoid arthritis (RA) patients in the UK. All participants were 
currently on treatment and purposively sampled to represent different 
ages, disease duration and activity and anti-TNF agent used. Data was 
analysed with a phenomenological approach. 
 Findings - Patients described a willingness to face increased cancer risk due to 
treatment if sustained relief from RA symptoms could be achieved. 
- Fear of disease symptoms and long-term effects influenced the desire to 
start and stay on anti-TNF medication; side effects were considered 
secondary. 
Gale et al 
(2012) 
Context Meta-ethnography of qualitative literature on usage of medication for 
prevention of cardiovascular disease, seeking to explore variations in 
behaviour and implications for practice. 
 Findings - The context for patients’ decisions about medicines goes beyond the 
clinical setting – social interactions in the personal community, other 
people’s experiences and various sources of information are influential. 
- Doctors are trusted sources for information about medicines; 
information from academia, pharmaceutical companies and media is less 
trusted. 
(table continues overleaf) 
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Sale et al 
(2011) 
Context A phenomenological study conducted to investigate patients’ experiences 
with the decision to take OP medication after sustaining a fracture. 
Participants aged over 65 years who had had a fracture in the last five 
years and were at high risk for having another one were recruited via an 
OP screening programme in Canada. Two thirds of the 21 patients were 
currently taking OP medication. Cost for medication was covered by a 
local drug plan for all participants. 
 Findings - A decision to use or not use medicines is often not permanent; patients 
report they have changed their mind about medicines or might do it later. 
- The decision to start OP medication is often based on trusting the 
prescriber’s recommendation. 
- Discussing the decision about medicines with friends or family or 
searching information elsewhere often resulted in not accepting 
treatment. 
Adams et al 
(1997) 
Context Asthma patients’ attitudes to prophylactic medication are explored with a 
patient-centred perspective. In-depth interviews were carried out with 30 
participants recruited from a GP practice in Wales. Participants 
represented different ages, social backgrounds and duration of asthma. 
 Findings - Using medication every day is closely linked to the idea of having a 
disease. 
- Those patients that accepted the treatment as part of living with asthma 
still disliked using medicines every day. 
- Negative views on steroids, associated with illicit use, were overcome 
by the fact that they are needed by the patient and prescribed by a 
professional. 
Stack et al 
(2008) 
Context Patients beliefs about multiple medicines are addressed in interviews with 
19 patients diagnosed with cardiovascular disease and type II diabetes. 
Authors acknowledge that usage of many medicines is associated with 
poor adherence and self-management in patients. Recruitment was done 
via two urban GP practices in the UK. 
 Findings - Diabetes medicines are seen as necessary, whereas medicines for the 
management of cardiovascular risk, especially lipid-lowering agents, are 
given lower status. 
- The patients that describe a perceived risk for cardiovascular events have 
experienced heart attacks or strokes among family or friends. 
Marshall  
et al 
(2006) 
Context Relations between level of cardiovascular risk, acceptance of treatment 
and demographic characteristics were investigated quantitatively. Patients 
without diagnosed cardiovascular disease from GP practices in the UK 
were invited to participate in coronary risk screening and a research study. 
Preferences regarding treatment in hypothetical scenarios were recorded 
from the 181 participants before the screening, and a second interview was 
conducted afterwards to see whether patients changed their minds when 
told about their own risk. 
 Findings - Patients’ preferences are stable over time but vary between individuals. 
- A difference in acceptance of treatment between patients from different 
social classes is suggested to be related to ideas about moral obligation 
to use medicines. 
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Chapter 3 
The public debate about cardiovascular risk 
 
3.1 Chapter overview: newspaper coverage of an updated clinical guideline 
From researching the influences on patients’ understanding of the benefit of risk management 
medicines, and concluding from my synthesis of the literature that factors both within and 
outside the medical field contribute to that understanding (see chapter 2), the lay debate about 
medicines and risk is clearly an important source of knowledge. In this chapter I present an 
analysis of how CVD risk and risk management medicines were portrayed in UK newspaper 
articles, and discuss the content and format of messages about health and disease that are 
available in the press. 
 
3.2 Medicines in the media 
In the scoping conversations with GPs at the start of this project (see appendix A1), the internet 
and print media were repeatedly mentioned as influential on patients’ willingness to accept 
treatment that targets risk factors for cardiovascular disease (CVD). Newspaper stories and 
internet forums have also been suggested as playing a part in shaping patients’ views, 
expectations and demands regarding prescribed medicines.[119-122] 
With the current availability of information on health-related topics in both traditional and new 
media, and possibilities for anyone to publish, share and comment, this area is vast and 
changeable – and therefore challenging to research. However, an opportunity to explore a few 
aspects related to CVD risk management arose at the time when the UK National Institute for 
Health and Care Excellence (NICE) released suggestions for an update of the clinical guidance 
on CVD risk assessment and lipid modification in February 2014 (see figure 3.a).[123] The 
content provoked a debate in the medical community, and both the dispute and the new 
guidance were also discussed in public media. The reporting around the extension of treatment 
with statins to people at lower levels of risk offered an opportunity to research how CVD risk 
and the benefits and harms from statins were represented in a lay context; i.e. in UK 
newspapers. Key features in the discussion were the appropriate end-points for assessment of 
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benefit and harm in a population at low risk.[124-127] Two systematic reviews of side effects 
attributable to statins [128,129] were published in the month after the suggested updates to the 
clinical guidance, and they were also widely discussed in the newspapers.  
 
NICE press release: NICE advises much wider use of statins in draft guidance 
- Doctors are recommended to consider many more people to be at risk for heart disease, stroke 
or peripheral arterial disease and systematically search for people at risk. 
- The threshold for starting preventive treatment should be halved from 20% to 10% risk. 
- The guideline is updated due to new evidence on risk assessment tools and a lower price for 
statins that makes treatment cost-effective. 
- CVD causes 1/3 of deaths in the UK; 180.000 cases/year but rates have halved since the 
1970’s and 1980’s. 
- Before the guideline update, 7 million people in the UK are prescribed statins at a cost of 
£285 million per year. 
- CVD disproportionally affects socially deprived people or those with a low income, and the 
rates are higher in the north of England. 
 
Figure 3.a Key messages in the updated guideline, as stated in the press release from NICE in 
February 2014 [130] 
 
3.3 Health care policies and the social world 
Whilst relations between risk factors and outcomes established within a biomedical model of 
health and illness guide prescribing, factors in the social world also influence how medicines 
are used. Contextual and societal factors may facilitate or hinder implementation.[131] From 
this, it follows that the impact of for example prescribing policies depends not only on their 
content, but also on how they are received by the people whose health they are to influence. 
Patients’ acceptance or rejection of prescribed medicines is a key determinant of 
implementation success.[98] Media is one of the factors that have been shown to influence 
patients’ perceptions of the need for medicines – their portrayal of health and medicines are 
influential on how health services and interventions are used.[132] It should be noted that print 
and broadcast media have been criticised for shortcomings in the representation of risks and 
benefits [133] and single-sidedness in their descriptions of medicines’ effects.[120] 
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In relation to the theoretical background for my study, this review of how CVD risk and risk 
management are described in UK newspapers is informed by the suggestion that the media 
contributes to the view that health problems can be solved with medicines.[56] As outlined in 
chapter 1, one aim of this project is to test the concept of pharmaceuticalisation in the context 
of CVD prevention in UK primary care. This review focuses on descriptions and debate around 
statins, and seeks to understand them as a source of social influence on patients’ understanding 
of this class of CVD risk management medicines. In addition to considering to what extent the 
biomedical evidence is correctly presented, my attention is also directed towards which other 
explanations are offered in relation to CVD risk and how professionals’ and patients’ accounts 
are presented. 
 
3.4 Statins prescribing as a model of prevention policies 
In the particular case of CVD risk management in UK primary care, statins are a central class 
of medicines. Simvastatin was the pharmaceutical product with the highest number of items 
dispensed in 2014 and atorvastatin also make the top 20-list.[134] The proposed (and 
subsequently adopted) change to the clinical guideline for blood lipid modification entails a 
lowering of the risk threshold at which people should be offered high-intensity statins treatment 
from 20% or higher risk for developing CVD within 10 years to 10% or higher risk. As reasons 
for updating the guidance, NICE states new evidence regarding risk assessment tools and also 
the price and availability of generic statins.[73] 
Together with medications against high blood pressure, statins are at the core of cardiovascular 
prevention in primary care. For the purpose of this research project; exploring whether 
prevention policies contribute to polypharmacy and overprescribing, they are therefore a 
suitable object of study. As the new guideline was motivated with arguments about the 
evidence around risk assessment, it reflects the current focus on population-level prevention, 
and the link between lower prices for statins and increased prescribing shows how not only 
clinical features have a strong influence on primary care practice. 
Others have also used the introduction, establishment and extension of treatment with statins 
as examples to examine influences from the social world on the use of medicines for the 
purpose of disease prevention. For example, Greene [61] writes about how regulatory changes 
in the US paved the way for large, industry-sponsored clinical trials of statins between the 
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1970’s and 1990’s. Their results were used to change the definition of what a ‘normal’ 
cholesterol value was, and a ‘desirable’ value that made the majority of adults in the US eligible 
for treatment was introduced into guidelines. Increased testing of blood cholesterol, facilitated 
by pharmaceutical manufacturers through distribution of screening equipment to surgeries and 
pharmacies, has been used to expand prescribing in the US and the UK.[60,135] Will and 
Weiner [136] used the introduction of statins OTC in the UK to examine consumerism and 
demand for medicines, but found the highest expectations of benefit from this change, in the 
form of foreseen increased sales, among policy-makers and industry instead of among people 
wanting to access medicines. 
With this analysis of the representation of CVD risk in UK newspapers, I aim to examine how 
a current prescribing policy is represented to the public. My research question was “What 
representations of CVD risk, and the benefits and harms of statins in managing that risk, are 
communicated by UK newspapers?” 
 
3.5 Methods 
Qualitative analysis of texts can be done with several different approaches, including content 
analysis, discourse analysis, narrative analysis and thematic analysis. To allow for both testing 
of a-priori suggestions based on the research question and other emerging findings, I chose to 
use thematic analysis. This method is flexible and therefore useful across a potentially diverse 
range of texts such as extracts from newspapers.[137] 
3.5.1 Identification of articles 
Articles were identified from a purposive sample of eight national UK broadsheet and tabloid 
newspapers including their weekday and Sunday editions. For a description of the idea behind 
purposive sampling, see chapter 4, section 4.4.4. The selection of newspapers was done based 
on their circulation size and seeking maximum variation in terms of editorial stance and 
readership,[138] see table 3.1. Included newspapers represent a range from ‘serious’ to 
‘tabloid’ publications.[139] Local or free newspapers (Metro, Evening Standard) were 
excluded since they are not available nationally. The time frame for sampling was from 
February 12th to March 31st 2014, which was the period when stakeholders could comment to 
NICE on the draft guideline. 
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Table 3.1. Sampling framework. 
Name of newspaper Circulation 2014 
(weekdays/Sunday) 
Readability (Flesch 
Reading Ease Test)* 
The Sun/The Sun on Sunday 2.2M/1.8M 62 
Daily Mirror/Sunday Mirror 1.0M/0.9M 57 
The Independent/Independent on Sunday 66K/0.1M 50 
The Times/The Sunday Times 0.4M/0.8M 49 
Daily Telegraph/The Sunday Telegraph 0.5M/0.4M 48 
Daily Mail/The Mail on Sunday 1.8M/1.6M 40 
The Guardian/The Observer 0.2M/0.2M 33 
Financial Times 0.2M/NA 35 
* A readability score higher than 60 represents plain English accessible to 13-15 year-olds; 50-59 
represent fairly difficult text accessible to15-19 year-olds and 30-49 represents difficult text 
accessible to those educated to a college/university level. 
 
The Lexis®Library database of newspapers was searched in two stages, on March 18th (40 hits) 
and March 31st (27 hits) 2014. The same broad search criterion was used in both searches: 
appearance of the word ‘statins’ in the headline or text. Texts that mentioned statins but did not 
refer to the updated guideline were excluded, for example letters with personal questions about 
statins use, comparison between statins and foodstuffs that have an effect on cholesterol, or 
texts casually referring to statins. Duplicates as well as texts of the type ‘corrections and 
clarifications’ were also excluded, so that the material for analysis consisted of final versions 
of published articles. 
3.5.2 Analysis of articles 
To find answers to the research questions while also looking for indications of other ways to 
present CVD risk and its management, I used open coding and thematic analysis.[137] As a 
conceptual framework for the critical examination of articles, I used the applicable aspects of 
the pharmaceuticalisation framework. It describes influences of the social world, such as health 
care governance, market forces and the media on the portrayal and use of medicines, and the 
involvement of pharmaceutical industry in these processes.[56] For the purpose of this analysis, 
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the changing definitions of health problems, the relations between regulatory bodies and private 
interests and the influence from media’s portrayal of health, illness and medicines were 
particularly useful. 
The analytical process started with a search through the included articles for data that addressed 
the research question – namely what images of CVD risk and risk management with statins are 
communicated by newspapers. The search was also open to pick up data that confirmed or 
challenged the a-priori questions, for example by describing the usage of medicines for risk 
management in novel ways or portraying risk as something different than what is indicated in 
the clinical guideline. Extracted data were collected in a spreadsheet along with a brief 
description of what aspect of the research question it related to. An overall assessment of whole 
articles was also done at this stage, to summarise the context from which each of the data 
extracts had been taken.  
The next step was interpretation of data to establish meaning, guided by the conceptual 
framework. All data extracts were assessed and given one or more descriptive codes that 
indicated for example the type of language used, whether it described specific cases or risk 
management in a population context, if it focused on the guideline, the reports about side effects 
or the clinical efficacy of statins, and how it described different stakeholders (professionals, 
academics, pharmaceutical industry or patients) in relation to the new guideline. 
As analysis progressed and the list of descriptive codes grew, the codes were grouped together 
into emerging themes. For each addition of a category to a theme, the included data extracts 
were compared with other ones in the group, so that each theme described as many aspects as 
possible of related phenomena but still stayed separate from the other themes.[100] A final 
adjustment of the themes was done during the writing up of the findings, by critically reviewing 
them in relation to the research question and the conceptual framework for this study. 
After the detailed coding and initial appointment of descriptive categories, I discussed the 
further interpretation of data and development of themes with Prof Walley and Dr Reeve. 
Included in the analytical process was also questioning of the trustworthiness of the research 
methods and the emerging findings – whether the processes of data collection and interpretation 
were valid with regards to the research question and if the analysis was a useful contribution 
towards explaining the phenomenon that is being investigated. Informed by the questions 
suggested by Miles and Huberman,[94] I focused this validation on the authenticity (i.e. do the 
findings make sense and are they giving a truthful presentation of what is going on), the 
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transferability (i.e. can the findings and the identified meanings be used in any other context) 
and the applicability (i.e. do the findings offer any usable knowledge) of the process. 
 
3.6 Findings 
Sixty-seven texts mentioning statins were identified, of which 42 were excluded according to 
the previously defined criteria. The distribution of articles between newspapers is displayed in 
table 3.2. 
Table 3.2 Number of articles identified and excluded. 
Name of newspaper Number of 
articles retrieved 
Number of articles 
excluded 
The Sun/The Sun on Sunday 6 4 
Daily Mirror/Sunday Mirror 3 2 
The Independent/Independent on Sunday 2 2 
The Times/The Sunday Times 14 10 
Daily Telegraph/The Sunday Telegraph 22 15 
Daily Mail/The Mail on Sunday 11 5 
The Guardian/The Observer 9 4 
Financial Times 0 - 
Total 67 42 
 
Twenty-five articles matched the inclusion criterion of referring in some way to the updated 
guideline. They are displayed in table 3.3 at the end of this chapter. Included pieces consist of 
editorial material (short items, reports, columns, Q&A sections and readers’ contributions) and 
texts written by external contributors that are medical and academic professionals. In contrast 
to previous analyses of newspaper articles about medicines,[121,133,140] most of the longer 
pieces written by journalists contained information about positive as well as negative effects. 
Some of the external authors took a clear stance in supporting or criticising the proposed new 
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guideline, focusing either on the anticipated benefits or harms from extended prescribing and 
also accusing each other of lacking in scientific skills or plainly being wrong. 
Amongst the sometimes dramatic accounts of the updated guideline, I identified four themes 
related to descriptions of CVD risk and its management with statins. These include the a priori 
themes, being descriptions of the nature of risk for CVD and the effects of statins in CVD risk 
management. The additional emerging themes were the newspapers’ roles in helping patients 
make informed choices about statins and the lack of discussion about social aspects on health. 
3.6.1 CVD risk is identifiable and measurable 
Articles portrayed the risk of suffering from CVD as dependent on a combination of discreet 
and identifiable factors: age, sex, smoking, diet, blood pressure and blood cholesterol – the 
same risk factors that were mentioned by NICE in the press release.[141-146] There was a 
particularly strong focus on age as a risk factor, and the guideline was said to make “most men 
over 50 and women over 60” eligible for treatment.[146-149] 
The aspect of the updated guideline that considered changes to the assessment of CVD risk 
was discussed far less extensively than the extension of prescribing. Only two articles 
[143,144] elaborated on how the risk assessment is done; one of which was a response to a 
reader’s question about how people at risk are identified. Past medical history, age, weight and 
levels of cholesterol and blood pressure were said to be used by doctors as they come up with 
a “best guesstimate” of the risk for disease.[143] 
Risk was described as something that could and should be controlled by individuals, whether 
by using medicines to do it in a “clean and effective way”[150] or by people changing habits 
to make sure they “lost weight, exercised more, ate healthily, stopped smoking and drank in 
moderation”.[151] Although lifestyle changes were acclaimed in all articles, there were also 
comments about how difficult they are to sustain; and as most people will not succeed, statins 
are needed instead.[152] 
3.6.2 Statins save lives – but they also cause problems 
A range of metaphors illustrated how statins work in CVD risk management. By lowering 
cholesterol they were said to “reduce the risk”, ”protect the heart”,[142] “guard against strokes 
and heart disease”[144] and “cut heart attacks and strokes”.[145,153] Most articles stated the 
preventive effects of lowering cholesterol with statins but there were also cases of questioning 
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it. For example, a doctor referring both to research and to his own experiences of using statins 
said “high cholesterol has been a scapegoat for too long”.[147] 
Possible benefits and harms from statins were also described. The benefits were depicted with 
reference to the whole population and clinical trials. Statins were said to “save 7000 lives in 
the UK every year”[148] and the new guideline “will save 2000 lives”[154] and “could prevent 
10.000 heart attacks”[141] annually. The benefits were described in an ascertained way, saying 
that using statins will save lives (or; not using them will cause deaths).[154-157] Hence, the 
effect of the medication – a reduction of the risk for heart attack and stroke – was illustrated 
by means of extreme outcome measures. 
In contrast to the cohort-based outcome measures for benefits, side effects from statins were 
illustrated with personal stories from the writers, their patients or other named individuals. 
Readers get introduced to an elderly lady who “suffered such painful muscle aches (…) that 
she had to give up the tea dances which were keeping her fit”[158] and a GP that had been 
forced to “give up badminton, his favourite form of exercise”.[142] There were also accounts 
of people stopping using statins and feeling “great” or “better than I have in years”.[147,159] 
Experts speaking in favour of the guideline were quoted saying that the benefits of treatment 
“will outweigh any harm”,[141,144,146] citing the small number of side effects reported in 
clinical trials. Prescribing statins to people at the new, lower risk level “undoubtedly represents 
a good deal for the British public” according to one author, who thereby summarised the 
complex issue of risk management into mundane, everyday language while also wording it in 
a way that take benefits for granted.[141] 
However, implementation of the new guideline was also described as “a public health 
disaster”.[160] Journalists and medical professionals taking a critical stance stressed that 
people becoming eligible for treatment under the new guideline “are in good health”[160] and 
“not ill”.[150] They contrasted a lower CVD risk in the population with the possibility of 
individuals experiencing side effects: “most of the patients do not need the pills, will never 
benefit from them, and may be harmed by them”.[158] In one of these critical articles the 
population perspective was instead referred to as “the taxpayers picking up the ever-growing 
bill” for looking after people with side effects.[160] 
The trade-off between benefits and harms that is a central feature of risk management 
prescribing was addressed in most of the included articles. In describing possible outcomes, 
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seven of them focused on the positive effects, six on the negative and nine offered a 
combination of both. Even so, only few examples of straightforward descriptions of the 
underlying principles for the guideline were described. None of the articles presented any 
numerical value – absolute or relative risk reduction – indicating the effect of statins for an 
individual. I also noted an absence of any discussion of the discrepancy between the effect 
measures of ‘lower risk due to lower blood cholesterol’, which might be achievable for most 
people treated, and ‘life saved’ that will be achieved only by few. Rather, the frequent picturing 
of statins as live-saving medicines points towards a conclusion somewhat like ‘lowered 
cholesterol means survival’. An example is a medical professional who writes that the 
prescribing of statins to people at the new, lower risk level is required “if we want to stop deaths 
which seem to come out of the blue”.[141] 
One attempt to clarify the balancing of possible benefits and harms from statins was available 
in The Times on March 25th, where a medical professional contributed a column illustrated 
with ‘number needed to treat’ and ‘number needed to harm’. The author also points out that 
although an alleged 25% reduction of the risk for a heart attack sounds good, even a large 
proportional decrease will still not have a very big protective impact if the risk is low to start 
with. This is put in relation to a remark about possible negative effects: “The downsides remain 
the same whatever your underlying risk, so there comes a point where the drugs are likely to 
do more harm than good.”[151] 
Whilst some articles presented evidence for statins’ benefits largely as described by NICE in 
the press release (see figure 3.a) or stated brief conclusions from the two reports about side 
effects, others offered a more discursive debate of the topic. Short, single-sided reports 
appeared in the newspapers with the highest readability. Stronger opinions and elaborate 
discussions were published in papers using more difficult language. Some of these were written 
by medical professionals either supporting the message from NICE [141] or criticising the 
guideline based on a combination of personal experience and medical evidence.[147,160] The 
longer articles written by journalists discussed the guideline in the light of the ongoing 
scientific controversy over benefits and harms from extended treatment.[142,149,150,155] 
3.6.3 Making an informed choice 
One of the emerging themes stems from the observation that in addition to reporting about the 
scientific disseminations, the newspaper articles also went on to consider the implications for 
their readers’ decisions about using statins. Some articles described the guideline in terms that 
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indicate it being a rule – people “will be urged”, “will be told to take”, “should be taking” or 
even “will be put on” statins.[144,150,154] A reader of The Sun had interpreted the prescribing 
guidance as “A health watchdog is trying 2 get the healthy addicted 2 statins with dangerous 
side effects cos they r cheap”.[161] However, the majority of articles were less prescriptive in 
interpreting what the new clinical guidance means, saying people would be offered the 
tablets.[145,153,162] 
In the face of possibly being considered for a statins prescription, the newspapers stress the 
importance of making a personal decision about whether to use statins or not. Some articles 
suggested that this individual interpretation of risk and benefit should be done together with 
one’s own doctor, who could provide “a discussion, weighing up the risks and benefits” and 
“trustworthy advice (…) support and continuity of care”.[146,152,158] 
By using headlines such as “The truth about side effects”[142] and “The risks you must know 
about” [151] newspaper articles also actively took on the role of helping patients make 
decisions. A direct and personal language was used in these texts. One journalist opened an 
article discussing benefits and harms with “Should I, or shouldn’t I take a statin?”[151] and a 
medical professional concluded his piece with “whatever NICE says, you won’t need those 
statins at all”.[160] 
A final possible source of information for readers’ decisions about medicines is the various 
experts that were cited in articles or appear as authors. In addition to the content of statements 
about the possible benefits or harms of statins and the impact of the guideline update on public 
health (which have been referred to above), the presentation of the contributing medical 
professionals might influence how people perceive the message about statins. Experts that 
expressed their support for extended prescribing were described primarily as academics, 
whereas those that criticise the lower threshold were portrayed as clinicians; GPs or specialists 
that speak from experience of their own or their patients’ use of statins. In describing the row 
between academics over the data that underpins the new guidance – both its quality and the 
access for independent parties to evaluate it – additional experts were cited. This debate 
highlights risk management prescribing on a more conceptual level, by discussing the types of 
data and knowledge that are created in different types of investigations. Some information that 
could potentially guide people’s decisions was provided, as clinical trials were contrasted with 
“real world data”.[162] However, alongside the discussion of strengths and weaknesses of 
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different approaches were accusations of inadequate research practice and fear-mongering 
[142,149,155-157] which might divert readers’ attention. 
3.6.4 CVD risk management is a medical issue 
The fourth theme arises from the realisation that the link between social deprivation and CVD 
was largely absent from the newspapers’ reports about risk management and statins. Although 
this association, along with an explicit example mentioning the higher prevalence of CVD in 
the north of England, was included in the epidemiological information in NICE’s press release 
(see figure 3.a), only one article picked it up. The Daily Telegraph mentioned the link between 
CVD and poverty in a critical examination of the new guideline.[158] It was suggested that 
“proper public health policy” should target lifestyle and poverty rather than turn to overly 
generous prescribing of medicines, albeit without any suggestions of how this could be done. 
On the contrary, information that was provided about CVD places it in an epidemiological 
context with references to it as being “Britains biggest killer”[146] and causing one third of all 
deaths in the UK. [145,162] Although the risk for CVD was described as largely related to 
lifestyle, medical approaches were put forward as the way to achieve change – whether by 
prescribing statins or using other methods: “GPs will hand out pills instead of tackling the root 
causes of heart attacks and strokes”.[162] The medical framing is strengthened by frequent 
references to general practice as the stakeholder that will be responsible for implementing the 
guidance. GPs will have to “do much more to identify patients between 40 and 74”[144] and 
will also have to withstand an increased burden of visits due to side effects.[160]  
The lack of alternative perspectives on this systems level stood in contrast to the critical 
descriptions of the new guideline as promoting medicalisation and being influenced by 
commercial interests. One journalist asked if “we really want our highly educated GPs to act 
merely as robotic functionaries of the public health” when “treating people as a undifferentiated 
mass”.[158] It was said the guideline “is going to benefit the pharmaceutical industry more 
than patients”[145] since NICE “seems to be siding heavily with the drug companies”.[160] 
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3.7 Discussion 
For the consideration of how this analysis contributes to my investigation of patients’ 
understanding of prescribing for prevention of CVD, this discussion will focus on how the 
newspapers portray cardiovascular health and statins to their readers. 
The co-existence of positive and negative effects from statins within the same articles differs 
from the findings by Prosser and Clayson, who found that newspaper articles often were 
dominated by one of two themes; that the drug in question was described in either solely 
positive or negative words.[121] This is a positive finding with regards to the topic of risk 
management prescribing, as more balanced or complex accounts of medicines’ effects might 
help to give a more comprehensive and realistic representation of risk management from both 
a clinical and a patient perspective. 
3.7.1 Individuals’ decisions about risk management 
My analysis revealed that CVD risk is portrayed as something that is possible for people to 
control by taking action, whether by using medicines or changing lifestyle. The risk assessment 
process is not elaborated on to any particular extent; although there were indications of a 
measured risk score being a ‘guesstimate’ and dependent on the method used, the very concept 
of assessing risk in asymptomatic, middle-aged people was not questioned. Thus, the 
newspapers’ portrayal of CVD risk as a matter that deserves medical attention is in line with 
current national strategies for prevention of ill health. So are the indications that risk is 
controllable, and the concurrent advice that emphasises individual responsibility for 
cardiovascular health by combining information about early medical intervention with 
messages about the need to stop smoking, eat healthily and exercise.[65] 
In addition to the image of CVD risk as being closely linked to personal habits, the usage of 
medicines to manage the risk was also described as an issue for the individual to make decisions 
about. As part of their characteristic “personalisation” of news items, some of the newspapers 
introduced conflict and experiences alongside the scientific messages communicated from 
NICE and researchers. The most apparent example of the focus on the individual is the personal 
stories about side effects. Here it should be noted that the nature of risk management 
prescribing – where treatment success is an avoided episode, that is, a ‘non-event’ – makes it 
difficult to produce equally personal stories of good experiences from statins. However, 
whereas I found several articles where medical professionals who criticised the new guidance 
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were writing about their own problems with side effects, there were no examples of those 
supporting extended prescribing of statins saying how they themselves used and appreciated 
the medication. 
All the newspaper articles illustrated the benefits from statins using national figures for 
morbidity and mortality from CVD – the same outcome measures that were used by NICE in 
the press release about the updated guidance. The protective effect from statins was said to be 
due to lowering of cholesterol in the blood, but figures showing the risk reduction attributable 
to statins – either in absolute or relative numbers – were not mentioned anywhere. There was 
no straightforward discussion of the discrepancy between the effect measures ‘lowered risk 
due to lowered blood cholesterol’ that might be achievable for most people treated and ‘life 
saved’ that will be achieved by only a few. Rather, the frequent picturing of statins as life-
saving medicines points towards CVD risk management as a matter of life and death, with an 
inference somewhat like ‘all that lower their risk will survive’. 
Thus, my analysis points to a dualism in how the concept of benefit from medicines used for 
risk management is communicated: as a way to lower population-level morbidity and mortality 
and as an individually achievable protection against an equally individual CVD risk. What is 
implied by the professionals behind the guideline differs from the assumptions that might arise 
from newspapers’ reports about it. The potential of thousands of lives saved might help to 
provide patients with a rationale for wider prescribing, but falls short of the individualised 
benefits hinted at in the newspapers’ interpretation of risk management. 
A novel theme that emerged during the analysis was how the newspapers stressed the 
importance of making a personal choice about whether to use statins or not. This again points 
to individuals’ responsibilities in balancing risk, benefits and harms, and also highlights the 
different sources of information that are presented. As suggested by Gale and colleagues,[115] 
people are often confident that their GP can interpret scientific information about CVD for 
them, whereas for example academics are less trusted sources. Alongside the focus on 
experiences from using statins, advice from a family doctor was indeed put forward as an 
important resource in decision-making. No corresponding advice was given by the newspapers 
regarding the value of trusting academic researchers (apart from when they appeared as authors 
and stressed it themselves). Moreover, the difference in how quoted professionals were 
portrayed in the newspaper articles may influence how their advice is perceived. Those 
speaking of their own experience of statins as a reason for their critique of the guideline were 
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described in terms of their clinical work, while those citing clinical trial data in support of 
extended prescribing were presented as academics. 
Overall, the implications of the guideline on people’s decisions about CVR risk management 
is presented as a discussion about statins – the risk assessment process was not given much 
attention. In contrast to the perceived certainty about risk, medication introduces uncertainty. 
Two parallel accounts of statins are made available to people by the newspapers: they are both 
life-saving and sources of problems in the form of side effects. 
3.7.2 Risk management as a systems issue 
Alongside presentations of the use of statins as an issue for individuals to decide upon, the 
newspapers also discussed the new guideline in the context of cohort strategies for disease 
prevention. In this sense, a majority of articles contrasted the potential public health gains with 
critique against possible motives behind extended use of pharmaceuticals. 
The reliability of data underpinning the new guidance was questioned on the basis of limited 
access for researchers to evaluate it. So was the applicability of clinical trial data produced by 
pharmaceutical companies on patients in clinical practice and daily life. Representatives for the 
research team that showed benefit from extended prescribing of statins defend their conclusions 
with regards to large amounts of data, the low cost and relative safety of statins. As indicated 
by Fontana and colleagues [88] this might still not reflect people’s perception of what is an 
acceptable balance between benefit and harm to consider using statins. The debate in the 
newspapers over the incidence of side effects highlights a difference in priorities between the 
producers of guidelines and the people whose acceptance their implementation relies on: statins 
are not primarily critisised for their lack of effect but for the potential for side effects. From the 
perspective of patients’ understanding of CVD risk management, this points to a weakness in 
the dominance of clinical trials for investigating the effect of medicines, as trials are usually 
designed to show a certain efficacy but do not capture other aspects. Previous critical 
examinations of the reliance on private interests for the production of data about the use of 
medicines have also focused on the consequences in terms of overprescribing of products with 
questionable efficacy.[45,62] However, my analysis suggests that the UK newspapers have a 
different focus when reporting about medicines. 
An emerging theme in my analysis was the apparent unwillingness of newspapers to discuss 
the role of deprivation for the prevalence of CVD. Overall, the newspapers expressed criticism 
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towards increased prescribing of statins to tackle CVD but they failed to address possible 
systemic causes of ill health. References to social determinants of health [163] or community-
wide strategies [164] to limit the harm from foods, alcohol and tobacco were absent from the 
articles. 
Taken together, the newspapers frame both personal and public health aspects of CVD in a 
medical rather than a social context. This observation links directly to the theoretical 
framework that informed my analysis: media contributes to the societal understanding of health 
matters and to expectations of pharmaceutical interventions as a way of maintaining health.[56] 
Although the newspapers may question particular medicines, as was the case with statins in 
this particular study, their framing of CVD risk and its management in a medical and 
pharmaceutical context instead of for example a social one could contribute to increased 
prescribing. 
3.7.3 A patient decision aid 
The publication by NICE of a patient decision aid for statins [165] in November 2014 (after 
this review was finished) adds some aspects to my findings. Firstly, it confirms that the 
initiation of statins in primary prevention of CVD is indeed far from straightforward and 
requires careful balancing of potential risk, benefit and harm. Secondly, it contributes to 
framing the decision as one that the patient does – although guided by a medical professional, 
the emphasis is on the individual’s involvement. 
The decision aid spells out that (for most people) lifestyle changes should be carried out before 
considering taking a statin to reduce one’s risk of heart disease. Such changes are also presented 
in a medical context, as the guidance refers to the health care practitioner for support. In terms 
of describing interventions to manage risk, they are centered on atorvastatin, which is the 
recommended first-line treatment for lipid modification in prevention of CVD.[123] The 
decision aid also emphasizes that all people who lower their risk will not avoid disease, and 
that it is not possible to predict risk perfectly. It gives graphic presentations of different levels 
of risk and the possible impact of treatment with a statin. Data for the incidence of side effects 
are presented, and patients are given a rating tool to summarise the importance of various 
aspects of risk management from their own point of view. 
In relation to my findings regarding the public debate about CVD risk management and statins, 
this decision tool brings together many important aspects. However, it still frames CVD risk 
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as a medical issue with medical solutions, and there is no acknowledgement of where the 
evidence for benefit from statins at various risk levels, or the data on side effects, comes from. 
The criticism voiced in newspaper articles, situated in a wider critique against the lack of 
transparency in clinical trials [166,167] is not addressed by NICE. 
3.7.4 Validity of findings 
This investigation of newspapers’ descriptions of cardiovascular risk and usefulness of statins 
encompasses only a small part of the media portrayal of medicines at a particularly 
controversial point in time. However, it provided an opportunity to assess the media 
representation of a guideline that might expand the usage of medicines in the UK and represents 
the type of prescribing that is the topic for this thesis. Indications of newspapers taking on the 
role of helping patients make decisions about health and medicines justifies its place in my 
examination of influences on patients’ understanding of CVD risk management. 
The analysis presented here draws on a purposive selection of newspapers representing a 
variety of editorial and readership stances. A limitation of my analysis is introduced by the way 
I approached this particular type of literature. When surveying the representation of CVD risk 
and statins in the newspapers, I sought to include publications representing different 
readerships. The resulting dataset thus contained stories aimed at various segments of the 
population – groups for which, perhaps, CVD risk has different impact in terms of both 
epidemiology and views on its meaning. Alternative ways to explore the media messages about 
statins could have focused on a certain type of newspapers and how they present CVD risk to 
a particular segment of the population, e.g. the “red tops” or those with a middle-class 
readership. 
The representation of CVD risk and statins that emerges from my analysis builds on critical 
reading of the texts both as whole stories and as compilations of detailed information, and 
construction of themes from the data. Informed by theoretical descriptions of how media 
contribute to the popular image that all health problems can be solved with medicines, my 
attention was directed towards accounts that would support or challenge that. 
The included articles discussed many different aspects of CVD risk management and statins, 
including conflicting ideas about using medicines to individuals and populations, and thus my 
analysis gives a comprehensive overview of how a scientific debate may be represented in a 
lay context. 
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However, the richness and density of information in newspaper stories presented a 
methodological challenge in this study. Many of the included articles were quite long reports 
and heterogeneous in terms of arguments and voices; the accounts of journalists, experts (of 
opposing opinions) and ‘ordinary people’ were weaved together throughout the texts. As the 
analysis progressed from coding to categorising, I started to question the open coding approach 
since each data extract contained so much information that it was difficult to convey all the 
meaning in them. To resolve this, a stricter coding method based on quantification of pre-
defined concepts could perhaps have been helpful – although at the detriment of less depth in 
the analysis. Another approach that might have captured the complexity and the multiple levels 
of storytelling in the longer articles would be narrative analysis. My strategy for maintaining 
focus in the categorising of data despite these challenges was to use the research question as a 
filter, and remind myself to leave out data that did not relate directly to it. 
An alternative way of studying the media representation of CVD risk and statins would be to 
follow the development of stories in one or a few newspapers over time. Given the many 
conflicting accounts presented in the articles, this approach could add to the understanding of 
how patients might get confused by the debate over changing prescribing guidelines. 
These reservations regarding the best method for analysis have consequences for the 
authenticity of my findings, that is, their ability to fully represent the included stories and 
contexts. A narrative or quantitative approach would probably have produced rather different 
accounts of the rich sample. Nevertheless, with regards to my research question and in the 
wider context of this thesis, the findings do contribute a valuable and coherent interpretation 
of the portrayal of CVD in UK newspapers. 
In terms of transferability – whether the findings and their meaning also say anything about 
other medicines, health issues and interventions – the themes could apply to other clinical fields 
and discourses about health promotion, since they describe processes that are similar 
throughout preventive health work and risk management prescribing. One example of 
applicability of my findings is the strong focus on individual responsibility, views and 
experiences in health care which resonates with both current health policy and social trends. It 
offers useful knowledge for communications around disease prevention and health promotion, 
by showing how different messages are shaped when they reach the public debate. The 
newspapers’ portrayal of CVD risk in an almost exclusively medical context also raises the 
question about the development of public health research. 
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3.8 Conclusions 
This analysis of newspapers’ accounts of an updated clinical guideline provides insights into 
an important aspect of strategies for disease prevention, namely how they might be represented 
in the social world and thereby contribute to patients’ understanding. In this study, I have seen 
how two parallel descriptions of CVD risk management can exist side by side; one building on 
personal responsibility, decisions and experiences and one driven by data and policies. 
The message from NICE focusing on population-level outcomes was delivered alongside 
individual perspectives on possible benefits and harms with statins when published by the 
newspapers. Personal experiences of statins use are contrasted with experts’ data about the 
effects, and the newspapers fail to reconcile the potential conflict between outcomes on the 
individual and population levels. Moreover, the newspapers discussed the motives behind the 
new guideline against the background of limited independent evaluation of data. 
The newspapers’ presentation of CVD risk as something measurable and controllable supports 
the message in national policies for disease prevention. Personal responsibility for health and 
disease prevention was put forward in the articles, strengthening the individual focus while 
leaving out structural factors influencing health. Most of the discussion focused on arguments 
for and against the extended prescribing and use of statins, and did not elaborate on the CVD 
risk itself. As I now turn to the empirical part of this research project, I aim to find out how 
patients understand both the diagnosed risk and the medicines that are prescribed against it. 
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Table 3.3 Articles included in the analysis, presented in chronological order. 
Newspaper Date Headline Type of text 
Daily Mirror 12-02-14 Another 5M in line for statins boost Editorial; news 
Daily Mail 12-02-14 Millions more to be prescribed daily statin Editorial; reporting the guideline update 
The Guardian 12-02-14 Nice recommends statins for millions more NHS patients: 10% risk of 
cardiovascular disease deemed enough: Critics suggest side effects will 
outweigh benefits 
Editorial; reporting the guideline update 
The Daily Telegraph 12-02-14 Statins to be given to one in four adults; Mass-medication is backed by 
evidence 
Editorial; reporting the guideline update 
The Times 12-02-14 Millions more qualify for drugs to cut heart disease Editorial; reporting the guideline update 
Daily Mail 13-02-14 The great statins divide Medical professional’s contribution; critical 
to the new guideline 
Daily Mail 13-02-14 Statins are cheap and effective way of avoiding 10,000 heart attacks 
and strokes a year, claims top academic 
Medical professional’s contribution; 
supportive of the new guideline 
The Daily Telegraph 13-02-14 Mass medication has serious side effects; The advice on statins is part 
of a medical trend that treats populations rather than people 
Editorial; opinion/column about the guideline 
update 
The Daily Telegraph 15-02-14 Why we're going to keep taking the tablets; the health agency with the 
twee acronym is guaranteed to get our blood pressure rising 
Editorial; opinion/column about  the 
guideline update 
Daily Mail 17-02-14 Ask the doctor Medical professional’s contribution; column 
The Sun 18-02-14 The healthometer Editorial; reporting the guideline update 
The Sun 18-02-14 TXT US Readers’ contributions 
Daily Mail 18-02-14 Why do so many GPs say they won’t take statins Editorial; focusing on the article showing 
statins do not cause side effects  
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The Guardian 22-02-14 Doctors' doubts over statins may be putting lives at risk Editorial; focusing on the argument between 
academics 
The Guardian 22-02-14 Statins-for-all debate becomes a prescription for big medical row: 
Doctors at odds over advice that taking anti-cholesterol pills should 
become the norm 
Editorial; summarising the guideline update 
and the argument over side effects 
The Guardian 24-02-14 The drugs don’t work: The claims being made for statins are 
overblown 
Medical professional’s contribution; critical 
to the new guideline 
Daily Mail 24-02-14 Doctors’ fear over statins are putting lives at risk Editorial; focusing on the argument between 
academics 
The Times 25-02-14 QA (readers’ contributions) Readers’ contributions 
The Daily Telegraph 03-03-14 Doctors warn over side effects of statins Editorial; reporting the guideline update 
The Guardian 13-03-14 Statin side effects minimal, study finds Editorial; reporting the guideline update 
The Daily Telegraph 13-03-14 Statins ‘have no side effects’ Editorial; reporting the guideline update 
The Daily Telegraph 22-03-14 Statins scaremongering will cost lives, expert warns Editorial; focusing on the argument between 
academics 
The Daily Telegraph 24-03-14 Why I've ditched my anti-cholesterol drugs for good; As experts clash 
over proposals that millions more take statins to prevent heart disease 
and stroke, vascular surgeon says he has never felt better 
Medical professional’s contribution; critical 
to the new guideline 
The Times 25-03-14 Statins could save your life but these are the risks you must know 
about 
Medical professional’s contribution; critical 
to the new guideline 
The Times 30-03-14 Millions to get statins despite missing data Editorial; focusing on the argument between 
academics 
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Chapter 4 
Empirical research methods 
 
4.1 Chapter overview: choosing research methods 
This chapter describes the methodological choices and the methods used in my empirical study. 
It explains the choice of research design and outlines the principles of recruitment of research 
participants, how data collection was done, how the data was analysed and how I will examine 
the trustworthiness of my findings. 
In this empirical part of my study, I return to the research problem that was formulated in 
chapter 1. Here, I will explore patients’ understanding of cardiovascular risk management and 
how it can add to a more comprehensive characterisation of polypharmacy. So far, I have 
examined influences on patients’ views of medicines through the critical examination of two 
published datasets: the academic literature on patients’ expectations of medicines and the lay 
press portrayal of CVD risk and risk management (see chapter 2 and 3, respectively). The 
findings from those studies raised a number of ideas that I now seek to explore further through 
empirical investigation. Firstly, I want to find out more about how people make sense of the 
asymptomatic ‘condition’ of being at risk for CVD, and especially how that understanding 
shapes decisions about using medicines (or not) to manage the risk. Secondly, I want to find 
examples of how people picture the possible benefits from medicines, for example if and how 
expectations of personal gains are negotiated with proposed outcomes on the population level. 
Thirdly, I want to see which sources of information people draw on when making decisions 
about CVD risk management and evaluating medicines. The research question I am asking is: 
“How do patients conceptualise CVD risk management with medicines?” 
 
4.2 Defining a conceptual framework 
As pointed out by Miles and Huberman,[94] research does not take place in a vacuum. Ideas 
and knowledge held by individual researchers and the wider community shape the questions 
we ask when designing studies and the way data are collected and analysed to create new 
knowledge. Identifying these concepts clarifies important relations and sources of information 
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for a particular study – they form a conceptual framework of key factors and associations to be 
studied. It also allows for critical examination of the research process and the findings. 
The conceptual framework for my study includes the ideas outlined in the theoretical 
background given in chapter 1, section 1.3; the pharmaceuticalisation critique [46,47,54,56] 
and the acknowledgement of patients’ practices, experiences and expertise as influential in 
their own use of medicines.[41] The main components of each concept are shown in table 4.1, 
and discussed further below. 
Table 4.1 Components of my conceptual framework; aspects of the pharmaceuticalisation critique and 
patients’ agency in medicine-taking. 
Conceptual framework component How it might be perceived in my study 
Pharmaceuticalisation  
New or changed definitions of health problems 
suggest that more conditions should be treated with 
medicines 
How patients might understand the 
condition of being at risk for CVD, and the 
role of medicines in treating it 
The medicines market is subject to changes that gives 
the pharmaceutical industry greater influence on the 
production and dissemination of information about 
medicines 
Patients thoughts about the scientific 
background for CVD risk management 
Media portrayal of health and disease supports the 
notion that all health problems can be solved with 
medicines 
How information from the social world 
might be used to understand medicines 
Increased use of medicines is presented as medical 
progress; new products and extended prescribing are 
said to fulfil health needs and pharmaceutical 
development is communicated as helping the sick 
Informing patients’ views on the increased 
prescribing for primary prevention of CVD 
Patients’ agency in medicine-taking  
Personal goals, experience, priorities and ideas of 
health and illness as well as notions of morality and 
responsibility influence how medicines are viewed 
and used 
How CVD risk management medicines fit 
in with patients’ views of their own health 
Choices to take or reject medicines are not merely 
following or not following instructions based on 
biomedical aspects of health, but also represent active 
actions based on personal understanding of prescribed 
medicines 
Many different types of knowledge and 
expertise might be available from patients 
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First, as described in chapter 1 (see section 1.3.3), is the theoretical work describing the concept 
of pharmaceuticalisation.[54,56] It outlines how circumstances in the social world influences 
the way in which medicines are prescribed and used. Among other things, this body of research 
indicates that the current model for producing and applying knowledge about the use of 
medicines and their possible benefit and harm is a cause for concern, through the potential to 
create iatrogenic effects in health care. Pharmaceuticalisation theorists propose that biomedical 
arguments are used in health care policy and practice to justify the need for pharmaceutical 
intervention. The dominance of a positivist scientific paradigm and the increasing influence 
from pharmaceutical companies over the available knowledge about medicines shapes the 
discourse around disease and treatment.[45,55,168]. Since most usage of medicines takes place 
in more complex, real-life situations there are growing concerns over the consequences of the 
current system.[35] This component of the conceptual framework acknowledges that the type 
of knowledge about medicines that is made available, and how it is presented, will have an 
impact on how medicines are used. 
The second component of the conceptual framework for this study frames the objectives of the 
two examinations of literature (see chapters 2 and 3), namely the recognition of patients’ own 
experience-based expertise in using health care services and medicines. Patients’ expertise is 
often different from the knowledge held by professionals, as it includes things like how to 
negotiate medicine-taking with social roles and obligations or how to balance effects from 
medicines with illness symptoms in the context of everyday life.[41] Yet it has the potential to 
influence health outcomes, since perceptions about both medicines and conditions influence 
how people choose to engage with treatment.[39,102] As described in chapter 2, patients’ 
views of medicines are dynamic and encompass dimensions that fall both within and outside a 
biomedical description. The conceptual framework for my empirical study therefore recognises 
social discourses on health, disease, illness and treatment [42,169], lay understanding and 
application or rejection of scientific knowledge [64,98] and prescriber-patient relations 
[170,171] as influential on how medicines are used. In relation to this particular study, the 
range of practices and influences that potentially surround people’s use of medicines prescribed 
to manage a CVD risk condition indicates that the biomedical model in only one of many 
possible descriptions. 
Together, the two parts of my conceptual framework outline that I am exploring patients’ 
understanding of CVD risk management medicines with an aim to explicitly include 
experiential as well as societal representations of health and medicines. 
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4.3 Methodological approach 
My conceptual framework thus describes a need to recognise that patients’ understanding of 
risk management may be different from the current, biomedical view that informs present 
prescribing policy and practice. This has implications for the ontological and epistemological 
approaches in the research, for which a background was outlined in chapter 1, section 1.5. 
Ontology refers to the understanding of what or how the world ‘is’, and from that follows an 
epistemological perspective of what constitutes knowledge about the world. Applied to my 
study, this describes what CVD risk and medicines are, and what ‘counts’ as valid knowledge 
about them. The knowledge I seek to produce in this study includes more perspectives than the 
biomedical, and the theoretical background that informed my research approach highlights for 
example patients’ experiences and practices and changes in the social world as influential on 
how medicines are used. In order to allow for more than one possible definition of CVD risk 
and medicines, and let multiple types of knowledge add to the understanding about them, I 
adopted a critical realist view in my research. 
Applied to my study, a critical realist perspective means that CVD risk exists not only by its 
biomedical definition; the associations between blood pressure, cholesterol and incidence of 
acute events. It is also present in the form of people’s views of what causes risk, how to act to 
manage it and which sources of information to trust for guidance. Similarly, CVD risk 
management medicines are not only represented by their effects on physiological processes 
and population mortality, but also by the moral aspects and values that people attach to them. 
As mentioned above, the ontological view in research informs the epistemological perspective; 
what is regarded as knowledge about the topic. This has implications for the methodology for 
creating knowledge – in which forms it is available and how it can be gathered. Kvale and 
Brinkmann [172] use the examples of a miner and a traveller to illustrate different types of 
knowledge production, where the former looks for pre-established concepts that can be ‘dug 
out’, and the latter creates and adjusts the knowledge in interaction with research participants 
‘along the way’. 
A study informed by a biomedical model of health might be designed to identify and quantify 
pre-established facts about medicines and risk in patients’ accounts, for example by using a 
survey to check what people know about heart disease or how often they experience a particular 
type of side effect. In contrast, in this study designed to form new theoretical understanding of 
a phenomenon beyond a biomedical description, the possible knowledge about what CVD risk 
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and medicines are, and how they might be related to health and illness, is not defined 
beforehand. Instead, knowledge will be generated as a result of questions, answers and 
interpretations throughout a research process that aims to produce a rich understanding of the 
topic. This view of knowledge has implications for my choice of research methods, which are 
described below. 
 
4.4 Recruitment and sampling of research participants 
The recruitment of participants depends on the research topic and question, the conceptual 
framework for the study and also practical aspects like time, budget and experience of the 
researcher.[94,173] In this study, recruitment and sampling were planned using Miles and 
Huberman’s and Lincoln and Guba’s advice for purposive and maximum variation 
sampling.[94,96] This choice reflects the study aim of exploring more understandings of CVD 
risk management than what fits into the biomedical definition of it. By striving for variation 
between my participants, I aimed at capturing as many aspects as possible of patients’ views 
and experiences. However, for practical reasons all participants were recruited in Liverpool. 
Ethical approval for the interview study was sought prior to any contact with research 
participants. It was granted by NRESC NW, Haydock; reference number 13/NW/0387 on June 
28, 2013 (see appendix A3). 
4.4.1 Participant population 
This study is concerned with patients’ ideas about the medicines that are prescribed to them for 
primary or secondary cardiovascular risk management. Since I was interested in long-term risk 
management rather than acute interventions, and such prescribing and monitoring is mainly 
done by GPs, I recruited participants to the study among patients listed with GP practices. 
Findings in the study of influences on patients’ expectations of medicines (see chapter 2) 
indicate that experiences of ill health and medicines’ effects over time are taken into account 
as patients develop their understanding of conditions. Therefore, I anticipated possible 
differences between how patients with little or no experience of ill health view risk 
management medicines compared to those that have conditions that impact on their daily life. 
Calnan [42] even suggests that people only learn about medical care through personal or 
vicarious experience of it. Therefore, previous experiences of ill health could be influential so 
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that people at high and low risk might reason differently about benefits from prescribed 
medicines. Information about treatments given to the patient by doctors and other health care 
professionals might also differ depending on the level of CVD risk, and including patients at 
both low and high risk could therefore give examples of different types of communication 
about risk. 
4.4.2 Invitation to GP practices 
An invitation to participate in the research study by recruiting patients for interviews was sent 
to 32 GP practices in Liverpool, a city in Northwest England with areas of both high and lower 
socioeconomic deprivation. Practices from across the city were invited, to allow for a purposive 
sample across areas of different socioeconomic status. The stratification of socioeconomic 
status was done using the Deprivation mapper published by the UK Department for 
Communities and Local Government’s official website for local data; 
http://opendatacommunities.org/showcase/deprivation, which displays deprivation by deciles 
(with decile 1 representing the most deprived and 10 the least deprived areas).[174] Invitations 
were sent by post to practice managers and followed up with phone calls. Initially, only one 
practice in a decile 4 area with an uptake of patients from deciles 3 to 8 agreed to participate. 
Fourteen other practices were reached by phone or email but declined due to time constraints, 
and the rest did not respond in any way. Personal contacts by myself and my supervisors led to 
two more practices, situated in decile 1 areas in different parts of Liverpool, agreeing to recruit 
patients. 
4.4.3 Identification and recruitment of patients 
Inclusion and exclusion criteria in the searches were chosen to identify patients at low and high 
risk for CVD, while also being feasible in terms of doing the database searches. For a discussion 
of the limitations of my search strategy, see chapter 8, section 8.3. The eligibility criteria are 
displayed in table 4.2. The combination of a low and a high risk group aimed at recruiting 
participants with asymptomatic CVD risk (such as the presence of one or more risk factors) as 
well as people with symptomatic heart conditions. All searches for eligible patients among the 
practice population were done by practice managers and/or staff members responsible for 
databases. 
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Table 4.2 Inclusion and exclusion criteria for the interview study. 
L
o
w
 r
is
k
 
 Criterion Explanation 
E
li
g
ib
il
it
y
 
Age 40-74 years The age range for NHS Health Check; a screening 
programme for heart disease, stroke, kidney disease, type II 
diabetes and dementia which is offered to all adults in 
England without pre-existing conditions 
10 year CVD risk ≥20%* Threshold for primary prevention of CVD to be initiated, 
according to NICE guidelines for lipid modification 
(CG67)** and hypertension (CG127) 
Prescribed CVD risk 
management medication 
within the last 6 months 
Including anti-hypertensives (calcium-channel blockers, 
diuretics, beta-blockers, ACE-inhibitors and angiotensin II-
receptor antagonists) and statins 
E
x
cl
u
si
o
n
 Diagnosed with ischaemic 
heart disease, atrial 
fibrillation, stroke, heart 
failure or diabetes 
No previous symptomatic heart condition 
H
ig
h
 r
is
k
 
E
li
g
ib
il
it
y
 Age 18 years or older 
In the QOF register of 
heart failure patients 
Any adult could participate 
Including NYHA classes I-IV, acute and congestive heart 
failure, left and right ventricular failure 
E
x
cl
u
si
o
n
 Myocardial infarction <12 
months ago 
Patients needed to be stable on medication 
A
ll
 p
a
ti
en
ts
 
O
v
er
a
ll
 e
x
cl
u
si
o
n
 c
ri
te
ri
a
 
Not on end-of-life care Not ethically justifiable to include people in research when 
they are unlikely to benefit from it 
Not in residential care Having medications dispensed, and also ethically 
questionable (as above) 
Under 18 years old Only adults were eligible to take part 
Unable to give consent Informed consent is a prerequisite for partaking in research 
Unable to speak or 
understand English  
Practical reasons 
Deemed unsuitable to 
participate by GP 
Practical and ethical reasons 
 
* A person is considered at 20% or higher risk for having a heart attack or stroke in the next 10 years. 
** The threshold for lipid modification has since changed. 
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Low risk patients were identified in the age group 40-74 years by using functions in the 
practices’ database which picked up all patients that had been diagnosed as ‘at 20% or greater 
risk for CVD in the next 10 years’ and had been prescribed medication to manage CVD risk 
within the previous six months. The medicines that were used as search criteria were various 
types of anti-hypertensives (calcium-channel blockers, diuretics, beta-blockers, ACE-
inhibitors and angiotensin II-receptor antagonists) and statins. In some practices the search 
function was called “10 year CVD risk – Framingham”, and in some “QRISK2”. Patients 
diagnosed with ischaemic heart disease, arterial fibrillation, stroke or heart failure were 
excluded in this search, in an aim to reach patients with little or no experience of symptomatic 
CVD.  
High risk patients were identified as adults on the practice’s Quality Outcomes Framework 
[175] register of heart failure patients. Here, the aim was to reach participants living with 
symptomatic CVD. To ensure that participants had some experience of using risk management 
medicines, anyone that had had a myocardial infarction in the last 12 months was excluded. 
From the database searches, a list of patient names was put together for partner GPs at the 
practice to review and from personal knowledge identify anyone that met the exclusion criteria. 
Since the database searches returned more patients than I planned to recruit from each practice, 
the list of names was condensed by the person who did the search for me. This was done by 
hand but according to a principle; selecting for example every third name or the first ten on 
each page. 
The condensed list of these was reviewed by partner GPs at the practice to identify anyone that 
met the exclusion criteria. These were: living in residential care, being in Gold Standards 
Framework or other palliative care, inability to give informed consent or participate in an 
interview in English or deemed unsuitable to participate in an interview study for any other 
reason. People in palliative care were excluded on the basis that their views on health risks and 
possible harm and benefit from medicines might be heavily influenced by their terminal 
condition, and the research undertaken here is unlikely to benefit them in a way that would 
justify taking up their time. Similarly, people in residential care might be frail enough to make 
it questionable if they would benefit from the research. Care home dwellers’ relation to 
medicines might also be different from that of independently living people due to the 
circumstance that they do not entirely decide for themselves about how to use medicines. Since 
the interviews needed to be conducted in English and research cannot be undertaken without 
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the participants’ informed consent, anyone who did not meet these criteria had to be excluded. 
The final exclusion criterion was applied so that GPs could use their personal knowledge of 
patients to avoid anyone not suitable for participating in the study being contacted by the 
researcher. The remaining patients were invited to join the study. 
An invitation letter (appendix A4) was sent to 300 eligible patients from the practices. Along 
with the letter was a participant information leaflet (appendix A5), a consent form (appendix 
A6) outlining the details of anonymity and data protection and specifying that the interview 
would be recorded, and a questionnaire (appendix A7) asking about contact details, age, 
gender, number of medicines, physical and mental wellbeing, current medical problems and 
duration of any heart problems. All invitation material was approved by the Research Ethics 
Committee. Twenty eight patients replied stating an interest to participate in the study. 
4.4.4 Selection of participants 
A purposive sampling of patients was done among those that expressed their interest to 
participate in the study. The sampling frame is available in appendix A8. When selecting 
participants, I followed the principles of sampling by maximum variation.[94,96] This is a non-
random method that seeks to produce a sample in which the investigated phenomenon can be 
explored from as many different angles as possible, within a group of participants where it is 
likely to occur. Within the sample, each case represents its’ own unique and distinct relation to 
the studied phenomenon, so that rich descriptions can be collected. It also offers a possibility 
to look for shared features or central aspects of the studied topic to be identified across different 
types of accounts.[176] 
Categories in the sampling frame [94] were: gender (male or female), age (18-40, 41-60, 61-
80, 80+ years), recent or long-standing diagnosis, single or multiple conditions, self-reported 
health status (good, mixed or bad on indicators of physical and mental wellbeing) and number 
of medicines (no, 1-5 or more than 5 medicines per day). 
The age and gender criteria were applied to get a wide representation from different stages of 
life. The other categories were informed by the literature review (see chapter 2), notably the 
influence on expectations of medicines’ effects from different experiences of living with ill 
health and how such expectations might change over time. By seeking representation of 
different numbers and duration of health conditions, I aimed to speak to people that had 
experienced from little to considerable ill health and contact with health care. Self-reported 
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physical and mental health status were used to achieve variation in terms of how people might 
associate CVD with being ill or healthy, and also to include patients that might both manage 
well and struggle with their daily life. The number of medicines used every day was used to 
allow for results to possibly be examined in relation to the quantitative literature on 
polypharmacy. 
The number of included participants was not decided beforehand, but instead determined in 
relation to the analysis of data, which ran alongside data collection. When no new or relevant 
insights are added by additional interviews, the data material is regarded as saturated with 
information about the researched phenomenon and data collection ends.[94]  
4.4.5 Limitations of the recruitment methods and inclusion criteria 
Since the setting for this study is UK primary care, I recruited patients via GP practices. This 
limits the potential participants to people that have at least some contact with the NHS and that 
are likely to have heard some description of CVD risk being presented by their GP. The search 
criteria, which aimed to find one group of patients that had been diagnosed as ‘at 20% or greater 
risk for CVD within 10 years’ and prescribed one or more medicines to manage the risk, and 
one group that had experiences tangible heart-related ill health, were chosen to identify patients 
with a range of possible views on CVD risk. Other sets of search criteria, for example focusing 
on particular risk factors (such as type II diabetes, smoking, obesity or previous myocardial 
infarction) had also been possible to apply in order to reach people at risk for CVD. 
 
4.5 Data collection 
Several methods of data collection are possible to learn about patients’ understanding of 
medicines, for example focus groups, participant observation, case studies and various forms 
of interviews.[173] They all have the potential to generate new knowledge about the research 
topic, but differ in the type of accounts that might be made available. Focus groups could 
encourage sharing of experiences and discussions between patients and thus reflect multiple 
angles, but at the cost of less depth of individual accounts and less opportunity for the 
researcher to follow up particular issues. Observations could offer insights into practical 
aspects of medicine usage, but that was not the scope of this particular study. Case studies and 
narrative interviews would be a way to explore in depth certain participants’ sense-making, but 
might produce findings that would be quite difficult to apply to a larger context. Considering 
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my aim to explore a combination of biomedical and social understandings of risk, medicines’ 
role in managing risk and what might influence how patients make sense of it all, I chose semi-
structured interviews as the method for data collection. This approach uses conversation 
between the researcher and the participant to gather knowledge from experiences, opinions and 
beliefs while allowing for many different types of descriptions to be shared and developed. The 
interview method was mainly informed by Kvale and Brinkmann’s discussion of qualitative 
research interviewing.[172] 
My approach was that each interview was an opportunity to create new knowledge in the 
interaction between a participant and myself in the role of researcher. To be able to fully engage 
in the conversation and focus on what participants were telling me, I recorded all interviews 
digitally. The recordings were then transcribed verbatim for analysis. 
4.5.1 Arranging interviews 
Patients who returned the questionnaire stating their interest in participating in the study were 
contacted via telephone. The sampling frame was used to prioritise which respondents to 
approach. If I could not reach a patient after repeated attempts (typically trying for two weeks 
after the arrival of their declaration of interest), they were removed from the list of possible 
participants. When calling the potential participants, I confirmed their interest in the study and 
explained what it would entail to participate. Interviews were arranged at the participant’s 
convenience, either in their home or at the University. 
4.5.2 Consent 
All interview sessions started with a brief explanation of each point in the consent form 
(appendix A6), outlining how the recorded and transcribed data would be stored, protected and 
used. All participants consented to interviews being recorded digitally and data being used for 
research purposes. The form was signed by the research participant and me before the recording 
started. 
4.5.3 The interview schedule – preparing to gather information about my research topic 
The interviews were guided by an interview schedule which was adjusted during the course of 
the study to incorporate further exploration of emerging findings (the initial and final versions 
are shown in appendix A9). Since the recruitment of interview participants took longer than 
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expected, the two literature reviews described in chapters 2 and 3 came to run alongside the 
empirical data collection and therefore informed my interview questions. 
The interview schedule consisted of open-ended questions and prompts for following up 
answers. The questions manage the overall course of the interview, including ‘ice-breakers’ 
and concluding phrases, and the prompts are sub-questions for the researcher to use so that as 
many aspects as possible are covered.[172,173] 
Questions and prompts are connected to the theoretical background of the study, in terms of 
concepts to test and what type of information the researcher is looking for. My interview 
questions were formulated from the research question following the process described by 
Wengraf, where concepts from theory and previous research that informs the study are 
‘operationalised’ via theoretical research questions to empirical indicators that are useful as 
interview questions.[177] For example, the assumptions about societal influences on patients’ 
expectations of benefit from medicines that make up the characterisation of 
pharmaceuticalisation [56] (see chapter 1, section 1.3.3) informed theoretical questions which 
in turn shaped the development of my study protocol and the interview schedule. In 
conversation with participants, these concepts were addressed in terms of where the participant 
might look for information about medicines and how they regarded information from different 
sources. 
The questions were designed to contribute both thematically (to support the knowledge 
production) and dynamically (to support the interaction between participant and researcher) to 
the interview.[172] Thematic contribution came from direct questions about the participant’s 
experiences with CVD and medicine-taking, while dynamic contribution was sought by 
adapting the conversation to explore health-related issues that participants themselves brought 
up. Open-ended questions were used to elicit responses that showed participants’ reasoning 
around the topic, and also give a hint about how they had understood the question. In addition 
to the prepared questions and prompts outlined in the interview schedules, direct and indirect 
questions were used during the interviews to follow up, explore and clarify topics that the 
participants mentioned. To simplify my own use of the interview schedule, and thereby keep 
as much focus as possible on research participants, I constructed a graphical representation of 
the questions and prompts (see figure 4.a). 
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Figure 4.a The graphic version of the interview schedule. A full version is available in appendix A9. 
 
Early questions focused on opening the interview and emphasising that the study was about 
participants’ own views and experiences of using medicines. From these questions I aimed to 
get an initial picture of whether medicines represented something significant or un-interesting, 
whether medicines seemed to take up a lot or a little time and effort and whether they fit into 
or disturbed the participant’s daily life. Circumstances around the start of the treatment were 
elicited to guide further questions about experiences and views of for example health screening 
or acute illness. 
The following questions and prompts focused on any medicines mentioned as being used for 
cardiovascular conditions; “for high blood pressure”, “for the heart” or “for the cholesterol”. 
These questions sought to elicit what information about the condition and the medicines the 
participant had been given before treatment started, how the participant found it using the 
medicines, and whether there had been any evaluation of the effects of the treatment. One 
question addressed patients’ need for information and usage of information sources, with 
prompts to test where information was sought (internet, friends and family, professionals, 
written information such as patient information leaflets or books) and how they valued 
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information from different channels. Participants’ balancing of health risks and possible 
benefits and harms from medicines was addressed in questions about whether the participant 
found it worth the effort to take medicines every day, and if there was anything they would 
want to change about their medicines. Interviews were concluded with a question that let the 
participant address any topic that they might think had been omitted: “Is there anything more 
you would like to say?” 
As expected, the interview schedule was changed during the course of the fieldwork. 
Participants told me things that I had not previously thought to put in connection with each 
other, and surprising replies served as new prompts in later interviews. Statements from early 
interviews could be used to challenge or question participants at a later stage of the study, in 
the form of “some people say it’s like this, what do you think about that?” Changes were also 
brought about by my growing experience in the interview situation and in the role as a 
researcher. Every completed interview introduced adaptation and development of the interview 
questions in the following ones, since statements and replies from participants challenged my 
previous views of how things might be connected. 
4.5.4 Interview structure – finding out about participants’ experiences 
A semi-structured interview is not a test of the participant’s formalised knowledge. Neither 
does the researcher expect the participant to deliver statements that directly convey 
comprehensive ‘solutions’ to the concepts that are discussed. Instead, the interview is an 
occasion where new knowledge is constructed in the interaction between the researcher’s pre-
understanding of the topic and the participant’s shared experiences, opinions and 
thoughts.[172] 
The seemingly simple opening question “Can I start by asking you what medicines you are 
using at the moment?” elicited some short, factual answers focusing on medicines’ names and 
some long, narrative responses that included both formal diagnoses and personal reasons for 
using medicines. Based on these initial descriptions, I continued with questions from the 
interview schedule adapted to the situation. In accordance with the analogy of mining and 
travelling (see section 4.3), most of the interviews followed the ‘travelling’ trajectory since my 
questioning was closely adapted to how participants answered my questions or brought in 
topics to the conversation. However, ‘mining’ questions were used to explore concepts that 
participants seemed to have given considerable thought or when they surprised me with an 
answer that I needed to try and make sense of in the moment. 
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By adapting the questions towards medicines or a diagnosis mentioned by the participant, I 
sought to elicit examples of how the CVD risk condition and possible management of it had 
manifested itself or been presented to them – how they had made sense of the situation and 
which decisions they had made. To be able to compare patients’ views with a biomedical way 
of showing clinical effectiveness, I was also interested to specifically hear patients’ thoughts 
about the evaluation of prescribed medicines – whether they thought or felt that the tablets did 
something good. Participants’ balancing of health risks with possible benefits and harms from 
medicines was addressed for the same reason. 
The findings in the literature review (see chapter 2, sections 2.4.1-2.4.4) were tested during the 
interviews, to develop the understanding of patients’ expectations on medicines that are 
prescribed for the purpose of risk management. For example, one theme showed how patients 
might anticipate specific effects from medicines. Another theme was the development and 
adjustment of expectations over time. In the interviews, I explored these concepts in relation 
to CVD risk management by asking participants what they though the tablets were doing for 
them and whether their opinions had changed over time and with experience of using 
medicines. 
To conclude the interview, and to signal to patients that the meeting was coming towards an 
end I used the phrase “Now I think I have asked you about the things I had thought of before, 
is there anything more you want to add or discuss?” Thus, participants were invited to show 
what they thought was important in what we had discussed or if some valuable aspect had been 
omitted. Finally, I thanked participants for their time and contribution to the study. 
After each interview I noted down my impressions from the encounter together with structural 
aspects of the conversation, as support for the data analysis.[94,173] Examples of these types 
of notes were things that might have shaped my questioning during particular interviews; 
emerging thoughts about what had motivated participants to join the study and how the location 
for the interview influenced the interaction. A pseudonym was assigned to each interview 
participant by using a method that was suggested in qualitative research online forums: I chose 
a name with the same initial letter as the participant’s name that was popular in the decade 
when they were born. An advantage of this technique is that some consistency is kept between 
‘voices’ in the data and the generation they stem from. 
 
  
73 
 
4.6 Data analysis 
In my analysis of participants’ accounts, I took the approach described by Kvale and 
Brinkmann as ‘interview analysis focusing on the meaning’.[172] It entails finding information 
that is meaningful in relation to the research question among the many stories told during 
interviews, connecting that meaning to the research problem and then constructing a new story 
that can be told to show and share the new knowledge that was created between researcher and 
participants. In order to construct that story, I needed to condense the interview transcripts into 
an interpretive framework that displayed the new knowledge created in my study. 
As my objective was to develop new theoretical understanding from the empirical data, I took 
an inductive stance throughout the process. The inductive approach means that the analysis is 
driven by what is found in the data, with questions and hypotheses evolving and being tested 
throughout the process. This differs from a deductive analysis, which looks at the data using 
pre-formulated questions or theory and seeks to test or confirm certain concepts.[96,100,172] 
An inductive approach, however, does not isolate the analysis from the researcher’s previous 
knowledge derived from theoretical or empirical examinations of related topics. Obvious 
influences on my attention and understanding were the literature reviews presented in chapter 
2 and 3, which had highlighted aspects of individualism, responsibility and expectations of 
specific effects from medicines as issues to explore further. The conceptual framing of the 
study also contributed ideas that informed my analysis. 
For the organisation, interpretation and synthesis of participants’ many contributions of 
knowledge about the research topic into the ‘researchers’ story’, I applied thematic 
analysis.[137] Given my choice of a critical realist perspective,[91] this flexible analytic 
method can accommodate for various types of understanding and meaning attached to CVD 
risk and medicines among research participants and in relation to the frameworks that informed 
my analysis. 
The specific steps in my thematic analysis of data [100,137] were a combination of methods 
used in many qualitative research techniques; open coding and categorisation of data extracts 
based on constant comparison of meaning [178] and condensation of data by means of using a 
coding frame.[94] An overview of the process is shown in figure 4.b, and each step is described 
in the following sections. 
  
74 
 
 
Figure 4.b Overview over the analysis steps. Text in italics shows the use of different methods 
throughout the process. 
 
4.6.1 Defining data 
Following on from the ontological and epistemological views in this study, I regarded many 
different types of information as possible contributions to the descriptions of CVD risk and risk 
management. Data in the study were not only ‘results’ indicating for example presence or 
absence of certain features in participants’ accounts.[96] All parts of participants’ accounts 
were seen as data, including their answers to my questions and the way that they shared 
examples and stories. For example, biomedical and social accounts of reality were allowed to 
exist side by side or complement each other as I constructed the story about patients’ 
understanding of CVD risk management. Practically, it meant that I did not seek in any way to 
dispute or deny the presence of a real CVD risk in patients (for example individuals’ likelihood 
of suffering a cardiovascular event being higher than average), but I simultaneously looked for 
other descriptions of risk and medicines’ effects. Moreover, my field notes – recorded 
impressions from each interview encounter – and notes collected throughout the analysis 
process added to the data.[178] The field notes provided contextual information to each of the 
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accounts by reminding me of whether participants seemed for example interested, nervous or 
relaxed when talking about medicines and their health or whether things happened during the 
conversations that might have influenced what we talked about. Notes recorded throughout the 
analysis process helped me move from details towards more general descriptions by becoming 
a bank of emerging explanations to be tested, developed or discarded as the analysis proceeded. 
4.6.2 Inductive open coding to identify early themes 
My structured examination of the interviews started in parallel with the fieldwork. All 
interviews were first considered in their entirety – by listening to recordings while reading the 
verbatim transcripts – so that I would get familiar with the data and refresh my memory of each 
particular conversation.[137] Early reading of the transcripts was also an opportunity for me to 
reflect on how the questions and prompts shaped the conversation. Critical reviewing allowed 
for adjustment of the interview schedule according to emerging findings that challenged any a 
priori concepts from the planning of the study. An example is how I refined the interview 
schedule as I gained experience of how participants described their CVD risk conditions, see 
appendix A9. 
After getting an overview over the transcripts, the first step in structuring my whole data 
material into a dataset in which I could search for themes was to do an inductive open 
coding.[94,173] This is a way of identifying words, sentences or longer pieces of text that relate 
in some way to the researched phenomenon. Assembling examples like this transfers the 
foundation for analysis from the many individual accounts to one rich and diverse collection 
of descriptions of the phenomenon under study.[100] 
In my study, this meant reading the transcripts line-by-line while identifying and collating 
examples that showed or explained something about how participants made sense of CVD risk 
and risk management. My attention was directed towards information that related in some way 
to the conceptual framework and my research question: knowledge, personal experiences or 
stories about what other people do, how health care professionals act and how the 
pharmaceutical industry works. The process entailed listening back to the interviews and 
reading the transcripts closely and critically; marking, examining and comparing information. 
Field notes from the interviews were also reviewed; characteristics of each encounter and my 
notes of impressions from the interviews added to the richness of participants’ descriptions and 
helped indicate context and meaning. Markings and comments were labelled with a word or 
short phrase, and I used both purely descriptive and interpretive labels. 
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In order to capture as many aspects as possible of participants’ experiences of CVD risk and 
risk management I included many different types of descriptions. Examples include practical 
matters, personal experiences and hypothetical scenarios, examples from patients’ own lives 
or those of others, general thoughts about medicines and health care and specific statements 
about certain situations. At this stage, I recorded labelled data extracts along with notes of my 
reflections during the process (questions, possible explanations, apparent connections, 
contradictions) in the form of mind maps. This deliberately wide method identified many 
different possible entry points for a more focused, interpretive analysis. It also helped me to 
find relations in the data – both between and within cases – as well as gaps that needed to be 
addressed in coming interviews. 
For the purpose of producing anything but a superficial, descriptive account I needed to narrow 
the analysis and focus on a few themes that were directly relevant to my research question.[137] 
This would also allow me to move beyond particular examples shared by participants towards 
an interpretive, theoretical account. To concentrate my analysis on concepts central to the 
study, I reviewed the mind maps and picked out two central, provisional themes among the 
many descriptive labels. They both had great relevance for the research topic and the 
conceptual framework, and also were present in some form across all interviews: ‘blood 
pressure’ and ‘medicines’ effects’. 
4.6.3 Constructing a coding frame 
In order to do a structured and full exploration of the provisional themes I created a coding 
frame around them.[94,100] The construction of the coding frame was informed by Miles and 
Huberman’s [94] suggestion about coding for general domains, such as activities, relationships, 
strategies and perspectives, within the data. Moreover, I used what Strauss and Corbin [178] 
refer to as sensitising questions (identifying actors, actions, meaning) and theoretical questions 
(searching for conceptual relations and how events and actions develop over time). 
To keep my analysis focused on the research topic, I used my research question and the 
provisional themes from the open coding instead of the general domains when I constructed 
the coding frame. Three central concepts from the research question; ‘influences’, 
‘understanding’ and ‘risk management’ were thus combined with ‘blood pressure’ and 
‘medicines’ effects’. By formulating questions around these words, the coding frame would 
help me examine the data in a focused way while still capturing many different aspects and 
possible meanings of phenomena. Examples of the questions are ‘What is high blood pressure?’ 
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(combining ‘understanding’ and ‘blood pressure’) and ‘How do you learn about medicines’ 
effects?’ (combining ‘influences’ and ‘medicines’ effects’). The full coding frame is shown in 
table 4.3. 
 
Table 4.3 The coding frame for condensation of the whole data material into a dataset for further 
analysis. 
Provisional 
theme 
Concept from 
research question 
Coding frame component 
Blood pressure Influences Which are the involved stakeholders; who does what? 
Which actions – prompted or discussed – are related to 
discovering or having high blood pressure  
  
 Understanding Descriptions – what is (high) blood pressure? 
How is it made sense of? 
 Risk management What does the risk mean – (how) is it enacted and related to 
ill health? 
(How) can the risk be managed? 
Effect from risk 
management 
medicines  
Influences Looking for information before starting treatment? 
Which information sources are used? 
What do different information sources say? 
 Understanding What does it mean to use medicines for risk management? 
 Risk management How do medicines work? 
What do the medicines do for you and other people? 
 
4.6.4 Coding 
At this stage, I started using the qualitative data management software NVivo 10 [179] to 
organise data in the coding process. Transcribed interviews were imported one by one in full-
text format and coded line by line in the search for words, sentences or longer bits of text that 
related to any of the questions in the coding frame. Extracts coded as related to a specific 
question were collected using the ‘Node’ function, which allows for comparison across 
sources, e.g. transcripts. During the coding, I strived to minimise interpretation of the extracts 
in order to produce a rich and detailed dataset that retained the broad range of associations 
around each aspect of the coding frame. A generous approach was used, including whole 
sentences or parts of paragraphs rather than singular words so as to not lose any richness in 
descriptions. 
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This dataset produced by the applying the coding frame was the starting point for further 
analysis: interpretation of how and why certain things influence patients’ understanding of 
CVD risk and benefits from risk management medicines.  
4.6.5 Categorising and interpreting 
To start constructing my theoretical account from the collection of examples and descriptions 
related to the components of the coding frame, I needed to order the data according to my 
emerging interpretation of what it showed. This was done by way of reviewing the dataset and 
combining the coded extracts into categories on the basis of what they described and how they 
were related to each other. 
The categorisation started within data that had been collected under each ‘Node’ in NVivo10 
[179], that is, among extracts that referred in some way to one of the questions of the coding 
frame. Parallel to examining the dataset, I reviewed my field notes from each interview in order 
to assist my understanding and interpretation of each particular extract. By also returning to 
the interviews in their entirety, I reminded myself of the context of coded extracts. Things such 
as the framing of statements in a narrative about a personal experience or an account of what 
‘people in general’ think, or whether the mentioning happened in passing or was part of a 
reiterated statement provided additional layers of meaning to the data extracts and was helpful 
when placing it in categories. I did this stage of analysis without the support of NVivo 10 [179], 
for fear of the software introducing constraints on the creative and intuitive process of finding 
and testing associations across the dataset. 
Throughout the allocation of data extracts to categories, the categories were continuously 
reviewed and adjusted so that they accurately reflected all aspects of data included in them, but 
without overlapping with other categories. This technique is often referred to as constant 
comparison.[96,137] Each addition of a data extract to a category brought the analysis forward 
as it got incorporated into the construction of knowledge about CVD risk management and 
using medicines. 
Since the participants were sampled using the maximum variation technique, I paid particular 
attention to relations between extracted data; whether statements and explanations confirmed 
or contradicted each other, whether some findings seemed typical and other different, and how 
this might be related to certain characteristics.[94] For instance, apparent contradictions 
between participants’ viewpoints encouraged me to look for possible explanatory factors within 
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the different accounts. This took the analysis beyond comparison of separate accounts and on 
to a more abstract level – thereby starting to construct a theoretical description and forming the 
‘researchers’ story’.[172] 
It should be pointed out here that the data extracts were not handled as calculated units 
contributing towards an overall ‘tally’ of views or descriptions, but as entire explanations in 
themselves. A different view of data would handle the deviant case as an outlier or see an 1:n 
ratio of opinions. However, all explanations did not essentially get represented in the final 
account – my aim to construct a coherent theoretical description made the process of 
construction subjective rather than objective. As my attention was directed towards structure 
and relations that were present in the data (instead of seeking to test a pre-formulated theory), 
this subjectivity becomes a way to represent the participants’ views rather than a specific 
theoretical description in the emerging analysis. 
The categories derived from each of the dimensions of the coding frame were then brought 
together for overall comparison, combination and ordering into clusters. Also here, patterns of 
similarity or contradiction and gradients of phenomena were used as clues to identify relations 
and explanations. Critical review of data within and between categories continued, since every 
new addition was examined in relation to the overall, emerging story.[137] Here, I also actively 
used theoretical ideas from the conceptual framework and findings from the two literature 
studies to interrogate the emerging findings. 
4.6.6 Developing and testing themes 
As a thematic structure started to form within the dataset, I began testing it by means of writing 
the theoretical account; the ‘researcher’s story’. The writing process helped me test emerging 
associations and explanations [137] by showing whether they could be re-told in a meaningful 
way. It also identified areas of imprecise thinking and gradual differences in the application of 
the coding frame. Sharing the writing with Prof Walley and Dr Reeve served as an additional 
method of testing whether interpretive ideas held together as stories, by revealing ‘dead ends’, 
inconsistencies and gaps that needed further exploration. Interpretive findings in the form of 
hypothetical questions and suggestions about possible explanations continued to be recorded 
as field notes and discussed within the research team.  
Throughout the iterations of writing and critical review, which focused on the interpretive 
structure for my data, I also revisited the interviews in their entirety to check that the emerging 
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themes still reflected them in a truthful way.[137] Although my aim was to do a thorough 
analysis of a few central aspects rather than give a full description of the whole dataset, I wanted 
to ensure that the interpretation had not moved too far beyond particular accounts or introduced 
any contradictions. The critical reviewing was accompanied by continuous changes to the 
category names and their structure. 
After several rounds of critical review of the emerging findings and subsequent re-structuring 
of data, the categories formed a robust thematic framework describing patients’ views of CVD 
risk management. At this stage, I tested the framework by doing a line-by-line coding of the 
four last interviews. The remaining data did not challenge the thematic structure, for example 
by introducing a need for changes to the categories or completely new ideas. Thus, I considered 
the analysis finished. 
The final description of patients’ understanding of CVD risk management is presented as a 
framework of two major themes based on a structure of sub-themes and categories; see chapters 
5 and 6. Interpretations are presented as a written account of what it means to be at risk for 
CVD and how medicines’ effects are assessed, supported by quotes showing how patients 
expressed different aspects of risk management. 
 
4.7 Assessment of validity 
Having shown how I condensed my 18 research participants’ individual stories and examples 
into one theoretical account of patients’ conceptualisation of medicines in CVD risk 
management, I turn to the question of the validity of my findings. 
Since this study aimed to explore patients’ understanding of health and medicines beyond what 
is included in a positivist paradigm, the assessment of validity is not concerned with proving 
representativeness or generalisability of the findings in a numerical way. Instead, validity will 
be evaluated against aspects of how research methods, the collected data and my interpretation 
hang together and whether the findings are useful knowledge for answering my research 
question. An important aspect of validity is also that it is not a set of ‘checks’ at the end of a 
study, but something that needs to be built into and reflected on throughout the research 
process.[172] 
In studies with sub-samples or many researchers, formalised comparison of coding and 
triangulation of datasets can provide ways to test the robustness of codes and emerging 
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analysis.[94,100] As this study was done by only me, I relied on discussions with Prof Walley 
and Dr Reeve for external evaluation of explanations and the developing story. 
For reflections on validity and usefulness of the findings in the study, I used Lincoln and 
Guba’s [96] criteria for trustworthiness. The criteria entail a questioning of ‘truth value’, 
‘applicability’, ‘consistency’ and ‘neutrality’. These terms correspond to testing of internal and 
external validity, reliability and objectivity within a positivist view of knowledge by 
questioning the contingency of findings on characteristics in the sampled participants and the 
design of the study, and whether the findings hold true across populations and contexts. To add 
a more specific examination of the process of producing new knowledge, I included aspects of 
Kvale and Brinkmann’s [172] criteria for validity in interview studies. 
4.7.1 Criteria for the assessment of validity 
The first aspects that I will consider are the conceptual framing and planning of the study. This 
includes a review of its design and whether sampling and recruitment were done in order to 
produce useful and valuable knowledge.[172] 
The next aspect considers the truth value and neutrality of my findings.[96] It brings together 
reflections on the authenticity and credibility of the things I report, and includes questioning of 
how my choices of research methods influenced the production of knowledge. Truth value 
describes the extent to which the created and presented knowledge represents things that would 
be considered true by the participants. Neutrality refers to whether the research has led to 
findings that are determined by participants’ views on the research topic rather than shaped by 
the researcher’s biases, motives or perspectives. Moreover, this part of the evaluation looks at 
how answers and examples shared during interviews, including the transformation of talk into 
text, represents participants’ contributions. It also addresses whether my analytical questioning 
of the data has produced a truthful account of what participants meant and thought.[172] 
Finally, I will assess how my findings relate to the surrounding world by reviewing the 
applicability and consistency [96] of my research. This means to question whether the findings 
would be useful also in other circumstances – for example in relation to other types of 
prescribing or use of health services – and to what degree they would be similar if the study 
was repeated in a comparable population and context. This part of the criteria also considers 
how to critically assess validity in the study, including inviting readers to do their own 
validation.[172] 
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The set of criteria that I applied when reviewing my study is shown in table 4.4. An account of 
my application of the criteria in critical evaluation of my study is given in chapter 8. 
 
Table 4.4 Criteria for the assessment of trustworthiness and validity [96,172] 
Criteria How I will demonstrate it 
Conceptual framing and planning By clearly stating the theoretical background for the study and 
how it is connected to sources of information, research 
questions, interview questions, recruitment and sampling for the 
study. 
Truth value and neutrality By giving a transparent and detailed account of how I collected, 
handled and analysed data, including reflections of experiences 
from interviewing. 
By critically reviewing (alone and together with others) the 
structure and content of the emerging interpretation. 
Consistency and applicability By producing an account that is grounded in existing theory and 
developed with awareness of influences from structural factors 
(participants’ characteristics, my positionality) and thereby 
allows for comparison with other research areas. 
By presenting my data analysis and findings in a way that 
invites critical review from readers. 
 
 
4.8 Summary 
This interview study sought to create knowledge that would help answering the research 
question “How do patients conceptualise CVD risk management medicines?” It was designed 
with reference to a conceptual framework which outlines the major relations and actors that I 
anticipated would be influential. The framework highlights patients’ knowledge in medicine 
usage and the reliance in current health care policy on data produced with a focus on a 
biomedical understanding of pharmaceuticals. 
A critical realist stance accommodated for the creation of new knowledge in a way that 
acknowledges that there can be more than one meaning to ‘CVD risk management’. The 
biomedical definition of it might not encompass all representations that have bearing on the 
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use of medicines prescribed in conjunction with it. In order to explore patients’ understanding 
of the matter, I applied methods of data collection and analysis that would allow for research 
participants’ sense-making, experiences and ideas about meaning to be included alongside 
formalised knowledge. 
Data – in the form of patients’ stories, views and thoughts about using medicines – were 
collected in semi-structured interviews and as field notes and reflections alongside the analysis 
process. Prior to thematic analysis, I condensed the data material by means of using a coding 
frame constructed around the research question and central concepts in the data. A constant 
comparative technique was used when categorising data extracts. The combination of data 
across accounts highlighted themes that explained or described phenomena beyond the 
individual stories, and those themes formed my theoretical description of patients’ view of 
CVD risk management. The trustworthiness of my research and its findings has been supported 
by critical review and discussion throughout the planning, data collection and analysis. 
Having described how data were collected and analysed, I will now present the new knowledge 
that was created in the study. 
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Chapter 5 
Findings I: Being at risk 
 
5.1 Chapter overview: Findings 
In this chapter and the next, I present and discuss the results and findings in my interview study. 
Each of these chapters contains a descriptive account of one of the major themes, which is 
followed by a discussion section where the findings are linked to theory. Together, the chapters 
show the thematic structure for patients’ understanding of medicines in CVD risk management 
that was the outcome of my analysis. 
An overview of the results of the recruitment and participants’ characteristics is also given, to 
provide some context to the quotes that are part of my account of the findings (for the full 
record of characteristics, see appendix A11). Then I display the first theme, which is about 
being at risk for CVD. It shows how the risk assessment and identification of risk factors, which 
are core tasks in CVD prevention in primary care, are perceived by patients. 
 
5.2 Recruited participants 
As described in chapter 4, section 4.4, I applied a purposive sampling strategy to recruit 
participants for the interview study. Of the 28 people that responded to the invitation, I included 
18. This was after three people had not been possible to reach for arranging an interview, one 
person had declined upon being contacted by telephone, one person had concluded that we 
would not be able to meet during the course of the study due to him recently having had surgery 
and five people corresponding to parts of the sampling frame (see appendix A8) that were 
already filled. An overview of the 18 participants that were interviewed is shown in table 5.1. 
The single largest category of participants that replied to the invitation to participate in the 
interview study were men between 61 and 80 years of age, who were at low risk for CVD, used 
between 1 and 5 medicines every day and managed to do most daily tasks without assistance. 
In addition to this group of participants, I also recruited men and women from the age span 41-
60 to +81 years at low and high CVD risk. All people that replied were taking medicines to 
manage CVD risk; using between 1 and 5 or more than 5 medicines daily. 
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In relation to the initially planned purposive sample of participants of different age with an 
expected variety of experiences of CVD risk, illness and medicine-taking, I did not manage to 
recruit anyone in the age-span 18-40 years, anyone who did not take any medicines and any 
female participants at high risk of CVD or over the age of 80. 
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Table 5.1 Overview of the participants 
Name 
Risk 
level 
Age Health-related characteristics 
Holly Low 41-60 Lifelong experience of somatic conditions and use of pharmaceuticals, 
describes herself as healthy 
Richard Low 61-80 No experience of symptomatic illness, declining memory 
Albert Low 61-80 No experience of symptomatic illness 
Anthony High 61-80 Previous experience of cardiovascular condition; has had a heart 
attack and is under current investigation for heart symptoms 
Nathan Low 41-60 No experience of symptomatic illness, has had problems with side 
effects from medicines 
Gerald High 80+ Previous experience of cardiovascular and other conditions; has a 
pacemaker 
Rose Low 61-80 No experience of symptomatic illness 
Alfred Low 61-80 No experience of symptomatic illness, has had problems with side 
effects from medicines 
Norman High 61-80 Previous experience of cardiovascular condition; has a pacemaker 
Paul Low 61-80 No experience of symptomatic illness, has had problems with side 
effects, from medicines 
Joyce Low 61-80 Previous experiences of somatic conditions 
Judy Low 61-80 Previous experiences of somatic conditions 
Michelle Low 41-60 Lifelong experience of somatic conditions and use of pharmaceuticals, 
experience of dependency, depression 
Fred High 61-80 Previous experience of cardiovascular condition; has had a bypass 
operation, has a pacemaker 
James Low 61-80 Previous experiences of somatic conditions 
Samuel Low 61-80 No experience of symptomatic illness; depression 
Stephen Low 61-80 Previous experiences of somatic conditions; anxiety 
Tobias High 80+ Previous experience of cardiovascular condition; has had several heart 
attacks 
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5.3 Introduction to the thematic structure 
Two main themes – ‘being at risk’ and ‘seeking stability’ – form the structure for a framework 
describing patients’ conceptualisation of CVD risk management. They are built up by 
subthemes that focus on a chain of aspects of diagnosis and treatment of high blood pressure: 
initial and long-term interpretations of being at risk for CVD, the decisions made regarding 
interventions, and how treatment strategies are evaluated. Table 5.2 outlines the structure of 
themes and subthemes and shows how the descriptive categories come together to form a 
picture of CVD risk management from a patient perspective. 
It should be noted that the appearance of a chronological order between the categories is a 
product of my analysis, and represents neither a chain of reasoning nor a narrative structure 
that was uniformly present in patients’ own stories. The category structure is a matter of data 
presentation, which has the advantage that it facilitates comparison with the clinical approach 
of identifying, diagnosing, intervening and evaluating outcomes. 
Table 5.2. Overview of themes, subthemes and categories. 
Themes Subthemes Categories 
Being at risk Initial reactions negative feelings // indifference 
Contextualising causes and explanations // consequences 
Taking action medical information // personal representations 
Cohort strategies individuals // systems 
Seeking 
stability 
Individual assessment of 
effects 
experiencing // seeing // interpreting // balancing 
Thoughts about future 
outcomes 
for myself  // in general 
 
Data are presented as descriptions of the categories one by one, supplemented with quotes from 
participants to show examples of how they described things. A few quotes from participants 
have been slightly amended for readability, but with care taken to preserve the individual voices 
as they together with the words mediate the meaning. In some places, my question is included 
to show what we were talking about, and this is indicated in italics. 
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5.4 Being at risk 
This theme shows how patients conceptualise being diagnosed with a condition that means they 
are at risk for CVD (see table 5.3). Stories and information shared by participants about having 
high blood pressure show their reactions to and reasoning around the diagnosis and the 
decisions and actions that it gives rise to. This theme consists of four sub-themes: ‘initial 
reactions’, ‘contextualising’, ‘taking action’ and ‘cohort strategies’. The order of the sub-
themes progress from being diagnosed with high blood pressure, making sense of it by placing 
it in a context of causes and effects, which sources of knowledge are used and how, and what 
the reflections and conclusions about plausible actions are. 
 
Table 5.3 The first theme with subthemes and descriptive categories. 
 
 
 
 
 
Being at risk 
Subthemes Categories 
Initial reactions Negative feelings 
Indifference 
Contextualising Causes of and explanations for risk (before – what leads to 
CVD risk?) 
Consequences of risk (after – what will CVD risk lead to?) 
Taking action Medical advice and information 
Personal representations of the need for intervention 
Cohort strategies Individuals and populations 
System critique 
 
 
5.5 Initial reactions to the identification of a risk factor 
This theme outlines how participants first made sense of being diagnosed with high blood 
pressure or cholesterol. Some got the diagnosis at a routine visit to the GP, others while being 
treated for other illnesses including CVD-related problems. 
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5.5.1 Negative feelings 
Many participants in the low risk group expressed some astonishment related to finding out 
that their blood pressure was high; they had not noticed any symptoms. For some, it was 
difficult to come to terms with the diagnosis of a risk factor or a heart problem because it was 
interpreted as something quite serious that had been uncovered. This was the case for Holly, 
who saw CVD risk as something different from her other chronic health problems that she was 
used to having and which did not stop her from enjoying her life fully. 
“… because I didn't mind having… I didn't mind having things that weren't 
going to make me ill, like my psoriasis and my arthritis and stuff they are 
not going to make me ill, but my high blood pressure is something that 
could affect my life from a medical point of view. And that bothered me.” 
(Holly) 
An element of surprise is mentioned by some participants, for example by Joyce, who 
reacted to being diagnosed with something when she had not noticed any problems 
herself. 
“So really it was quite a shock that I had this because to me I didn't feel any 
different which you don't, you don't know you have got it do you?” (Joyce) 
A description of the high blood pressure diagnosis as an unpleasant surprise was also shared 
by Rose. For her, as well as for Joyce, the diagnosis did not fit in with a previous views of 
themselves as healthy, not needing doctors and going through stages of life without using 
medicines. It is upsetting to learn from doctors’ tests and statistics that this has changed. 
“At first I was a bit cross because I have never had blood pressure, ever, 
ever, not through pregnancy, not through anything.” (Rose) 
“It was a little bit of a shock to me because I had always been very healthy 
and never needed anything other than maybe a pain killer.” (Joyce) 
5.5.2 Indifference 
Some participants, however, said they did not react very strongly to the diagnosis. They had 
learned about the blood pressure at a routine examination and were not particularly frightened 
by it. There was no apparent difference between participants conveying indifference towards 
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the CVD risk diagnosis and those being upset by the news; people in both groups were equally 
interested in keeping active and maintaining good health and quality of life. However, to some 
participants the identification of a risk factor did not represent something threatening. 
“it was simply, something that happened which didn't surprise me knowing 
how other people my sort of cohort group… I mean it is not something you 
would normally talk about but you know, no, it was just very undramatic 
and very routine to me.” (Albert) 
Another example of the un-scariness of the diagnosis was given by Richard, who has always 
looked after his health and feels he is still able to keep up with both social and physical 
activities. He told me how little the high blood pressure impacts on the way he lives his life, 
for example in contrast to other conditions that are more tangible: 
“if it would have been something that was life threatening, even limiting me 
in sort of my activities then it would have had a much greater impact on me” 
(Richard) 
Participants in the high risk group, who were using medicines after having had a cardiovascular 
event, referred to dramatic experiences surrounding the event when I asked how it was to find 
out about the heart problems. Norman described his first angina attack and Fred gave a vivid 
account of how he perceived the pacemaker operation. 
5.5.3 Concluding the subtheme 
The information shared by a GP that there is a risk factor for CVD present appears to have the 
potential to be a significant event for patients. One group of participants describe a reaction 
that mirrors the approach in medical CVD risk management strategies – that it is beneficial and 
not particularly dramatic to identify the risk factor at an early stage. Other participants’ strong 
reactions add dimensions to the strategy of screening for CVD risk for the purpose of 
prevention: it can be distressing to learn that your blood pressure is high enough to render a 
medical diagnosis, since it indicates something has changed that might influence your future 
life. There was no clear evidence of factors that could explain the different types of reaction; 
people of both genders, with and without previous experience of illness were present in both 
categories.  
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In contrast to the examples participants gave about finding out about their high blood pressure, 
there was a lack of similarly straightforward descriptions of reactions to a diagnosis of high 
cholesterol. This suggests a difference in how those two risk factors are perceived by patients, 
with high blood pressure being more accepted while cholesterol is somewhat contested. 
 
5.6 Contextualisation 
Participants’ descriptions of causes and consequences linked to the diagnosed risk – in terms 
of high blood pressure or cholesterol – are a source for understanding more about how they 
perceive CVD risk. This sub-theme shows how the diagnosis is made sense of and how it is 
fitted in with thoughts about health and life in general. 
5.6.1 Causes and explanations 
Participants took different examples when telling me what might have caused their blood 
pressure or cholesterol to be high. These statements were not given as replies to direct questions 
about reasons for increased CVD risk, but often shared when I asked about the circumstances 
around when their medicines were introduced and whether they felt or thought the medicines 
were having beneficial effects. 
All participants gave examples showing that they had some type of knowledge about what had 
caused their blood pressure to become high. A few of the mentioned factors were things that 
are possible for individuals to influence: body weight, diet and one’s level of physical activity. 
Genetic makeup and family history were also named as explanations for high blood pressure, 
as was stress and other illnesses. Some participants had contemplated how different aspects of 
their lives and lifestyles contributed to their own condition. Norman was testing the idea of 
replacing the medicines with exercise, whereas Michelle, who was trying to cope with the 
effects of a long-term morphine treatment for a pain condition while also looking after her 
young children, saw her blood pressure as possibly related to all the daily struggles. 
“But if I stopped taking pills and did a lot of exercise, would the [angina] 
pain go away or not, or would the blood pressure reduce itself, if I lost a bit 
of weight as well?” (Norman) 
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“I don’t know if the blood pressure would come down if I lost the weight, if 
I got in a better place, if I got rid of all the other rubbish, you know, that 
might come down too.” (Michelle) 
Tobias’ explanation also draws on links between life events and cardiovascular health, but 
excludes the reasoning about diet and exercise. He had lived through several major heart 
attacks, and described how all the heart problems had come as a result of one particular event. 
“… if I suffer a loss, I just think about that moment, I’m shocked. Like, my 
father died, it was the biggest shock in my life. And that’s why I got the 
heart problems, since then.” (Tobias) 
Age as a determining factor was described by most participants as changing the body and 
making medical attention and intervention necessary. Together with your genes and family 
history of CVD – other internal, bodily causes that cannot be influenced – getting older meant 
that you could get high blood pressure despite having been healthy earlier in life, having had a 
physical job or making efforts to stay fit by means of eating well and exercising. High blood 
pressure is thus described as being brought on by some specific aspect of an individual’s life 
and not merely associated with risk factors. Richard, who was in the low CVD risk group and 
no previous experience of ill health, put it like this: 
“Throughout my life I have been as fit as a butcher's dog really. I have been 
very much involved in sport, football and athletics […] I used to go out 
running a lot to sort of try and keep fit. And I have never really been one for 
going into the doctors and never been on tablets so this is sort of a late life 
thing. […] Well I was obviously disappointed that it had finally caught up 
with me, that was more a psychological thing than a medical thing.” 
(Richard) 
The link between ageing and higher blood pressure was discussed further by Samuel, who 
was also in the low risk group: 
“So many diseases, or so many illnesses come by age, like when we are 
children we get certain diseases, in that age group. So I am subject to this 
kind of old age illnesses, which is why I have the blood pressure.” (Samuel) 
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In conjunction with the naming of age as a reason for their high blood pressure, some of the 
low risk participants pointed out that the condition is common among their peers or in the 
population in general. The same reasoning was used regarding elevated cholesterol. This is a 
diversion from the otherwise person-centred examples used in descriptions of possible causes 
for CVD risk. In contrast to telling me how “all the guys at work” (Nathan) or “everybody over 
the age of 50” (James) are on the same types of tablets, there are no groups that are identified 
as not being exposed to the risk. 
The explanations about lifestyle factors as causes for CVD risk were presented to me as based 
in people’s own thinking rather than as having been enforced by health care professionals. On 
the contrary, doctors’ and nurses’ actions are described as not supporting the view of lifestyle 
as a major influence; they focus on test results, charts, computer screens and prescriptions 
instead of giving advice on healthy habits. Norman, who mentioned several times during the 
interview that he used to drink almost every evening, did not seem to discuss that habit with 
his GP practice: 
Is it something that your GP has talked about, have they sort of suggested 
you can either go the diet and exercise road or you can take medicines? 
“No. She said I should lose a bit of weight, that is the last thing she said to 
me. She doesn't tell me to exercise, she doesn't tell me to stop drinking, she 
doesn't tell me to do anything, she just looks at the charts and the blood 
charts and checks my blood every year, or at least the nurse does. If things 
are the same as last year I don't get to see the doctor but if they have 
changed slightly, I get to see the doctor. She just weighs me, checks for 
diabetes, checks the bloods, tells me that my liver is ok.” (Norman) 
5.6.2 Consequences of risk 
Another aspect of placing the blood pressure into a context was related to a consideration of 
the consequences it might have for one’s health. Participants in the high risk group who had 
already experienced one or several episodes of CVD symptoms, like Norman, referred to those 
and were afraid that might happen again. 
“High blood pressure, angina attack, lost the use of this arm for about an 
hour. Scary so I went to the doctors the next day, he gave me two aspirins 
and sent me straight to the hospital so then they stuck a wire in the vein and 
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watched it all on TV. They couldn't find anything wrong, except I had high 
blood pressure.  […] Well, when you lose the use of your arm for a couple 
of hours, you don't want that coming back.” (Norman) 
Participants in the low risk group, like Nathan and James who had been diagnosed with 
high blood pressure and cholesterol at routine examinations, also illustrated their views 
of potential consequences of high blood pressure by giving examples of serious 
outcomes. Strokes that may cause permanent disability and fatal heart attacks were two 
particular ones mentioned. Here, descriptions of the process of CVD risk assessment 
and suggestion about interventions hint towards it being a straightforward prediction of 
what will happen in the future. 
“… having put all these factors into the PC it comes out with a figure you 
have 20% chance of having a heart attack by the time you are 65, I think oh 
rubbish.” (Nathan) 
“They give you your threescore and ten don’t they; you’ve only got ten 
years if you don’t do this, don’t do that. So I’ll be dead in ten years, that’s 
what they’re telling you.” (James) 
Less specific but still severe suggestions were given too: the diseases that follow high blood 
pressure or cholesterol could have detrimental effects on your life, causing suffering and need 
for heart surgery. Many related their fear for various outcomes to having seen it happening to 
family members, for example Holly who had learned about her high blood pressure at a 
relatively young age. The use of events in the family when giving examples of what the high 
blood pressure might lead to, suggests that people base their conclusions on their own limited 
experience of tangible events rather than anonymous but more representative data. Paul, who 
was in the low CVD risk group and needs only one blood pressure medicine to keep within 
target, also sees a clear link between his current diagnosis and future outcomes. 
“My mother died from a stroke, my aunty died from a stroke, high blood 
pressure obviously is fundamental to that happening, and I know I wouldn't 
be prepared to take that chance to be quite honest with you.” (Paul) 
“…whereas uncontrolled high blood pressure will give me a stroke and 
bump me off possibly, or give me a stroke and leave me permanently 
  
95 
 
disabled, which is a massive effect on your life when you are in your 40s 
and get told you have got high blood pressure, it was a real biggie” (Holly) 
In both high and low risk participants, there is a sense of directness in the descriptions of 
consequences of high blood pressure; people refer to their diagnosed risk as something that is 
likely to harm them. This observation is strengthened by the absence of other ways of 
reasoning. An attitude often referred to in other risk situations (for example in relation to 
condom use for prevention of sexually transmitted infections and sun protection to lower the 
risk for skin cancer) of the type ‘it will not happen to me’ is not expressed by anyone. 
5.6.3 Concluding the subtheme 
The causes and explanations echo lifestyle behaviours that tend to be mentioned in conjunction 
with cardiovascular disease prevention or indeed health promotion in general: diet, alcohol 
consumption and tobacco smoking. Age, excess body weight, lack of physical activity and 
stressful life situations or other medical conditions bringing about high blood pressure all 
mirror the biomedical descriptions of causes. Also the examples given as illustrations for the 
consequences of having high blood pressure are the same as those used in publicly available 
communication of CVD risk – participants allude to fatalities and severely disabling conditions 
and describe how family members have suffered from such conditions. 
The identification of a risk factor and subsequent suggestions about treatment to manage it 
becomes interpreted as the presence of a disease that requires intervention to avoid catastrophic 
consequences. Moreover, the specificity regarding perceived causes as well as consequences 
might set the expectations for an equally specific intervention to manage it. This quote from 
Joyce, who was in the low risk group, shows how simple the relation might be perceived to be: 
“You know, possibility of you dying, or taking a tablet; not a lot to choose is 
there?” (Joyce) 
 
5.7 Taking action 
As shown above, high blood pressure is seen by participants as an important discovery with 
potentially severe impact on their own lives. This subtheme shows what actions participants 
considered taking in response to being diagnosed. It looks for confirmation or challenging of 
the patient behaviour that is implicit in strategies for health promotion that build on treating a 
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large group of people at low risk: acceptance of the biomedical rationale and engagement with 
treatment despite little obvious individual benefit. 
5.7.1 Medical advice and information about risk management 
Being prescribed medicines for CVD prevention was an inclusion criterion in this study; all 
participants had thus had a doctor suggesting that some pharmaceutical intervention would be 
beneficial. This category describes how participants had perceived the recommendation to 
manage the risk by treating their blood pressure or cholesterol, and let it inform their decisions 
about what action to take. It also shows how other sources of medicines information such as 
websites and patient information leaflets in medication packages were used when making 
decisions. 
Descriptions around what doctors had suggested in response to elevated blood pressure and 
cholesterol centred on prescribed medicines. Participants that had been diagnosed at routine 
examinations described it as a very straightforward process that translated directly into 
intervention. 
“They just said this is your condition, this is what we are going to prescribe 
for you.” (Richard) 
“I have been prescribed tablets for hypertension of which I take two types.” 
(Nathan) 
For some participants, the acts of diagnosing and prescribing seem to carry the proof that 
intervention was indeed needed. This conclusion was shared by Joyce, who was very 
concerned about doing the right thing with regards to her health, as well as Samuel, who took 
a more critical stance to the doctor’s advice. 
“I don't believe that they are going to give you a tablet that, you know, you 
are not really going to need, they give it to you for a reason, if they are a 
good GP surely” (Joyce) 
“And you know, I take them out of necessity, not pleasure, because it’s been 
prescribed to me by the doctors.” (Samuel) 
Others, like Holly who had very high blood pressure after a flare-up and subsequent treatment 
in hospital of another condition, did not at first want to accept the diagnosis. Holly asked to be 
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given some time to let it settle while she was getting home to her own routines. However, 
further testing kept showing the pressure was high and her doctor insisted it needed to be 
treated. After a period of trying to “get her head around it” she acknowledged that the blood 
pressure was high and should be treated. 
“… it was still high and I am like yes, I have still got my joint problems, and 
all the stress of the hospital didn't do me any good. And they were really 
understanding, they said you can have your blood pressure done again in a 
fortnight. And then they brought me back another fortnight after that and 
after about six weeks they were like, we really need to treat this, we can't 
keep giving you an opportunity, you have to and that was it really.” (Holly) 
When treatments were started, the recommendation to use medicines for the blood pressure 
had come with the information that it was going to be a life-long treatment. Participants seemed 
content that their doctors had been open about that fact, and accepted it. Not much other detail 
was given around the actual initiation of treatment; it seemed that starting to take tablets was 
less dramatic than for example learning about the diagnosis. A few participants had revisited 
the need for medicines after a period of treatment, but had been told they could as well carry 
on taking them since the blood pressure was not going to get better by itself. This argument 
was also accepted. 
Some of the participants simply used the “doctor knows best” argument to describe why they 
had chosen to take treatment as their doctor suggested. However, others explained it further, 
telling me how doctors’ advice needs to be followed because it is based on something. Testing 
and examinations that had been done were given as examples of what underpin 
recommendations, as well as GP’s education, qualifications and professional experience. 
Richard, whose high blood pressure is his first reason to go “to the doctor’s”, trusts their 
recommendations to be the best for him. So does Tobias, who after his major heart problems 
might speak from experience of being saved by medical expertise. 
“I would go for it. For one thing, I would always take the advice, unless it 
just seems completely unsuited to me and my circumstances. Generally 
speaking, if a doctor looked at my medical condition, all the tests, all the 
readings and everything else whatever there is and he or she made a 
judgement that I need to go onto whatever then I would just take it. I would 
never question their decision.” (Richard) 
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“They are the medical doctors, they’re professionals. So naturally they 
know their field, what they’re talking about when they are telling me 
something. Then why should I argue with them, like why are you saying 
this? No, it’s their field, they’re expert in it, let them decide what to do with 
it.” (Tobias) 
Apart from notions of medical advice being suited to oneself, an indication of the perceived 
superiority of the doctor and of medical knowledge is found in Rose’s description of how she 
and her doctor made a decision about stopping treatment with statins after she had been taking 
them for a couple of years. She puts it in the words of getting permission to come off the tablets 
after a new risk assessment procedure shows her risk is only marginally elevated: 
“The doctor said well, you can [come off them] if you like, because she did 
this Q test and things have changed over the years.” (Rose) 
Doctors keep representing expertise when it comes to medicines even after participants had 
been using the tablets for some time. The idea of patients building their own expertise about 
conditions and treatments over time (see chapter 2, section 2.4.2) was used as a question to 
challenge participants’ statements about the dominance of biomedical knowledge. I formulated 
it something like “Some people say well, the doctor knows about medicines and diseases but I 
know about my own body and how I feel when taking the medicines – what do you think of 
that?” Sometimes I was refuted with arguments of the type “my doctor knows a damn sight 
more than I do about it” (Albert) and sometimes participants offered descriptions of how to 
negotiate and combine the two types of knowledge. One such example is given by Judy, who 
has had breast cancer a few years ago and relates our conversation about risk and health to her 
experiences from that period. 
“I listen to my body, and that's when I was, it was advised by that GP that I 
needed to take these blood pressure tablets I just thought ok, yes if that is 
what my body is saying but also listen to it and, do what you feel is good for 
you, so...” (Judy) 
Samuel’s explanation displays another way of combining one’s own formal knowledge with 
that of medical professionals, but also with the tacit understanding that comes with 
experiencing health, illness and medicines. 
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“All right, I believe in science and I have a verified education myself. So 
science to me is God, that’s what it is. So you cannot just dismiss it. 
Although you know exactly what’s good for you because you live inside 
your body, your body lives inside you, so you know what works and what 
doesn’t. But still, you leave that grey area where you say “well, this is 
science; I just have to accept it that way.” (Samuel) 
However, the trustworthiness of doctors’ advice was challenged by a number of things. A 
couple of participants expressed criticism regarding the basis for doctors’ decisions. It was 
suggested that treatments might be experimental insofar as the doctor might not really know 
how necessary tablets are, but is still recommending them. Interestingly, this was mentioned 
by Richard, who also stated he would never question his doctor’s judgement about him needing 
a medicine (see above). 
“I dare say a lot of it could easily be experimental, they could turn round 
and say try this, probably feeling but not saying, chances are it is not going 
to do you much good, but it is better than nothing, you just might...” 
(Richard) 
Narrowly formulated, dogmatic reasoning about diseases influencing the advice that conditions 
needed to be treated with medicines was also criticised by participants. Notably, these examples 
were centred on treatments with statins against high cholesterol. Alfred, who was diagnosed 
with high blood pressure during a stressful time at work and has since tried a number of 
different tablets, is content with his blood pressure treatment but does not like his doctor’s 
persistent suggestions that he should take statins too. He has discussed the matter with his 
friends, and they share his view. 
“Every time you go they try and push statins and I am very sceptical about 
it. […] Going to the doctor’s nowadays is a bit like going to a dodgy MOT 
place where they will search and search and search until they find something 
wrong with you and then they can, they can you know find a drug to give 
you to sort out that problem. And as I say I am not the only one that thinks 
that.” (Alfred) 
In response to my question about other possible sources of information about medicines, 
information leaflets in medicines’ packages were brought into the conversations. Participants’ 
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views of the helpfulness of these leaflets differed – some said they always read them and others 
made sure not to. The former group wanted to read up to find out how the tablets worked so 
that the medicine could be used optimally and also prepare themselves so that they would be 
aware of their own positive and negative reactions to the treatment. Those participants that 
despised the information leaflets did so on the grounds of them containing too much information 
about unlikely events. Reading them, you might get afraid of side effects and start looking for 
symptoms. Michelle, who had experiences of both physical and mental suffering, did not want 
to be reminded of more health problems possibly being caused by the medicines. Paul, who was 
experiencing a period of skin irritation that he suspected could be caused by the medicines, still 
thought the lists of potential side effects were too detailed to be helpful. 
“No, that’s fatal I think. Because you can get yourself all wrapped up in 
looking for symptoms, looking for side effects.” (Michelle) 
“I mean I think we have perhaps got to overkill now of what you don’t do 
and what you do because I think the drug companies are terrified that if they 
don’t tell you, like one in ten thousand, you might get this, you might get 
that.” (Paul) 
Internet as a source for information about medicines was also brought up in the conversations. 
The predominant opinion was that it is unreliable – anyone can post their thoughts and therefore 
it gets out of proportion. Anthony had built his knowledge about medicines and their effects 
from being attentive to his own health, reading books about medicine, asking doctors and also 
helping out at a community health centre. Paul and Holly both had experience of learning about 
managing practical aspects of other conditions from sharing experiences and advice on online 
forums, but when it came to CVD risk they did not think the internet was a good source of 
information. 
“I won’t go on the internet; I think you get too much information on the 
internet.” (Anthony) 
“… what you know I am certainly not going to go away now and Google it, 
in fact I think that is the worst thing you can do personally, because you get 
so many conflicting messages I think you come off Google more concerned 
than when you went onto it.” (Paul) 
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“You will get them saying oh you know you have got to try honey! So many 
teaspoons of honey a day and it will cure your high blood pressure and all 
this. And I mean honey is very good for you, I like honey but it has never 
done anything for my blood pressure.” (Holly) 
Participants were concerned about the quality of medical information and advice. Most of them 
preferred sources that are controlled by experts – getting advice direct from your doctor or 
pharmacist about your own condition and the medicines you have been prescribed. However, 
too much detailed medical information, such as data about rare side effects, was regarded as 
possibly fabricating symptoms. On the other hand, information from one’s doctor – albeit also 
based on average results from large groups of people – was seen as important to act upon. 
5.7.2 Personal representations of the need for intervention 
In addition to giving the above reasons for accepting their doctor’s advice about addressing the 
high blood pressure, participants shared their own arguments for what should be done in terms 
of treatment. Again, examples of when it is necessary to act upon the CVD risk were mainly 
related to high blood pressure while cholesterol seemed a less strong reason to take action. 
Many stressed individuals’ responsibilities in terms of prevention of future problems. 
Participants gave examples of what they do themselves and also how ‘people in general’ might 
behave. 
First and foremost, participants said, it is important to do something to lower the blood pressure 
and contain the risk. Taking action is important, both for participants like Paul who was not 
especially frightened by the diagnosis and for people like Joyce who found it upsetting. Nathan 
had even been sceptical of the initial information that his blood pressure was high, but had later 
come to agree with the doctor’s conclusion that medicines would be of use to him. 
“I have no problem I mean, certainly at that stage I could see that when the 
doctor said; your blood pressure is now beginning… It wasn't extremely 
high, but she said I am the sort of person, who says right what are we going 
to do about it. And if that is what it means, taking a couple of tablets, I have 
no problem with that.” (Paul) 
“I don't take medicines because I want to; I take them because I have to.” 
(Joyce) 
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“A lot of people put it in the hands of fate; well I’m a bit more proactive, I 
try and do something.” (Nathan) 
No-one said the diagnosed CVD risk could be left without intervention, although some initially 
wanted to find non-pharmaceutical ways to manage it. Participants referred to general wishes 
not to take tablets unless it was absolutely necessary, and also gave more specific examples of 
why one should be restrictive with medicines. Many described aspects of their lifestyle as 
helpful in maintaining health. Walking, yoga, running, going to the gym, staying away from 
fatty foods and cutting down on smoking were put forward as examples. Albert had been 
diagnosed with high blood pressure and high cholesterol but did not experience any problems 
with his health at present. However, he put his current use of medicines in relation to a possible 
future need for effects and took this into the equation when he considered his tablets. 
“I would say on balance you know the less I am taking the better because 
one day I might really need to you know and if you are starting from 
nothing then it's easier to ramp up obviously.” (Albert) 
In some contrast to the reasons shared for not wanting to use medicines, participants had come 
to the conclusion that they ‘had to’ do it anyway. The necessity of addressing the blood pressure 
was emphasised by some participants via statements of it being ignorant to not follow the 
doctor’s suggestion about treatment. In the following quotes, Joyce and Rose – who have both 
been very healthy though their lives – point out that if a doctor says medicines are needed, that 
advice should be followed. James agrees, with a little caveat. 
“I think if you have to have them, then take them. That is the advice from 
the GP; don't suffer unnecessarily. And some of them are essential, so 
therefore you are very foolish if you don't take them.” (Joyce) 
“Yes, I mean I would take tablets if they say you have to. You know, I do 
know people who won't take them, and I think that is a bit silly if they know 
that they are going to do you good.” (Rose) 
“Yes, it is my own will to take them, and I believe what he [the doctor] is 
telling me is true. In a fashion.” (James) 
The personal conviction that one has to do something about the blood pressure strengthens the 
sense of participants perceiving an association between being at risk for and actually 
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experiencing an outcome. Actions thus appear to be based on the conclusion that if you have 
high blood pressure and do not treat it, you can or will die from a heart attack, and the tablets 
will prevent that. The notions that CVD events may happen despite treatment, or that one can 
have elevated biomarkers without suffering from the associated events, are not discussed by 
participants. An alternative reason underpinning the conclusion that medicines are needed, 
other than the necessity spurred by envisaged severe illness, could be a reasoning based on 
‘might as well’ – that the medicines might be beneficial and are at least not doing any harm. 
However, although some participants found the risk condition quite undramatic, they wanted 
their tablets to help manage it. Patients’ anticipations of effects of medicines will be explored 
in detail in the second theme, which is presented in chapter 6. 
The necessity of treating high blood pressure was expressed unanimously by participants in 
this study, albeit with slightly different causes given for why. In the case of elevated 
cholesterol, their views about the need for statins were less consistent. Through examples based 
on their own or other people’s thoughts, participants indicated that statins are sometimes more 
contested in terms of the underlying reasons for prescribing. Here, influences from prescribing 
guidelines and marketing of medicines were mentioned in addition to personal views regarding 
the need for medicines. Statins appear to be ‘less necessary’ than medicines which target high 
blood pressure. One example of this is Alfred’s comparison with a questionable MOT garage 
(see above), and another is given by Holly who had to convince her husband to take his tablet 
every night: 
“I mean I fight with my husband because he won't, he wouldn't take one of 
his tablets and it is a cholesterol tablet. You have to take it, and I fight with 
him, when he first got it you know. One tablet a day, one a day!” (Holly) 
Once medicines are accepted as necessary, which they were in some way or another among all 
participants in this study, they are to be used to a person’s best ability. This means reading up 
about the tablets, being aware of your experience when starting to take them or making changes 
to a treatment, and feeding this information back to your doctor if anything needs to be altered. 
Confusing stories about medicines in the newspapers or on the internet should be discussed 
with the doctor before you decide to change anything yourself, as explained by Rose who has 
slightly elevated blood pressure and cholesterol. Perhaps unsurprisingly, participants that 
described high trust in their doctors’ knowledge regarding the need for medicines also stressed 
the responsibility to involve him or her in further decisions about the tablets. Tobias, with a 
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history of severe heart-related illness but a very calm outlook on health and medicines, also 
points out that it is possible to be attentive to changes in the need for medication without getting 
worried about it. 
“… or statins wonder drug, you know, it is, so… But I don't think you 
should go on what you read in the paper like that, it should be, you should 
discuss it.” (Rose) 
“If something takes place and you get worried, that’s all right. And if you 
get sick, you must worry about it, you must take medicine, go to the doctor, 
like this, you can’t say I don’t mind anymore, I am sick so I don’t mind, I’ll 
be all right. That is again wrong. You must take some action about it. But 
not worrying about it.” (Tobias) 
However, a few participants had decided to disregard the instructions about how to take the 
medicines and instead devised their own routine that suited their daily activities. For Norman, 
this was a way of not giving in to medicines as a sign of old age, and for Gerald who was in his 
eighties and struggled with memory problems it was a strategy to remember the medicines and 
then focus on more important things. 
“Although one of them says to take it on an empty stomach, from what I can 
remember one says take it at night and the other one says take it in the 
morning and after a meal. So I just pop the lot in one go.  And as long as I 
have eaten something it's usually ok. […] If you read the instructions I have 
to take one pill at four different times of the day and not drink, well then life 
is not worth living is it?” (Norman) 
“So usually I take most of them in the morning and then those two, the 
warfarin, about six o’clock at night. The other I take first thing, you’re not 
supposed to take them all together but it gets it out of the way.” (Gerald) 
Aside from using medicines, changing your lifestyle or maintaining healthy habits also 
formed a large part of participants’ descriptions of actions prompted by being diagnosed with 
high blood pressure. Some participants told me in critical words about friends or “other 
people” that just took tablets and did not engage with other efforts to stay healthy, or even 
used tablets as an excuse to eat unhealthily. 
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“I had a friend who was naughty because she would be out and having fatty 
things and she said oh it’s great when you are on statins, you can eat what 
you like. I said well you can’t really, you shouldn’t be. […] It is very wrong 
if people are being given medication for things and they are still over-eating 
and not exercising. I think that is awful, I really think.” (Rose) 
Nathan’s account of how he came to the decision to use medicines illustrates how medical 
information and one’s own views might be combined. He described how the doctor’s risk 
calculation computer software had indicated he was at risk for developing heart problems 
within the next decade, and how he has tried to reconcile that with his own healthy lifestyle: 
“You know to say I have 20% chance of having a heart attack by the time I 
am 65, well not if I run 4 or 5 miles every day and eat healthily you know 
so, I don't actually necessarily believe what they are telling me is true.” 
(Nathan) 
Many of the accounts of action taken by participants in response to the high blood pressure 
diagnosis were given with great emphasis. Patients’ responsibility for partaking in treatment 
and doing your best in terms of lifestyle habits described as healthy was a recurring and 
prominent feature in the interviews. Whether it was motivated by the fear of what might 
happen if they did not treat it, by wishes to promote one’s health or just because your doctor 
said it was necessary – engaging with the management of your CVD risk is the “right thing” 
to do. 
5.7.3 Concluding the subtheme 
Despite the apparent principal difference in approach between patients and health care 
professionals when it comes to explanations for high blood pressure (lifestyle used as example 
by patients but this explanation is not supported by how health care professionals act), 
medicines have an undisputed place in both sides’ strategies for what to do when the blood 
pressure is high. Patients emphasised their individual responsibility for engaging with actions 
that will lower the blood pressure, and active intervention with both medicines and lifestyle 
changes was favoured. In terms of cholesterol as a risk factor, it was much less prominent in 
participants’ accounts of CVD risk. 
 
  
106 
 
5.8 Cohort strategies 
Alongside the highly personalised ideas about causes for and consequences of the identified 
risk and the individual responsibility for partaking in interventions, indications of awareness of 
the large scale aspects of CVD risk management treatments were also present in participants’ 
accounts. 
5.8.1 Individuals and populations 
In a few interviews, the mentioning of age as a cause for high blood pressure or cholesterol 
was combined with the reflection that most people in one’s peer group were suddenly on 
medication for CVD risk-related conditions. This normalised the diagnosis, and allowed for 
the sharing of information and experiences within groups of friends or work colleagues. James 
and Albert, who had been diagnosed at routine examinations and then had medicines prescribed 
to manage CVD risk factors, suggested that people might more or less routinely get medicines 
prescribed at a certain age. 
“you know all the lads I speak to at work, soon as they came about and I’ve 
read in the papers many times, you know doctors are putting people on 
statins as soon as you hit that sort of bracket.” 
And why do you think that might be? 
“Well I think, unless they didn’t go for any check-ups and they 
automatically got put on statins because the doctors say so, that’s to each 
individual.” (James) 
“people are telling you often enough that high blood pressure as you get 
older does lead to risks so it doesn't seem an unreasonable thing and erm... I 
suppose most of my contemporaries are also gobbling the same things so...” 
(Albert) 
In some senses, though, participants seem to set themselves apart from others. This again 
emphasises that for patients, an individual perspective on health and medicines is always 
present. One example is references to “older generations” that will uncritically accept doctors’ 
decisions, as opposed to the participant, who would always question if the medicine is needed. 
Albert has reflected on the fact that there are incentives for GPs to diagnose more patients with 
high blood pressure, but he still trusts that his diagnosis was the result of a personalised risk 
assessment. Rose tells how simple and available the QRISK test is, and that doctors base their 
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decisions on it – but trusts the recommendations about blood pressure medicines and statins to 
be suited to her personally. The link between being part of a cohort and getting personalised 
medical advice seems to lie in having a good relation with one’s doctor. 
“I mean I have no reason not to trust him as a competent doctor, and I do 
know from other friends who are in the business as it were that you actually 
sort of can tick a box these days by putting people on some of these things 
but... I will give him the benefit of the doubt he is not just doing it to get his 
numbers up.” (Albert) 
“she said now we would do this test with you, we wouldn't just give you 
them […] but she said you can do it yourself really it is on the internet 
where they take into account what your parents died of, your weight, you 
know different things like that” (Rose) 
5.8.2 System critique 
Although the participants in this study were all using medicines – most of them with the 
understanding that their CVD risk meant they had to – some criticism towards the prevention 
approach was voiced. The principle of prescribing to individuals on the basis of evidence of 
effects in populations was questioned both in terms of the accuracy of the risk assessment and 
the possible outcome of treatment. In addition, a couple of participants expressed criticism 
against the idea of widespread pharmaceutical intervention to promote health. Health checks 
were seen not so much as opportunities to identify and address things that could potentially be 
problematic in the future, but instead as doctors looking for diseases. Connections were also 
made to the higher levels of health care provision, for example by Samuel who in addition to 
describing his own thoughts and views about medicines also discussed the idea behind how the 
NHS aims to promote health and prevent disease. Another reflection on the systems behind the 
preventive strategies was made by Nathan, who referred to his career in engineering as the 
reason for why he pondered over the statistical aspects of CVD risk management. 
“Doctors are governed; they have got a guideline and have to follow it. They 
are officers for the government; to apply its policies. […] Well that goes 
back to the government, the reasons, the policies, each government has its 
own set of rules of budgeting, that’s the result of it. So it’s about money.” 
(Samuel) 
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“so they hit you with these statistics and whether they are true or not I don't 
really know, I mean there has got to be some evidence to show that, you 
know, that could be the case... but are they supplied with enough 
information? I don't know. […] it might be true for some individuals, you 
know, but you have got to look at other factors as well.” (Nathan) 
 
5.9 Discussion 
Having presented the first main theme, I will now review my findings in relation to literature 
on patients’ understanding of risk management and medicines. The discussion is structured 
along two topics that condense the findings: participants’ individualised interpretation of the 
CVD risk, and the imperative to take action to manage it. 
5.9.1 An individual interpretation of risk 
Being diagnosed with CVD risk in the form of high blood pressure was unsettling to some 
participants because of the image of the condition as something that could shorten their life. 
There was also an element of surprise that the blood pressure was high, which added to the 
unpleasantness of being diagnosed. Notably, participants’ examples of how it was to find out 
about CVD risk focused on blood pressure as a risk factor, whereas cholesterol did not figure 
so often in these descriptions. With regards to the event of being diagnosed, Nettleton outlines 
the many ways in which biomedical diagnosing shapes patients’ understanding of 
conditions.[49] Getting a diagnostic label on something that is ‘wrong’ may validate and 
explain symptoms of illness as legitimate diseases and enable patients to access services. In a 
wider perspective, diagnostic classification provides a system for the allocation of health care 
resources, and is a central feature of medical authority. Although the majority of my interview 
participants were at low risk and had not experienced any symptoms of CVD, they interpreted 
the diagnosis as a sign of imminent disease. In high and low risk participants alike, the 
diagnosis led to engagement with behaviours aiming at containing the risk – many of which 
were based on the doctor’s approach to risk management. Thus, the concept of getting 
diagnosed may not rely on symptoms to have an impact on patients’ understanding. 
An important feature of primary preventive CVD risk management is indeed that the risk 
factors are identified by a doctor at an asymptomatic stage. This invites suggestions regarding 
the impact of the process of examination and diagnosis on patients’ understanding of the 
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condition they have. In a study of patients’ experiences of CVD risk screening, Saukko and 
colleagues [180] suggest that the risk assessment in itself frames conditions as naturally 
defined, when it in fact rests on socially negotiated thresholds. The levels of high blood 
pressure and cholesterol that are considered high enough to be a reason for pharmaceutical 
intervention are not determined by clinical or symptomatic signs but decided based on 
statistical exercises in clinical trials in combination with cost-effectiveness analyses.[61] 
Dumit [135] offers a suggestion for how a general, asymptomatic state of elevated biomarkers 
might get to be interpreted as a personal disease or condition. He suggests that risk management 
medicines have been marketed, and are thus known in the social world, on the basis of 
everybody’s potential to be afflicted by disease. Emphasis is placed on the presence of 
symptoms or signs that can underpin a diagnosis, while weak causal associations and predictive 
values of treatment are obscured. Decades of this type of communication about medicines has 
established the idea that health-related issues are medical problems and that pharmaceutical 
intervention will be beneficial. This reasoning could explain how participants that reported 
themselves as being in good health and telling me how they looked after themselves still found 
it plausible that they needed medicines. The identified signs of disease might introduce an 
element of uncertainty into the image of one’s health. 
Participants expressed an individualised understanding of their CVD risk diagnosis. Although 
many referred to generalised causes for their own elevated risk (age and lifestyle) they did not 
see themselves as part of the cohorts that are the targets of large-scale prevention. Their own 
high blood pressure was described as brought on by some particular reason, rather than as a 
function of combined risk factors. As expected from reasoning centred on the individual, the 
imagined effects of CVD risk were also pictured in terms of threats to the person. When 
picturing the possible consequences of for example high blood pressure, both primary and 
secondary prevention patients refer to cases of fatalities or disability in their immediate family. 
They mention not wanting to die or fear of getting a worse quality of life when describing what 
might happen. The use of personal experience or knowledge about particular cases rather than 
numerically supported evidence is called heuristics, and is a classical way to make sense of 
things that are difficult to conceptualise, such as determining the value of future health 
interventions or medicines.[181] 
Hence, participants apply the arguments and endpoints that underpin prevention strategies on 
the population level onto their own personal situation. This demonstrates that one of the 
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defining features of primary prevention in CVD risk management is eliminated from the 
reasoning, namely the weak causal associations between elevated biomarkers and 
cardiovascular mortality.[124,182] A result is that for patients, a personalised, black-or-white 
interpretation of CVD risk management comes to dominate over the grayscale of risk reduction 
that underpins policies of disease prevention. Notably, my impression from the interviews was 
not that the understanding of CVD risk as rather closely associated with cardiovascular events 
and mortality had frightened participants into taking medicines. Instead, it shaped their view 
of the value of risk management. The result is a distance between ‘the personal risk people 
perceive’ and ‘the clinical risk that is reduced by medicines’. 
5.9.2 Taking action – using medicines 
The perceived connection between the CVD risk and aspects of their own life probably 
contributes to patients’ feeling that it is their responsibility to do what they can to control the 
blood pressure and, to some extent, cholesterol. In contrast to other risk conditions that might 
be ignored with the thinking that ‘it will not happen to me’, a diagnosed CVD risk seems to be 
interpreted as important enough to intervene against. 
Advice from medical professionals, in particular GPs, about treating the CVD risk with 
medicines was accepted by all participants in this study. Although having and expressing their 
own thoughts and opinions about using medicines, patients ultimately adopted the GP’s view 
that treatment would be beneficial. Those that initially were hesitant towards starting to take 
medicines transitioned to acceptance of taking tablets every day. Even those that did not fully 
believe the risk calculation, or felt convinced about the benefit, thought it safest to start taking 
the medicines anyway. Patients in the low and high risk groups used similar reasons in 
explaining why they had chosen to take the tablets, indicating that even a moderately increased 
risk for a CVD event is understood as a strong cause for treatment. A recurrent impression of 
mine from the interviews was that a diagnosed CVD risk becomes somehow separated from 
the person, and instead becomes the professionals’ domain. Such a process could lead to the 
patients perceiving that their own opinions on using medicines are no longer fully valid. 
The doctor’s recommendation was interpreted by many participants as personally adapted 
advice rather than application of a guideline on a target population. Even those that brought up 
population-level aspects of risk management strategies in interviews (such as incentives for 
diagnosing and risk assessment algorithms) stressed that their doctor gave them personal 
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advice. Here, as in the case of interpreting the relation between the CVD risk diagnosis and 
possible outcomes, the denominator used by patients is again their own singular person. 
Regarding benefits from risk management medications, there was a difference in how 
treatments for blood pressure and cholesterol were perceived. All participants had incorporated 
anti-hypertensives into their daily routine, whereas the use of statins divided the group. The 
difference in how the drug classes are valued might be explained by where statins are in their 
life-cycle; they were introduced to the CVD risk management arsenal in the 1980’s and thus 
have a shorter history of use. Recently expired patents on several statins make producers seek 
for expanded areas of use, leading to professional debate and presence in the public sphere (see 
chapter 3). Efforts to clarify aspects of efficacy and safety might mitigate the ongoing 
controversy.[126,183] Increased familiarity or socialisation with time – perhaps aided by the 
increasing reliance on pharmaceuticals in health promotion – may lead to statins eventually 
becoming as accepted as anti-hypertensives currently are. Another possible explanation for the 
difference in perceived necessity between anti-hypertensives and statins could be the 
availability of possible alternatives: alongside statins are multiple food items that are marketed 
on the basis of their cholesterol-lowering properties,[136] whereas no such specific products 
are present for high blood pressure. These questions would need to be addressed in further 
studies of patients’ perceptions of CVD risk management. 
All participants in this study had made the choice to take medicines for their blood pressure – 
sometimes as the only way to address it and sometimes as one of several efforts to maintain or 
improve health. Some were also using statins. Although being diagnosed with high blood 
pressure was a noteworthy event, taking medicines to ward off the anticipated effects was not 
described as particularly dramatic by participants. In their examples of what they did to 
decrease the risk that comes with having high blood pressure or cholesterol, taking tablets 
blends in with examples of lifestyle behaviours such as eating well and keeping active. 
 
5.10 Summary 
Personalised causes for CVD risk were given as explanations for high blood pressure or 
cholesterol, and reasons for intervening were likewise expressed with an individual focus. The 
indications of a close relation between high blood pressure and serious outcomes are far away 
from the arguments that form the logic for a population strategy in CVD risk management; 
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treating cohorts to achieve a small average risk reduction and eventually influence overall 
mortality in the population. 
People made sense of the unsettling diagnosis by using personal experiences and expert advice. 
Both these things contribute to the dissonance between the risk that patients perceive they are 
facing and the ‘real’ risk that is targeted in preventive interventions. The medical context that 
surrounds the introduction of the concept of CVD risk might lead to a medical method of action 
– in the form of taking prescribed medication – being favoured as a strategy to contain the risk. 
However, in spite of placing CVD risk in a context of dramatic personal illness, the medicines 
taken to avoid it are, or quickly become, an undramatic part of everyday health work. How this 
happens is explored in the next chapter. 
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Chapter 6 
Findings II: Seeking stability 
 
6.1 Chapter overview: the second theme 
In the previous chapter I presented the theme that shows how patients perceive being at risk for 
CVD, drawing together aspects around diagnosis and decisions about interventions. Here, I turn 
to a discussion of how the management of that risk is experienced and evaluated. The second 
core theme arising from the dataset was that of stability of blood pressure and cholesterol as a 
central feature of participants’ evaluation of the medicines they take to manage CVD risk. 
 
6.2 Seeking stability 
To find out how effects from medicines were experienced or pictured by participants, I asked 
if and how they felt or thought the tablets helped them. Answers to these questions contribute 
to the understanding of patients’ reasoning around conditions associated with CVD risk, by 
showing how management of the risk factor is put in connection with the outcome that is 
supposed to be prevented. The subthemes describe the ‘continuous individual assessment’ that 
patients were engaged in and the ‘thoughts about future outcomes’ they shared with me. Table 
6.1 outlines the structure of subthemes and categories. 
Table 6.1 The Seeking stability theme with subthemes and descriptive categories. 
 
 
 
 
Seeking stability 
Subthemes Categories 
Assessment of present 
effects 
Experiencing medicines 
Seeing results 
Interpreting strategies and effects 
Balancing the present and the future 
Thoughts about future 
outcomes 
For myself 
In general 
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6.3 Assessment of present effects 
Although most CVD risk management medicines are prescribed for the purpose of preventing 
future disease, they are also part of everyday life for the patient using them. As shown in 
chapter 2, a continuous evaluation of effects is an important part of how patients relate to 
medicines and form expectations about future outcomes. Experiences of illness and medicine-
taking build knowledge about how to balance conditions and effects of treatments, and how 
these things can be fitted into daily life.[22,39,41,184] This subtheme shows which indicators 
participants used to assess effects, and their ways of interpreting what the medicines do. 
6.3.1 Experiencing effects 
This category describes participants’ assessment of the effects that medicines presently have 
on their bodies, on their health and in their lives. After the initial decision to follow the doctor’s 
advice and try to use medicines to manage the blood pressure, a major influence on continued 
engagement with treatment is whether the medicines are seen as suitable for one’s own body. 
The way to find out is by being attentive to your body when it tells you if the medicines are 
working for you; if they produce the desired effects and not bring about any unwanted changes. 
James, who has tried a few different medicines to get his blood pressure and cholesterol 
treatments right, describes how he has a routine of checking the information about possible 
side effects in the information leaflets and monitoring himself when starting a new treatment: 
“I’m not just gonna pop them in my mouth and say ‘that’s all right doc’, 
whatever the doctor gives you. I do my own little bit of read-up of them and 
see how I am, give it time to come on to me and then… I take the tablets 
and see how they are in the next few weeks, am I feeling all right? And if 
they’re ok well then, yes.” (James) 
Other participants also conveyed how they evaluated the medicines by using their bodily 
feeling. Negative effects, or the absence thereof, helps in making this evaluation as described 
by for example Samuel who valued his own experience of health when considering his 
medicines. Paul, who had recently noticed a side effect from his blood pressure medicine, and 
Judy who compared the current treatment with the more tangible regime brought on by breast 
cancer, also looked to their previous experiences for evaluating the medication. 
“Well I believe how I feel. Because nobody can feel the way I feel except 
me, ok.” (Samuel) 
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“I suppose apart from literally this last two weeks where I have had to say, 
yes, my body now is telling me that there is something wrong. You know I 
started on some tablets, so for it to be a coincidence would be amazing.” 
(Paul) 
“I don't really think about it, I just take it in the morning, when I have my 
breakfast, I have not noticed any side effects it's a very, very, very low dose, 
so I don't know whether I am expected to notice anything.” (Judy) 
Broad descriptions of how the medicines affected one’s health were also present in 
participants’ accounts. Some shared stories about side effects that had had effects on 
their daily lives and induced investigation and changes between tablets. The GP had 
been a reliable help in finding a medicine that was suitable. The feelings of being 
‘stable’, ‘in shape’ and ‘on an even keel’ are not directly related to the CVD risk, but 
indicate that the medication prescribed as a result of specific risk factors can be 
perceived as having general effects on one’s body. 
“I just feel everything is like normal, if that’s what it is. It’s helping me that 
way, keeping everything on sort of an even keel if you like.” (James) 
In a long-time perspective, the absence of problematic effects gives a sense of security 
even when frightening information about medicines comes out in the news. Both Fred 
and Stephen have had symptomatic health conditions for a number of years, and they 
referred to their history of taking medicines as a reason for not worrying. Again, the 
personal experience of a certain medication in your own body weighs heavier than data 
from large populations when it comes to patients’ evaluation of their medicines. 
“Yes the aspirin can cause all kinds, strokes and everything, so you do think 
to yourself ‘oh’ but then you think ‘well I’ve been taking them for 17 years’ 
so I just keep on taking them.” (Fred) 
“I asked my doctor about that and he said ‘look, do you feel all right taking 
them?’ and I said ‘of course’ and he said ‘well carry on then, don’t worry’.” 
(Stephen) 
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6.3.2 Seeing results 
Some participants did contrast the treatment of their high blood pressure or cholesterol with 
other medical conditions where you can actually feel or see the effect of efforts to make it 
better, such as headaches, ulcers or cuts that heal. However, they had found ways to get 
indications of whether the risk management medicines were helping the particular risk 
condition. Immediate effects from blood pressure- and cholesterol-lowering treatments were 
readily described in terms of a controlled blood pressure or a cholesterol value within range. 
Similar descriptions were used by participants who were content with their medicines, like 
Alfred, and by those who had a more problematic relation to their health, like Michelle and 
Stephen. 
“…your blood pressure is up and I think it was very high at that time, and 
then the drugs did actually bring it right down. And it seems to be fine now 
quite honestly so…” (Alfred) 
“I was on a particular tablet and for 12 months, we tried to get it down. And 
it was sky high all the time. And we couldn’t get a hold on it. So they put 
me on a combination of three, apparently it’s very common, once you go on 
these three you come down. And I’m now on them three and it’s been 
magical, my blood pressure’s been down.” (Michelle) 
“I couldn’t control my cholesterol because I don’t know what it was, he said 
best go on the statins and touch wood it’s been ok since you know. I take 
them every evening.” (Stephen) 
Aside from seeing the blood pressure or cholesterol come down at the start of treatment, regular 
confirmations that it stays stable are taken as indications that the medicine continues to be 
needed and beneficial. Several participants told me they have got their own blood pressure 
machines and monitor themselves; as a way to check whether they have remembered to take 
the medicine or just because they got interested in measuring it. 
“But with other medicines, like the problem with high blood pressure, you 
don’t always notice the effects quite in the same way but as I say I do 
monitor my blood pressure.” (Alfred) 
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“I check it myself yes. It is the way I remember if I take the pills or not.” 
(Norman) 
Blood pressure monitoring done at check-ups with the doctor, or in Fred’s case every day via 
tele-health equipment, also inspires trust, since it is interpreted as saying everything is fine in 
the body. The monitoring of risk factors was described by all participants as an un-dramatic, 
routine event. GPs that keep an eye on you by measuring and feeding back results also provide 
signs that the efforts to look after your blood pressure and cholesterol are worthwhile. 
“Like in every February I get my annual test, round my birthday you know, 
going for my bloods and then I go back in two weeks after and you see how 
your blood results are, you see the doctor, and they tell you that everything 
was fine. You know, from the year previous, it’s come right down. They go 
back over the records.” (James) 
“… and I have my checks every year and it’s always the same you know.” 
(Judy) 
“And I’m on this thing that has come out now, it’s on the telly, every 
morning I’m monitored. I’ve got to give me weight, so I need to get this 
thing to stand on, and then I get off that and the thing goes on my arm for 
the blood pressure. And that all goes through the telly, and wherever it goes 
after that. And that it tells you ‘your blood pressure is ok today, your other 
things are ok today.’” (Fred) 
Some participants discussed the possibility of getting an additional confirmation of the effects 
of their medicines from a period of not taking them. In parallel to following the lowering and 
stabilisation of measurements when the treatment started, seeing the blood pressure or 
cholesterol go up as a result of not taking the tablets seems to strengthen the conviction that 
the medicines are really doing something. Such testing of effects was done either as an active 
decision to stop the tablets for a period of time to see what would happen or involuntarily, for 
example due to a shortage at the pharmacy. 
“I mean I have a fairly sedentary, I work in an office so I am not running 
around and I thought ok, I am prepared to take the risk and I did, for a 
week I thought I will just see.” (Paul) 
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“… last time they did my pills I hadn't taken the statins for about a week 
because the local chemist here had run out, bloody hopeless they are, so 
when she took it I was 6.1. She asked me why, had I been eating fat, and I 
said I haven't been taking the statin for a week, so it jumped straight back 
up.” (Norman) 
Participants evaluated the test by checking biomarkers or their general feeling. Richard, who 
did not have any experience of ill health, even suggests that the only way to find out what the 
medicines do is to actually stop taking them, but he does not want to test the effect. 
“And I know if I don’t take them I can feel something is not right in my 
body.” (Stephen) 
“I don't know, how can I evaluate that because I can't turn round and say, if 
I stop taking those for 3 months then by now I would have been able to... 
because I don't stop them.” (Richard) 
Throughout the interviews, two ways of knowing about effects from medicines were present 
side by side. Participants followed changes in the blood pressure and cholesterol, but they also 
observed how the tablets suited their bodies. The first of these methods for evaluation fits a 
biomedical description of CVD risk management, and might help patients ‘check’ whether the 
doctor was right in suggesting treatment. The second approach points to the importance of 
patients’ experiences, past and present, in evaluating the use of medicines. 
“Well the external sort of demonstration of my life doesn’t seem to have 
altered at all... the only way I notice the difference is the fact that my blood 
pressure has settled down and is you know, at a reasonable level now.” 
(Alfred) 
6.3.3 Interpretations of the medicines’ effects 
Since a core topic in this research project was how patients perceive benefits from medicines, 
I asked the interview participants explicitly how they felt or thought the tablets were helping 
them. In answers and examples that followed from such questions, participants referred to the 
immediate effects they had seen on their blood pressure or cholesterol. The fact that the 
biomarkers had come down and were controlled was turned into a description of the medicines 
fulfilling a specific task. Thus, accessible confirmations of medicines’ effects – whether 
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provided by one’s own blood pressure readings or mediated by the doctor at check-ups – help 
to define both the risk condition and the need for medicines to manage it. 
In addition to assessing whether you ‘feel ok’ with the medicines, and in the absence of 
symptoms to be relieved, these confirmations became the sign that something was happening 
due to the tablets. One way of describing this was as the medicines ‘doing their job’ – indicating 
that management of risk factors is indeed seen as a distinct outcome of treatment. Nathan, who 
doubted the applicability of risk assessment methodologies to himself and made an effort to 
have a very healthy lifestyle, used the effects on his blood pressure and cholesterol as proof 
that he had really been at risk for heart disease and thus needed the medicines. 
“I think because my blood pressure was so high, and now it is at a level… I 
think it proves itself that the medication is doing its job.” (Joyce) 
”I mean yes my blood pressure is down to normal because I am taking the 
blood pressure tablets so that is an indicator that they are doing something.” 
(Nathan) 
Another way of elaborating on the beneficial effects was to allude to the logic that they must 
be doing something good for you – just like medicines from which you actually can feel the 
effect. As in the case with the CVD risk diagnosis, participants accepted their doctor’s approach 
to risk management and therefore concluded that since they had been recommended and 
prescribed, the medicines would be helpful. Fred relates his idea of effects from medicines to 
his tangible heart conditions that were the need for heart surgery in the past, whereas Paul who 
has very little experience of illness draws on how other medications work. 
“Obviously, I’ve had the heart problems, I’ve had the bypass 17 years ago 
so I think if he’s given me them at least they must be doing something there, 
to make sure everything is ok. That’s the way I think about it.” (Fred) 
“I still can’t believe that you take a tiny little white thing like that and it can 
have such a dramatic effect, that is beyond my comprehension but we all 
know if you have got a headache you take an aspirin, it has an effect, so, I 
know their effect and obviously you wouldn’t be given them if they didn’t.” 
(Paul) 
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However, the view that the medicines are beneficial and therefore should be taken was not 
unanimous. A couple of participants used examples from their own or other people’s lives to 
show how experiences could make you question the necessity of medications. The first 
example is from Samuel, who realised that he could manage his blood pressure and diabetes 
without medicines during a time when he could not get hold of any, even in a stressful situation. 
Despite this, he returned to taking the tablets when he could, stating his respect for science as 
the reason for deciding beyond his own experience. The second example was shared by Fred, 
who pointed out that he knew of people that chose not to take medicines – sometimes for good 
reasons. 
“Roughly between four and six months I didn’t take none of these, because 
simply I ran out, I was in a war zone where nothing was available to me. 
But I still managed, and I found my health better off without it. I just got on, 
there was more exercise, and watching what I ate, my food you know. And 
that somehow, it worked. At that period, although I was stressed because of 
the war, but my blood pressure was ok. And my diabetes, absolutely all 
right. So I didn’t see why one should take these things. […] No, I don’t 
think they’re doing anything for me right now but they might prevent things 
ahead. Yes, that’s the reason I take them.” (Samuel) 
“I know a lot of people, doctors give them tablets, but they won’t take them. 
A good friend of mine, he won’t take them, and he reckons he feels better! 
He said, you know, where he lives, to get to the bus stop you’ve got to walk 
over a hill. He said ‘for years I’ve struggled, getting over that hill, but since 
I packed those tablets in I’m like a young 21-year-old, walking over there.’ 
So then sometimes you think, are these tablets doing you well or are they?” 
(Fred) 
6.3.4. Balancing the present and the future 
As a consequence of the perceived or anticipated benefits and experiences of or worries about 
negative effects from the medicines, participants had several types of information that could 
be taken into account when evaluating the tablets and making decisions about whether to 
continue taking them. Information from their doctor was one trusted source, but experiences 
make up an important part too. The balancing of disease risk against possible benefits and 
harms from medicines is a central feature of risk management prescribing, but might be done 
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differently depending on if it is done from a patients’ or a clinician’s perspective. The following 
quote from Albert, who takes blood pressure tablets as well as statins for his cholesterol, sums 
up the challenge of risk management prescribing, and shows that also patients can have a very 
good understanding of this medical challenge: 
“I would like to think I am not taking anything that is unnecessary as it 
were… I suppose it is what you are asking and how can I answer the 
question; what is the balance between alleged side effects or you know, the 
doubted benefits of a stable blood pressure, I don’t know. […] I appear to 
be suffering from no side effects, there is an alleged tangible benefit, so I’m 
happy to carry on.” (Albert) 
After hearing participants describe their own experiences of ill health and use of medicines at 
the start of each interview, I used their examples in questions about if and how they combined 
the ‘pros and cons’ with the medications. Prompts related to these questions included which 
aspects they took into account and whether their opinion had changed over time. I was 
interested to hear what went into the balancing from participants’ point of view, and also what 
type of language they used to describe CVD risks, effects and possible outcomes. 
As seen in the quote from Albert above, some of the participants in this study sided with a 
medical description to illustrate their reasoning around positive and negative short- and long-
term effects. Others extended it by using hypothetical descriptions or including previous 
experiences of using medicines when describing how they did it. Nathan describes how he 
wants to understand the medicines in much the same way as he wants to understand how other 
things work. Michelle and Judy compare their blood pressure treatments to having used other 
medications, causing tangible effects and side effects. 
“I mean even if you had a slight negative effect in some way… I think you 
have got to find out, you know, by asking the doctor, what is the balance 
because even though in the, well say in the long term living with that 
negativity... might not be as bad as having a problem for which the drug you 
are taking is supposed to prevent, so yes you have to understand. Well for 
me anyway, just for my peace of mind.” (Nathan) 
“I think it was the morphine that kicked it over the edge. Had I not gone on 
the morphine I think I had just trundled along and not thought about 
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medication because my life was… it was such a norm for me to take it.” 
(Michelle) 
“Compared to what I have had before, there is absolutely no impact 
whatsoever, which is good.” (Judy) 
After incidents with experiencing side effects from treatments, participants tell me how they 
had become aware of what can happen when you start taking a new medicine or change the 
dosage of an old one. This has prompted an apprehensive attitude when a change is suggested, 
and there are several ways to try and find out as much as you can beforehand. Here, other 
people’s experiences add to one’s own knowledge. Information is shared with friends and 
family, and explanations from the doctor are balanced with one’s own active testing of the 
medicine and thoughts about future outcomes. Anthony and Alfred had experienced some 
unpleasant side effects from medicines and medical procedures in the past, and Paul was 
acutely aware of how present problems needed to be balanced with future outcomes. 
“… so if I get a new medication, I will question what it does and what it is 
supposed to do, and as long as you have got that in your mind you can sort 
of go along and you toe the line, that has worked for me. But it is only 
through questioning.” (Anthony) 
“But it wasn’t until I spoke to other people that I realised it was the 
felodipine that was doing it.” (Alfred) 
“It’s a risk assessment in effect, and as I say I know whilst it is sometimes 
unbearable, uncomfortable, irritating this dermatitis… As I say, with being 
a lay person, I think to myself well that’s never going to kill me, why take 
the risk? And say ok, the blood pressure may, I could have a stroke.” (Paul) 
Participants also mentioned more general thoughts on the concept of using medicines that were 
included in the balancing. Having to take medicines is framed as both socially and personally 
undesirable – for example by Joyce who describes how some people use medications as a 
reason for giving up on trying other ways to stay healthy. Examples of the individual 
disadvantages included thoughts about whether using medicines for a long time has negative 
effects aside from those that are immediately discernible; damage might build up over time, 
which is of great concern to Stephen who worried quite a lot about being on life-long 
medication. The amount taken every day was also of concern, and low numbers of tablets or 
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milligrams taken every day were given as justifications of participants’ own use of medicines 
being acceptable and manageable. From a social perspective, participants mention ‘other 
people’ who unfortunately have to take many tablets every day. Their own medicine-taking 
was justified by referring to the diagnosed CVD risk; many participants stressed that they did 
not particularly want to take tablets, but did so because they had to. 
“I think the less tablets you can take, the better to be honest with you, 
because everything is going to have a side effect a bit isn’t it?” (Rose) 
“What I worry about is the side effects on your internals, kidneys and 
especially your liver. With this chemical compound that I’m taking, that it 
won’t cause me jaundice or things like this. When I’m taking the vitamins I 
know they’re not doing any harm to me but when you’re taking chemical 
compounds every day, twice a day, 365 days a year you get to think well, is 
there a build-up of all this chemical going round in my body?” (Stephen) 
“people I think a lot of people take a tablet, sit down and think well that's 
my life over, you know if they are taking medication which I could have 
done, I am just going to sit here now and you know I am taking tablets and 
that's it. You can't do that, you have to try and continue as best you can.” 
(Joyce) 
6.3.5 Concluding the subtheme 
Participants’ assessment of effects from the risk management medications comes together in 
their conclusions about whether the medicines work for them – if they bring the blood pressure 
or cholesterol down without causing unpleasant side effects. Testing, visualisation and physical 
experience of effects build patients’ knowledge about how the medicines work and what they 
achieve. 
In relation to the unpleasant experiences surrounding the CVD risk diagnosis (see section 
5.5.1), visual and numerical repeated proof of one’s blood pressure being stable seems to 
reassure participants that they are managing the condition. Those that were not worried by the 
diagnosis felt they had taken steps toward prevention. Accessible and practical approaches to 
depicting the risk condition appeared to be strong motivators for treatment. 
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Throughout this subtheme, the user of medicines is present as an active agent, testing and 
evaluating to assess the medications. This role, also exemplified by the feeling of responsibility 
to take action and control one’s risk, exists in parallel to a more acquiescent one that trusts and 
follows the doctor’s advice (see for example section 5.7.1). However, both types of reasoning 
still rely on two assumptions regarding CVD risk management: the applicability of medical 
evidence onto oneself is taken for granted, and CVD risk is regarded as serious and potentially 
life-threatening. Participants’ acknowledgement that the initial decision to take medicines was 
not to their own liking or choice, but was made out of necessity, shows how the view on CVD 
risk and its management is negotiated with personal opinions about medicines. 
 
6.4 Thoughts about future outcomes 
To find out how participants pictured the long-term preventive effect from CVD risk 
management medicines, I asked which results they hoped the tablets would produce and 
whether they felt it was worth the effort to take them every day. Both high-risk and low-risk 
participants referred primarily to the immediate effects on the risk factors – as shown above, 
stable blood pressure and cholesterol values were seen as treatment success – but thoughts 
about future outcomes were also present. 
6.4.1 Effects for me 
As shown under the sub-theme ‘Contextualisation’ (see section 5.6), part of participants’ 
understanding of their high blood pressure diagnosis was that it would lead to severe 
consequences. In response to my questions about whether they felt or thought the medicines 
were effective not only in controlling the blood pressure but also in preventing heart attacks or 
strokes from happening in the future, participants combined the generalised statements about 
protection from disability and death with ideas based in experience and personal understanding. 
The balancing of tangible effects at present with hoped-for prevention from serious illness in 
the future was mentioned by a few participants. In their examples, they used references to their 
presently controlled blood pressure to explain what the medicines would achieve in the long 
run. Both Michelle and Nathan, who had very different backgrounds in terms of experience of 
ill health, made a direct connection between effects now and outcomes later. 
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And even if you don’t kind of feel the effect of the blood pressure tablets, do 
you trust that they can help you? 
“Yes I do. I hope they are. Yes, because they’ve lowered my blood pressure 
so therefore I would imagine I’m less likely to have a heart attack or a 
stroke. So that’s the bottom line really.” (Michelle) 
“I mean I am you know… quite willing to take them just to prolong my life, 
you know, stop any serious problems.” (Nathan) 
Influence on the eventual outcome was not elaborated on as much as the visible, accessible 
sign that the blood pressure has come down. However, most participants indicated that they 
trust that the tablets play an important role in preventing serious events. The following quotes 
are a reminder of how the CVD risk diagnosis is perceived, and also show how effective 
medicines are seen to be for saving one’s life. Here, Norman relates to his previous angina 
problems whereas James puts CVD prevention into a community perspective. Taking 
medicines to manage the risk is presented as a case of either-or, rather than shifting 
probabilities. 
“Well you know as I said before you don't have a choice. Do it or croak. So 
you have got to take them at their word. I mean, you hear about bad doctors 
and they prescribe the wrong drugs and things like that but at the end of the 
day, you have got to feel these things out for yourself haven't you.” 
(Norman) 
“… and being in the funerals [running a funeral home] I know it’s nowhere 
near the average. My wife was only 59, and I can go to the cemetery and I 
know more people there than what I do out in the streets. And I look at the 
ages: 36, 24, 48, 37 when I go to her grave and as I go around I think ‘there 
but for the grace of God’, so I keep taking the tablets.” (James) 
Participants’ reasoning about medicines and prevention was related to different aspects of 
health. Some wanted to ensure longevity, like Nathan who made sure to live healthily with a 
lot of exercise and good food. Those that had young children, like Michelle and Samuel, 
mentioned capacity to take care of one’s family. Holly, who had a lot of experience of health 
problems but also had worked out how to manage them, wanted to be able to enjoy life. This 
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highlights some of the expectations that participants place on CVD risk management, and also 
points to the individual as being the centre of interpretation. 
“I would prefer not to take anything but it’s medicine, it keeps you alive so 
yes.” (Nathan) 
“give it me, I don’t care what it is, as long as it keeps me standing for my 
kids” (Michelle) 
“I have to live, not just for myself. I’ve got very young children as well. So 
I have got to look after myself to be able to look after these people who 
need my help. Now, if I was just a person on my own, probably I wouldn’t 
care that much. So I have to look after them. In order for me to look after 
them, I have to look after myself. And that’s my philosophy about the 
whole thing.” (Samuel) 
“I value my life too much. I value my quality of life too much. Because I do 
know if I didn't take my arthritis drugs I wouldn't be able to walk, I do know 
my psoriasis would just be horrendous, but then that is just a part of life, but 
my asthma would bother me, my high blood pressure would bother me, and 
life is for living […] We live every day we possibly can, you know to the 
best of filling in every minute of what we want to get done.” (Holly) 
6.4.2 Effects in general – CVD risk management as a principle 
This final category entails the descriptions of how the strategy of CVD risk management was 
perceived by participants. As shown throughout the previous display of findings, participants 
used multiple sources of knowledge when making decisions about their own use of medicines; 
most notably personal experiences and information shared by their doctor. Similar resources 
were used also in participants’ appraisal of prescribing and its outcomes on a more general 
level. 
Opinions on cohort strategies for disease prevention revealed some criticism towards the 
current strategy of extended prescribing. Alfred had declined the addition of statins to his blood 
pressure treatment, and describes how a focus on more medicines could challenge the trust in 
doctors. His complaints focused on statins, whereas Samuel questioned pharmaceutical 
intervention in general. 
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“Well I don't know, I think, like this business with the statins I think, I feel 
sometimes that they can be a bit blinkered, that they tend to be looking 
down a sort of narrow avenue, rather than looking at the wider picture. I 
don't know whether that's right or wrong but that is what I generally feel.” 
(Alfred) 
“people like myself should be encouraged to, instead of all this stuff which 
is too expensive and they might have side effects, to encourage to do more 
things […] how to eat, dieting, exercising, stuff like that. But the doctors 
don’t do that, they immediately prescribe these things. […] All this which I 
think is expensive, and also probably they’re not working as good as they 
may think, the doctors might think.” (Samuel) 
However, some participants expressed examples of how risk management medicines also have 
a place within the wider context of health promotion. These accounts related to the person’s 
own health and perceived outcomes, as well as hinting at the principle behind large scale 
prevention. Paul, who is in the low CVD risk group and manages his blood pressure with a 
singular type of medication, does not see the daily tablet as infringing on his life, and Nathan 
has also come to see the medicines as yet another part of his efforts to stay healthy. So does 
Joyce, who refers to her and her husband’s situation describes their medicines not as an 
indicator of illness but as a way to health. 
“No-one is asking me to do much, they are not asking me to run a marathon 
every day, are they? It’s simply take these tablets so… I would do it.” (Paul) 
“We consider ourselves very lucky that we have got to this stage and we are 
still in our, you know, reasonably healthy with the help of medication.” 
(Joyce) 
“So I don't believe the risks were there but having said that... It is beneficial 
obviously to be more healthy so if you can lower your blood pressure down, 
to a moderate level, that in the long term should benefit me, I recognise that 
that is... I still don't like taking the drugs, but I am willing to do that for the 
longer term health benefits.” (Nathan) 
Participants’ accounts of risk management medicines form a complex picture, where the 
arguments of personal health promotion and a view that one has to take medicines against CVD 
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risk are combined. The last few quotes display yet another aspect of how participants apply an 
individual perspective in understanding risk management prescribing; the conclusion that 
medicine-taking adds to healthiness was based solely on one’s own situation and did not extend 
to the population perspective. 
6.4.3 Concluding the subtheme 
Risk management medicines are interpreted as effective against personal CVD risk – they are 
a way to avoid death and disability from heart attacks and strokes. Some critique was expressed 
against the strategy of prescribing for prevention, particularly regarding statins. However, 
scepticism against one type of drugs did not preclude acceptance or perceived necessity of for 
example blood pressure medicines. 
 
6.5 Discussion 
The findings presented under the ‘Seeking stability’ theme describe how patients evaluate the 
medicines they are taking and how that informs their understanding of CVD risk management. 
Below, I discuss the mechanisms around evaluation of medicine-taking in relation to a 
diagnosis based on risk for future events, and possible challenges to the strategy of prescribing 
for prevention. 
6.5.1 Seeing is believing 
All participants in this study had made the choice to take medicines to do something about their 
CVD risk. When evaluating the effects of their tablets, participants used several sources of 
knowledge. Experiences play an important part; it was stressed that the medications have to 
‘suit you’ and many refer to a personal feeling of what is acceptable. In addition, the 
quantifiable signs that the medicines were effective are a key feature in evaluation. 
The visual indication of lowering and stability of the blood pressure was described in terms of 
providing knowledge that the medicines are effective. This confirms findings in studies of 
patients’ perceptions of blood pressure medicines, where the changes in pressure are a main 
way to evaluate effect.[185,186] Also participants that expressed initial doubts about various 
aspects of the risk assessment process (the calculation of an individual’s risk for disease, the 
mechanism of action for medicines, their own need for medicines and also the overall causes 
for high blood pressure) saw the change as a confirmation of effect. Despite questioning the 
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reasons underpinning risk management prescribing, once the medicine is ingested and seen to 
exert an effect on the body, that experience overrides the criticism and medicines become 
accepted. These empirical findings resonates with two of the themes in the literature review 
(see chapter 2), that patients’ expect medicines to achieve particular effects, and that on-going 
evaluation of medicines contributes to changeable views on them. In the case of CVD risk 
management, accessible and practical approaches to depicting the risk condition appear to be 
strong motivators for treatment. 
From seeing that the once high blood pressure or cholesterol has come down due to one or 
several medicines, participants have concluded that the medicine was effective, thereby 
justifying its use. This interpretation was also somewhat extended to include wider outcomes; 
the confirmations of stability were translated as ‘everything is fine’. However, the repeated 
visual indications of stability and control also serve to maintain the image that medications are 
continuously needed. Confirmation of effect in this way offers patients a way to evaluate and 
get to know their otherwise intangible condition. As suggested by Nichter and Vuckovic [187] 
in their outline of anthropological aspects of pharmaceuticals, patients may come to understand 
a condition by means of the medicine prescribed against it. The interpretation of a controlled 
biomarker as effect on long-term outcome is also in line with the suggestion by Saukko and 
colleagues [180] that risk assessment technologies which focus on particular measurable 
aspects of CVD risk – such as cholesterol or blood pressure – shape patients’ understanding of 
what the risk is and which interventions will be useful to manage it. The visible effects on 
biomarkers become a way to understand also the CVD risk, and this creates a feed-back loop 
that supports the need for medicines. It also adds to the picture of CVD risk as being a specific 
condition rather than a classification according to designated thresholds. 
The production and recording of data – blood pressure readings and cholesterol tests – that 
shows the induced stability appears to support patients’ reasoning. As suggested by Berg and 
Bowker,[188] medical records play a part in showing, but also defining, patients’ bodies. In 
my study, participants readily referred to their own measurements and those done by GPs and 
nurses as confirmations that the medicines were effective and their state was good. Thus, a type 
of data that is defined by a biomedical view of the body and closely connected to the principle 
of cohort approaches in medicine appears to also be embedded and interpreted within patients’ 
daily lives. Following the reasoning by Mol [189] this visualisation of CVD risk in the form of 
controlled biomarkers offers experiential knowledge of what CVD risk is; it confirms that there 
was indeed a condition which is now being managed. 
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Although the medicines contributed to the establishment of an ontology of CVD risk for the 
low risk patients (who had no experience of cardiovascular ill health), their significant role did 
not fully make the condition a disease in participants’ accounts. For example, indications that 
the long-term usage of prescribed medicines means getting labelled as sick or that it infringes 
on people’s autonomy or integrity [41] were largely absent in my data. Instead, participants 
showed how normalised the risk management medicines are by telling me how they discussed 
them with friends and colleagues. Strategies to avoid medicine-taking [98] were also absent, 
apart from the alternatives to tablets (diet, exercise and avoiding tobacco) that were mentioned 
by some participants. The tablets had been incorporated into daily life and I heard many 
examples of how simple it was to just take them every day. Having to take tablets is seen as 
either simply a routine thing or as an unfortunate but necessary sign of getting older. In spite 
of placing CVD risk in a context of dramatic personal illness, the medicines taken to avoid it 
are, or quickly become, an undramatic part of everyday health work. The interpretation of the 
CVD risk diagnosis as serious and the subsequent suggestion about treatment as personalised 
advice (see chapter 5, sections 5.6 and 5.7) might explain this observation. 
A major argument in explaining why to use medicines is that the doctor recommended them. 
The recurring logic referred to by patients is ‘my GP would not prescribe the medicine to me 
if it was not going to be beneficial’. Perhaps this can explain why the medicines were not seen 
as a negative labelling – they are justified since they are necessary for the treatment of a 
supposedly serious condition. Interpreting the application of a clinical guidance as a 
personalised recommendation undercuts a main principle of population-level risk management. 
Here, as in the case of interpreting the relation between the CVD risk diagnosis and possible 
outcomes, the denominator used by patients is again their own singular person. 
6.5.2 Sources of doubt 
In terms of patients’ views on CVD risk management as a health care strategy, the conclusions 
from the interviews divide in two. There was uniform acceptance of using medicines to achieve 
control over one’s blood pressure and thus over one’s risk; those medicines do not infringe to 
any particular extent on daily life and taking them is seen as a small effort for the anticipated 
gain. Since the risk management medicines were depicted by patients’ as a way to promote 
health, it was feasible even for people that doubted the generalisability of risk assessment data 
to themselves to come to the conclusion that they should keep taking tablets. However, 
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participants also expressed criticism against aspects of prescribing for the purpose of risk 
management. 
Here, the apparent difference between anti-hypertensives and statins comes to attention. In the 
interviews, the value of the former type of medicines was uncontested by participants whereas 
the latter were to some extent doubted. Regarding statins, suggestions were put forward about 
financial rather than health-related motives for prescribing, in a way similar to what I found in 
the analysis of newspaper articles (see section 3.6.4). The changeable environment of advice 
about health and medicines was seen as confusing; one example being the public debate around 
statins. Some participants referred to their own experience of GPs seeming to have an agenda 
of wanting to find conditions to prescribe medicines against, and formulated this as general 
criticism against extended prescribing. These views stand in contrast to the description of 
statins as a safe, simple and straightforward way of managing CVD risk and saving lives that 
was communicated in some of the newspaper articles about them (see chapter 3, section 3.6.) 
In the light of patients’ desire for confirmation of medicines’ effects, the availability of self-
measuring devices for blood pressure but not for blood cholesterol might facilitate the building 
of trust in anti-hypertensives in a way that is not currently possible for statins. Anti-
hypertensives were thought to be safe and reliable – their place in CVD risk management was 
fully accepted by participants in this study, much on the basis of their clearly visible effect on 
the blood pressure. In contrast to the heavily debated statins, neither the recent questioning of 
the historically accepted associations between blood pressure and CVD mortality found in the 
Framingham study [182] nor reminders of the complexity of risk assessment and management 
[190] have reached the public debate. 
In the case of blood pressure the monitors are even owned and thus incorporated into daily life, 
making it possible for patients to fully engage with the responsibility for risk management. 
Monitoring creates a context for the daily medicine-taking, by confirming effects and 
reassuring patients that the daily routine will bring about some change also in the future. 
Besides perhaps being used as an explanation by the prescribing GP, this message is also 
abundant in the public domain. As charities strive to increase awareness around the 
consequences of disease and pharmaceutical companies strive to maximise their markets, 
public campaigns have planted the idea that medicines against risk promote health and 
longevity.[61,135] Patients’ knowledge and understanding could thus be influenced by the 
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narrative that depicts taking control over one’s cholesterol and blood pressure as favourable, 
and medicines as the way to do so. 
Intervening towards risk by prescribing medicines has traditionally been considered a specific, 
exceptionalistic approach in prevention strategies – in contrast to broad, universalistic ones that 
promote health for whole populations. [75,191] (see also chapter 1, section 1.4) What comes 
across in my interviews is an indication that this might have changed in patients’ views. This 
confirms the finding of the previous chapter; that medicine-taking fits in amongst other efforts 
to increase or maintain health and is not primarily a demarcation of illness. 
 
6.6 Summary 
Participants interpreted the stability gained from medicines as indicative about future 
outcomes. This resembles the biomedical model where the risk for CVD is represented by a 
number of isolated associations between biomarkers, behaviours, incidence and mortality. In 
this sense, participants have adopted a reasoning that is patterned after the campaigns to raise 
awareness about, and promote interventions towards, CVD. 
After this detailed account of the findings in the empirical part of my study, I will now review 
them together with what I learned from the two literature reviews and consider the overall 
findings in my research. 
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Chapter 7 
Review and discussion of findings 
 
7.1 Chapter overview: Formulating an answer to the research question 
In this chapter I reflect on the findings in the three studies – the two reviews of scientific and 
lay literature, and the interview study – and give my account of the research problem that was 
formulated at the beginning of this thesis. Hence, I will consider how the new knowledge about 
patients’ views and practices around medicines presented in this thesis can contribute to a better 
understanding of the complex issue of polypharmacy (see section 1.1) and how my findings 
contribute to shaping the concept of pharmaceuticalisation (see section 1.3.3). 
Over the course of the research, I have addressed different aspects of the research question 
“What are the influences on patients’ understanding of the use of medicines in cardiovascular 
risk management?” Contributions from each study are presented below, and combined in a 
discussion about how patients’ views shape the use of medicines in CVD risk management. 
Possible implications of the findings are considered for health care practitioners, policy-makers 
and scholars working on issues related to pharmaceuticalisation and excessive use of 
medicines. To relate my findings to the field of polypharmacy, I discuss them in the light of 
three recent documents on the prescribing and use of medicines; one from a professional 
organisation, one commissioned by an independent think tank and one reflecting the views of 
UK health care policy-makers. The documents are the Royal Pharmaceutical Society’s report 
on Medicine’s optimisation,[24] the King’s Fund report on Polypharmacy and medicines 
optimisation [1] and the NHS five year forward view developed by NHS England, Public 
Health England, Monitor, Health Education England, the Care Quality Commission and the 
NHS Trust Development Authority.[23] This critical review of my findings will consider what 
incorporating a more comprehensive model of patients’ views of medicines would mean for 
the efforts to manage polypharmacy. 
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7.2 General influences on patients’ expectations of medicines – findings in the literature 
review 
The review and synthesis of literature on patients’ expectations of medicines (chapter 2) was a 
scoping, exploratory analysis at the start of this research project. Its research questions were: 
“What are the influences on patients’ expectations regarding prescribed medicines?” and 
“What benefits do patients expect from medicines prescribed for long-term prevention of 
disease?” Descriptions of influences on views, beliefs and expectations were collected from 
empirical studies of medicine-taking for a range of conditions. Thematic synthesis produced 
four themes showing different types of influences on patients’ expectations on medicines. The 
themes are outlined in figure 7.a, together with the major findings that informed the subsequent 
parts of my research. 
Themes and findings of importance to the overall research question 
A need to achieve a specific outcome 
 
Naming of specific targets with treatment 
Confirmation of effect on targets 
Wishes for high and guaranteed benefit from risk 
management medicines 
Experiences and evaluation develop over 
time 
Own and vicarious experiences are used 
Medical and social sources of information 
Negative values – dependency, criticism 
and social stigma 
Certain medicines have negative associations 
Number of medicines might be too high 
A personalized meaning of medicines; 
their necessity and usefulness 
The view on medicines is related to one’s personal 
understanding of health and illness 
Medicines have different roles in peoples’ lives, 
e.g. helping or hindering normality 
 
Figure 7.a Summary of the findings in the review and synthesis of literature on patients’ expectations. 
 
This analysis provided me with an overview of the mechanisms that influence patients’ 
expectations. In terms of informing me about the particular field of CVD risk management 
prescribing, a number of aspects were identified. One was the significance of specified targets 
for treatment. In symptomatic illness, those targets reflected the symptoms. In the case of risk 
management, patients had likewise specific expectations that the medicines would produce 
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certain effects. There were indications that patients expect more benefit from such medications 
than is clinically possible, for example larger risk reduction and longer predicted survival time. 
Another prominent gap between the biomedical and patient-based understanding was indicated 
by how patients seem to expect guarantees of beneficial effects from preventive medications 
such as anti-hypertensives and statins.  
From the review, I could also conclude that experiences play a large role in patients’ short- and 
long term evaluation of medicines. Perceived effects of medicines are balanced with illness 
symptoms, for example in cycles of testing a medicine’s effect versus illness symptoms. 
Vicarious experiences and professional as well as lay advice also go into the evaluation process. 
This raised the question about which mechanisms are at play in the sense-making around 
interventions targeting asymptomatic CVD risk, where no symptoms or improvement are 
tangible but an abundance of information is available: positive and negative accounts are 
disseminated by health care professionals, the media and perhaps also shared in discussions 
among peers. 
The theme describing personalised meaning of medicines’ usefulness and necessity highlighted 
how patients using medicines for the same condition can hold different and even opposing 
expectations of the function of the medication in their lives. It indicated that the position of a 
medicine within a patients’ understanding of health and illness is strongly influential on what 
the medicine is expected to do. If the understanding of CVD risk management medicines is 
similarly individualised, that highlights a possible tension regarding the idea behind large-scale 
prevention strategies where many people need to take treatment for the average benefits to be 
delivered. 
This first study confirmed the possible diversity of views of medicines and their use that is 
reflected in the sociological literature (see chapter 2, section 2.2 for examples), since my overall 
finding was that patients’ views on medicines and the usage of them are indeed more complex 
than accounted for in a biomedical description of health promotion and risk management. It 
highlighted patients’ conceptualisation of preventive benefit from medicines as particularly 
different from that which is offered on a biomedical basis. Thus, it strengthened the focus for 
my research towards exploring patients’ understanding of the concept of CVD risk as a way to 
investigate the consequences of extended risk management prescribing. 
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7.3 Societal influences on people’s concepts of CVD risk management – findings in the 
review of newspaper articles 
The review and thematic analysis of descriptions of CVD risk and risk management in UK 
newspaper articles (chapter 3) focused on how a message about new guidelines for risk 
assessment and prescribing of statins transferred from the professional and policy perspective 
into a lay context in print media. The research question in this study was “What representations 
of CVD risk, and the benefits and harms of statins in managing that risk, are communicated by 
UK newspapers?” Four themes were identified; see figure 7.b. 
 
Themes and findings of importance to the overall research question 
CVD risk is identifiable 
and measurable 
CVD risk presented as a combination of individual, specific risk factors 
Risk assessment is not questioned 
Statins save lives – but they 
also cause problems 
Statins are protective and ‘cut’ the risk for disease 
Benefits are presented as summary measures on the population level; 
harms as individual stories about debilitating side effects 
Making an informed choice Readers were encouraged to consider their own risk and make a 
personal decision about whether to use medication 
Some newspapers took on the role of guiding people to a decision 
CVD risk management is a 
medical issue 
References to social determinants of health, such as the link between 
poverty and CVD, were largely absent in the articles 
Despite criticism against medicalisation of unhealthy lifestyles, 
suggestions about approaches to improve the situation did not go 
beyond saying that individuals need to change their habits 
 
Figure 7.b Summary of the findings in the analysis of newspaper articles about statins in CVD risk 
management. 
 
One influence on patients’ understanding of medicines for CVD risk management was 
indicated in the newspapers’ portrayal of the risk itself. Age, sex and lifestyle factors were 
given as causes of CVD risk and some articles offered examples of how combinations of these 
make people eligible for treatment under the new guideline. The naming of specific causes was 
accompanied by statements that encouraged people to address their own situation and decrease 
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the risk by living healthily – possibly with the help of medicines. Newspapers presented CVD 
risk as a distinct condition that can be identified and controlled. 
Alongside the rather contained image of CVD risk, the newspapers presented a more diverse 
account of the medicines prescribed to control it. The message from NICE about how many 
lives would be saved by increased prescribing and use of statins was complemented by 
accounts of various negative effects from the medicines, illustrated by personal stories and 
observational studies. The presentation of evidence produced in randomised clinical trials side 
by side with experience-based and observational data broadens the image of effects from statins 
and provides people with examples of when the decision to use them has had negative 
consequences. It may also indicate to readers that personal experience plays an important part 
in decisions about medicines. Thus, the implied control over risk was complemented with 
aspects of uncertainty originating from medicines. 
While reiterating the message from policymakers that statins are effective, safe and cheap, the 
reporting in newspapers also reflected the complex balancing of medical information, 
experiences and personal views in making decisions for individuals. Critical accounts of the 
quality of data underpinning the new guideline and possible influence from private interests 
added elements of uncertainty to the image of CVD risk management with statins. However, 
in response to the difficult decision about whether to use statins or not, the newspapers 
recommended that readers see their GP to get personalised advice on what is right for them. 
This reframes the complex issue of CVD risk management in a seemingly simpler context of 
professional expertise and presents it as a predominantly medical issue. Adding to the medical 
framing was the fact that other possible discourses about cardiovascular health were absent 
from the descriptions. Articles focused the stories on whether or not to take tablets in response 
to a diagnosis instead of discussing for example social determinants of health, the availability 
of food, alcohol and tobacco or the link between poverty and CVD. 
In summary, I saw a variation in the newspapers’ presentation of different aspects of CVD risk 
management. While the risk for disease was portrayed as an established condition, the 
medicines used in its management were presented in a context of uncertainty regarding both 
positive and negative effects. The newspapers place the individual person at the centre of 
decisions about statins, and GPs are appointed as the experts to help negotiate risk, benefit and 
harm. 
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7.4 Individual understandings of using CVD risk management medicines – findings in the 
empirical study 
The empirical part of this project was my opportunity to directly address patients’ 
understandings of CVD risk management. My research question was “How do patients 
conceptualise CVD risk management with medicines?” The interviews explored each 
participant’s experiences and views, and also made it possible to test emerging conclusions 
from the two literature studies. Thematic analysis produced the two themes described in 
chapters 5 and 6, namely how patients perceive being at risk for CVD and how they understand 
medicines as a way to manage that risk. The themes are summarised in figure 7.c. 
Themes and findings of importance to the overall research question 
Being at risk A CVD risk diagnosis is pictured in terms of its ultimate consequences 
 Knowing about the risk encourages patients to take action to lower it 
 A GP’s suggestion about risk management treatment is interpreted as 
personally adapted advice 
Seeking stability Effect on biomarkers confirms that the medicine was needed and is 
beneficial 
 Controlled biomarkers are interpreted as controlled risk 
 
Figure 7.c Summary of the findings in the interview study. 
 
My starting point for this thesis was to question what makes people accept and take CVD risk 
management medicines despite the low and indiscernible benefit. In the empirical part of the 
project I set out to investigate what might influence patients’ understanding of the benefits 
from such medicines. I can now put together some factors that seem important in explaining it. 
An individualised interpretation, shaped by personal or family experience and advice from a 
health care professional, is the foremost mechanism that explains patients’ reasoning and 
actions. Information indicating both negative (the consequences of having high blood pressure, 
the risk for side effects) and positive (benefit from CVD risk management medicines) events 
is interpreted not as ‘one chance in a large number’ but as being about a specific person. In 
short, it seems like medical information made available to people gets applied to oneself. 
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The CVD risk conditions of high blood pressure and high blood cholesterol were 
predominantly understood in a medical context rather than a social one, and portrayed in terms 
of their potential to cause heart attacks and strokes. With the individually based reasoning just 
mentioned, participants thus saw the diagnosis as a personal indication of imminent, severe 
illness. Since the information about the risk was given to people by their GP, it was deemed to 
be valid and valuable for them as individuals. In a similar way, the medicines prescribed to 
manage CVD risk factors were seen as beneficial for the individual. Participants referred to 
visual clues of effects that were available to them – the lowered and stable blood pressure and 
cholesterol showed that the medicines worked. 
The conclusion that the individual person is at the centre of patients’ reasoning is also supported 
by how it can be traced in their negative notions about CVD risk management. One example 
of this is the question of whether the otherwise trusted scientific base for decisions to intervene 
to contain risk were true ‘for me’. In other words, some participants told me they trusted the 
science and the benefit of medicines in principle, but had their doubts about applying it directly 
to themselves. Strategies used to overcome that doubt were either seeking support in the 
decision from one’s doctor, or trusting one’s own experience from trying and evaluating the 
medication for discernible immediate effects. 
Regular monitoring of biomarkers offers a connection between medicine-taking and 
medicines’ effects, and what is seen is interpreted by patients as a sign of benefit from the 
medicines. The stabilised blood pressure and cholesterol were understood as straightforward 
indicators of a lower risk for future events. Thus, patients used the visualised effects as a 
context that linked their daily tablets with future health and also confirmed that the doctor was 
right in suggesting that treatment was needed. Whilst being consistent with the underlying 
principle for risk management prescribing, patients’ perception of the situation entails two 
types of exaggeration of the association between biomarkers and outcomes: they manifest 
themselves as an overestimation of the level of preventive effect, and in the assumption that 
both the CVD risk and the benefit from medicines are directly applicable to oneself. 
Taken together, patients’ conceptualisation of medicines for CVD risk management seems to 
involve a personal interpretation of the risk and the benefits from attempts to contain it. The 
actions prompted originate from a medical view on health and illness, since the risk is mediated 
by health care professionals. Feedback in terms of effect on biomarkers is used as a 
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confirmation of the personal aspect of risk and benefit, and also keeps the reasoning in a 
medical context. 
 
7.5 Patients’ understanding of medicines in CVD risk management 
When the literature reviews and empirical work are considered together and in relation to the 
research question, three themes come across as present throughout the findings. These are 
presented (see table 7.1) and discussed below, showing my suggestions regarding the central 
influences on patients’ understanding of medicines in CVD risk management. 
Table 7.1 Key findings in the research, and the overall themes in the study 
General influences 
on patients’ 
expectations 
Newspapers’ 
representation of CVD 
risk management 
Patients’ conceptualisa-
tion of medicines in 
CVD risk management 
Overall themes 
in the study 
Patients expect 
guaranteed outcomes 
and more benefit 
than clinically 
available 
Risk can be identified, 
measured and controlled 
A diagnosed CVD risk 
needs to be treated with 
medicines 
A simplified 
representation of 
CVD risk and risk 
management 
Experiences inform 
an ongoing 
evaluation of the 
utility of medicines 
Medicines have both 
positive and negative 
effects, that need to be 
balanced by the 
individual 
Individualised 
interpretation of CVD risk 
and benefit from 
medicines 
A desire for defined 
and identifiable 
effects from 
medicines 
The role of 
medicines is shaped 
by personal beliefs 
Individuals should make 
their own, informed 
decision about the need 
for medicines 
Visual feedback confirms 
the individual 
interpretation of CVD risk 
and benefit from 
medicines 
A responsible 
patient expecting 
personal benefit 
from medicines 
 
7.5.1 A simplified representation of CVD risk and risk management 
The ‘patients’ perspective’ image of CVD risk that emerges from the findings in this project is 
one of a defined condition that can be measured by medical instruments and controlled with 
medications. Although patients may have unrealistic expectations on the level of risk reduction 
available, their approach to the condition is in fact close to the one presented in information 
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about CVD prevention published by for example the NHS and NICE. These emphasise risk 
factors such as blood pressure, cholesterol levels, age and lifestyle and also provide summary 
figures of how many people die from cardiovascular events every year. Patients have 
internalised the biomedical understanding of an association between biomarkers and risk level, 
and that getting older will lead to a need for medicines. The fact that a risk is diagnosed seems 
to indicate that it is valid – GPs are trusted representatives of a likewise trusted medical science 
– and once it is known about, it cannot be ignored. Here, my findings indicate that CVD risk 
might be perceived as a more serious threat to health and wellbeing than other diagnoses that 
lead to preventive medicines. Other studies on patients’ decisions about whether to engage with 
long-term prevention (of type 2 diabetes and osteoporosis) report more varied reactions to 
suggestions about treatment, including doubt regarding medicines’ possible beneficial effects 
[104,107,108] and the need for experiencing symptoms before the diagnosis is seen as a reason 
to take action.[105] Notions that aging bodies will suffer from increasingly frail hearts and 
blood vessels and thus are quite likely to die from a heart-related condition – or even that 
everybody will eventually die from something – are not present. Neither are acknowledgements 
that risk factors have a weak predictive value for CVD-related mortality.[192] 
Further explanation for patients’ views on CVD risk comes from the importance of experiences 
in the evaluation of illness and medicines. When a diagnosed condition is asymptomatic, such 
as elevated blood pressure or cholesterol, patients draw on other types of experiences: cases of 
illness in the family or among friends become examples of what might happen if the risk is not 
contained. The result of the risk assessment, which isolates a few features of the individual’s 
situation and predicts the risk for a certain type of events, gets interpreted in terms of impact 
in a context that encompasses many more aspects of life. In their response to a CVD risk 
diagnosis, patients apply a risk score which represents an average measure in a population to 
themselves. 
The simplified representation of CVD risk and its management indicates that the meaning and 
character of preventive prescribing has changed since the strategy was adopted. When large-
scale intervention was introduced as a method to prevent CVD, the discourse differentiated 
between individual and population approaches.[76,192] The former, consisting of prescribing 
medicines or devising lifestyle changes for people at high risk, was seen as specific but 
requiring the motivated effort of individuals and clinicians. The latter, aiming to lower 
incidence of disease by decreasing exposure in a whole population, requires a compliant 
population that accepts changes such as lower salt-content in food or restrictions on tobacco 
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smoking. One conclusion from the current character of CVD risk and risk management that I 
have encountered in this study is that the concepts of individual and population strategies are 
starting to overlap. Drawing mainly on the findings in the interviews and the analysis of 
newspaper articles I find that risk for CVD is normalised as a common condition, but also 
interpreted as a disease that warrants intervention. Lifestyle changes are everybody’s 
responsibility, not just encouraged for those at high risk. Even a slightly elevated risk is now 
indication for prescribing [73,182], and the argument of ‘might as well’ is used as a reason to 
take medicines. 
7.5.2 A need for defined and identifiable effects from medicines 
The importance of tangible signs of medicines’ effects has been clear in all three studies, and 
in patients’ understanding of CVD risk management this is provided by monitoring of 
biomarkers. This reflects findings in other studies of medicine-taking in asymptomatic risk 
management, where numerical representations are reported by patients to be helpful when 
evaluating their medicines.[105,108,193] Medicines seen as doing a specific job in lowering 
the blood pressure and cholesterol is a recurrent interpretation of the phenomenon of risk 
management. This view of preventive medications resonates with the biomedical description 
of CVD risk that was offered by newspapers and also dominated in patients’ accounts. In short, 
the medicines are seen as tools to alleviate the risk. Contributing to the expectations of this 
defined effect from medicines might be the fact that the relation actually emerged the other 
way around. As shown in critical examinations of pharmaceutical drug development and 
marketing [61,135], the targeting of risk factors such as blood pressure and cholesterol was 
initiated only after suitable pharmaceutical compounds that controlled them were identified. 
Therefore, the available knowledge about CVD risk is entwined with claims about how it is 
affected by medicines. 
As in the case of patients’ interpretation of CVD risk, experiences also influence their 
understanding of medicines prescribed to manage it. Accessible, visual confirmations that one 
has achieved some change regarding the factors that signify the risk (blood pressure and 
cholesterol measurements) offer confirmations that the values were actually high – since they 
are now visibly lower. The emphasis on seeing the biomarkers come down when taking tablets 
suggests that once treatment has started, the measurements indicate that the action taken was 
worthwhile and beneficial. Perhaps informed by the popular imagery of CVD risk as closely 
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connected to biomarkers, the immediate and sustained effect is interpreted as a causal relation 
that also suggests an effect on CVD morbidity and mortality. 
Experiences of side effects are also influential on how medicines are understood in CVD risk 
management, and the review of literature on expectations identified it as an area where patients’ 
views might differ significantly from a biomedical description. My findings indicate that the 
negotiation between sources of knowledge regarding side effects is more complex than the 
straightforward interpretation of medicines’ effects on biomarkers. The newspaper articles 
presented harms and benefits from statins as opposed to each other, indicating that people gave 
up the tablets completely due to side effects. However, some of their critique towards extended 
prescribing of statins focused on the inadequate reporting of side effects in the trials that 
supported the guideline, perhaps suggesting that the correct way to know about statins’ effects 
is to feel for oneself. The interview participants indeed used both negative and positive 
experienced effects as a way to evaluate prescribed medicines, and balanced them against their 
general feeling of wellbeing and the perceived severity of the diagnosed CVD risk. This way 
of including experiences appears to be a recurring finding in qualitative research into long-term 
use of medicines, and is reported as influential on decisions about antidepressants,[102] 
medicines prescribed to manage CVD risk,[194] osteoporosis,[104] and type 2 diabetes.[105] 
These findings regarding how effects from medicines are interpreted indicate that patients 
devise a context of experienced and visualised results into which the daily taking of medicines 
for an asymptomatic condition is fitted. Since biomarkers can be easily assessed and visualised, 
they become the way that patients understand risk management medicines. The absence (from 
patients’ accounts as well as the newspaper reports) of the concept of risk reduction or other 
acknowledgements of a less-than-direct relation between biomarkers and future outcome 
suggests that patients do not necessarily discriminate between immediate and future effects 
from medicines. Thereby, the accessible signs of controlled blood pressure and cholesterol 
values shape patients’ understanding of the principle of risk management – medicines are seen 
as contributing to healthiness. 
Patients’ prioritising of stability as a sign of successful treatment of the asymptomatic CVD 
risk is not an obvious choice. Alternative indicators could perhaps be reaching the lowest 
possible blood pressure or cholesterol, striving to use a low number of tablets per day, finding 
a non-pharmacological way to intervene, or aiming for as little change to one’s daily routines 
as possible. The choice of stability might indicate an influence from pharmaceutical marketing 
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on patients’ perception of value from medicines; it builds on the narrative that health conditions 
are medical problems that can be solved with medicines [56] and that medications offer the 
transition from a state associated with disease and uncertainty towards normality and control 
over one’s life and health.[135] It could also reflect the way that health services are set up to 
treat people ‘to evidence based targets’ for biomarkers. When no further gain is implied from 
getting it lower, health care professionals might stop actively encouraging patients to take 
medicines, and this could be seen as an indication that health is restored. 
7.5.3 The responsible patient expecting personal benefit from medicines 
Throughout the investigation of influences on patients’ understanding of CVD risk and its 
management, it has been clear that people interpret information, conditions and short and long-
term effects from medicines with a perspective that puts themselves at centre. As shown in the 
two previous sections, the individual person is the denominator for both CVD risks and benefits 
from medicines. This finding is perhaps not surprising – current public health has been 
characterised as highly individualistic [195] – but it has implications for the effects of CVD 
risk management policies for prescribing and practice. 
Prevention prescribing focuses on individuals by assessing risk factors that are closely linked 
to both the social person (lifestyle choices) and the physical body (biomarkers). The messages 
communicated in NICE’s press release about the updated lipid modification guideline [130] 
were directed to individuals, and used an argument around lifestyle habits that people should 
adopt – one of them being the use of medicines to keep one’s cholesterol under control. CVD 
risk management is communicated using a language that appoints actions by individuals as the 
way to achieve the population-level targets. 
This imagery of CVD risk management medicines seems to also be the one that patients are 
using, albeit while attributing the knowledge of what is the right thing to do to their particular 
doctor instead of to a generalised body of medical evidence. Objective, scientific knowledge is 
hailed as superior to people’s shared experience or industry’s objectives, but trusted the most 
when it is delivered in a subjective form; seen as personal advice from a particular GP. Findings 
in my interview study indicate that the possible uncertainty about medicines’ benefit that was 
depicted in the newspaper analysis is resolved with trust in the personally adapted advice from 
a doctor. Other literature on patients’ understanding of medications prescribed to prevent future 
ill health, both in CVD risk management and in prevention of fractures in osteoporosis or 
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complications arising from diabetes, also suggest that the role of the GP (or other well-known 
physician) is important for patients’ decisions about using medicines.[107,109,194] 
7.5.4 Remaining gaps in the description of patients’ understanding of medicines in CVD risk 
management 
Although findings in the studies largely add to each other, there were also some areas where 
gaps remain. One of them relates to the role of social determinants of health as a risk factor for 
disease and a driving force behind prescribing of medicines. As mentioned in chapter 3, the 
link between for example poverty and CVD was largely absent in the newspapers’ reports about 
CVD and risk management. Lifestyle was mentioned as contributing to the risk for disease, but 
structural factors were neither addressed as causes nor interventions for improvement. In 
contrast, the significance of poverty and education on health in general was alluded to by some 
interview participants, saying they themselves were able make good decisions and could afford 
to eat well but others might not be able to. 
The gap between social and biomedical understandings of CVD and its prevention is present 
also in the criticism against increased prescribing as a way to manage risk. Cohort strategies, 
influence from the pharmaceutical industry and ‘too much prescribing’ in general were 
addressed by interview participants and in many of the newspaper articles. However, the 
discussion remained linked to medical matters (such as individuals’ need for treatment) rather 
than being connected with social factors (such as people’s ability and options to look after their 
health). 
An observation that might challenge the dominance of the biomedical view in patients’ 
understanding of CVD risk management with medicines relates to the prominence of individual 
interpretation of information about health and disease. As shown above, patients’ application 
of evidence presented by a prescriber to themselves supports the increased use of medicines. 
However, the same desire for personalised advice was the basis for some interview 
participants’ criticism and avoidance of medicines. One example is the interpretation of CVD 
risk assessment as over-generalised procedures with little relevance “for me”. Some 
participants also expressed a view of GPs as limited to acting within a certain dogma or policy 
instead of adopting a holistic view of their patient’s health. These participants were happy to 
take medicines for conditions where they had some experience of symptoms or consequences 
(personal or vicarious), but were critical of prescribing for reasons other than tangible health 
problems. 
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The scoping interviews with GPs at the start of this study (see appendix A1) indicated their 
trust in the guidelines for CVD risk management. Although they had different views on how 
to motivate patients to engage with treatment, they shared the opinion that the guidelines reflect 
best practice and should be followed for the benefit of both singular patients and whole 
populations. Thus, the personally adapted guidance from a GP – which contributed strongly to 
the interview participants’ decision to accept medicines and also was put forwards by the 
newspapers – did not correspond to how the GPs described their practice. The initial scoping 
interviews also indicated that organisation, the availability of guidelines, drug prices and GPs’ 
personal approaches to prescribing for risk management influenced their advice to patients. 
 
7.6 Situating the new knowledge – relations to CVD prevention policy and practice, 
polypharmacy and pharmaceuticalisation 
In this section, I summarise the new knowledge that arises from my study and suggest what it 
might mean in relation to the areas that form the background for the research. Since I used 
CVD risk management prescribing as the setting in which I examined patients’ views on 
medicines, the major findings in this study relate to this particular way of prescribing and using 
medicines. However, the research was undertaken with an aim to contribute new knowledge 
about polypharmacy, and thus I will suggest how it adds aspects to the current discourse of 
multiple medicines prescribing and use. Lastly, I will also return to the theoretical background 
of my study and comment on what the findings might contribute in terms of the evolving 
concept of pharmaceuticalisation. 
To guide this examination of what my research has contributed, I will relate the findings to 
three current reports which address the same area as my research; polypharmacy, health 
promotion and the use of medicines in the UK. The ‘NHS five year forward view’ from 2014 
stresses the importance of health promotion for the future of the NHS and the country,[23] 
highlighting prevention as a shared responsibility between communities and the health care 
system. The King’s Fund report Polypharmacy and medicines optimisation – making it safe 
and sound [1] was published in 2013 with the aim of giving an overview of the knowledge 
about polypharmacy and also to suggest some solutions to problematic issues. Published in the 
same year, the Royal Pharmaceutical Society’s report Medicine’s optimisation: Helping 
patients to make the most of medicines [24] had the objective to get practitioners and patients 
to work closer together to improve the use of medicines. In table 7.2, I summarise the key 
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points from the reports that are applicable to the use of medicines in disease prevention and 
how my study supports, challenges or extends them. 
Table 7.2 Implications of my findings for current efforts in the field of polypharmacy, CVD 
prevention and prescribing. 
Report Findings in this study Implications of my findings 
NHS five year forward view  
- Patient and community 
engagement is central to effective 
prevention of disease, as patterns 
of ill health are linked to 
geographical regions and 
conserved through generations 
- National action on smoking and 
consumption of alcohol, junk food 
and sugar will be reinforced by 
the NHS 
- Failure to increase engagement 
with prevention of disease will 
have implications for health 
inequalities and life expectancy, 
and lead to unnecessary health 
care spending 
If health effects of aging 
or lifestyle are presented 
as diagnoses, people will 
see it as their responsi-
bility to take medicines in 
order to maintain health 
Visible stabilisation of 
biomarkers is a key part 
of patients’ understanding 
of how their health is 
improved when they take 
medicines 
Primary care gets a reactive role 
in relation to other parts of 
society, where consumption 
habits continue to cause the ill 
health that is mentioned as 
targets for preventive efforts 
Perhaps health improvement of 
for example stopping smoking 
is less valued by patients, since 
it does not give as clear 
representation of change as 
medicines do 
Polypharmacy and medicines optimisation – making it safe and sound 
- Polypharmacy is not about the 
number of medications but about 
their management; it can be 
appropriate in some cases while 
problematic in others 
- Clinicians should avoid 
‘prescribing cascades’ and ensure 
clinical benefit from all 
prescribed medicines 
- Patients’ views on medicine-
taking are important but 
potentially different from 
prescribers’ views*, and a 
compromise about 
appropriateness might be 
necessary 
Taking a few medicines 
can be interpreted by 
patients as necessary due 
to aging 
 
Risk reduction (the 
evidence /information 
from GP and the 
controlled biomarkers) is 
interpreted by patients as 
personally adapted advice 
with considerable 
applicability for 
themselves 
The notion of appropriateness 
of medicines gets new 
dimensions by patients’ feeling 
of responsibility towards a 
diagnosed risk for CVD – with 
the strong trust in personal 
advice from a GP, even a small 
potential benefit is perceived as 
need for treatment 
 
 
 
 
(table continues overleaf) 
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Medicine’s optimisation: Helping patients to make the most of medicines 
- Medicines optimisation means 
prescribing according to evidence 
and ensuring that medicines are 
taken safely and correctly, for 
best clinical outcome and patient 
experience 
- Patient-centred, individualised 
care, including reflection on 
medicines optimisation, should be 
part of routine practice 
- Examples of patients’ views focus 
on technical and practical aspects 
(dosage times, safe packaging), 
and optimal use entails making 
patients knowledgeable, engaged 
and confident about taking 
medicines 
Patients’ optimal 
outcomes from medicines 
are when you “feel ok” 
and see clear effects (for 
example stabilisation of 
biomarkers) 
Optimal use in daily life 
might not correspond to 
medical instructions – for 
example, some testing of 
effects can be necessary 
to establish that the 
medicines “do their job” 
Truly patient-centred care 
might need to be clearer about 
the evidence behind medicines’ 
effects at low levels of risk 
 
 
Advice to ascertain that patients 
are taking medicines as 
instructed might need to allow 
for a period of patients’ testing 
of effects 
 
*However, the report does not elaborate on what they might be. 
 
7.6.1 Implications for CVD prevention policy and practice 
In relation to the current policy for CVD prevention, which is framed by the NHS health checks, 
[65] my findings highlight some aspects that have implications for the impact of this approach 
to promoting health and preventing disease. 
The most notable finding is the emphasis on personalised advice from one’s GP, and the trust 
placed in a diagnosis of CVD risk when it is mentioned by a health care practitioner that is seen 
as providing specific advice “for me”. Although the notion of patient-centred care and joint 
decisions about medicines is present throughout the guidance about CVD prevention – and 
emphasised in for example the NICE patient decision aid about statins [165] – the rationale for 
a population approach is to treat cohorts to reap benefits on the large scale. Services are set up 
according to this, with short appointments for checking biomarkers and issuing prescriptions. 
The finding in my study – that patients view their GP as a personal interpreter and mediator 
between a body of medical science and their own life and wellbeing – thus demands a different 
role for GPs to be trained for and take on in their practice. 
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The emphasis on patient-centred care also gets a new dimension by the finding in my study 
that patients overestimate the individual threat to health from a diagnosed CVD risk and also 
the individual benefit gained from medicines. Considering the important role of trust in one’s 
doctor, CVD risk management could present GPs with a challenge if they are to offer patients 
a truly informed choice. Being clear about the level of risk reduction that medicines actually 
offer might threaten the perception of individual applicability of both the risk and the protection 
from medicines, and thereby undermine patients’ trust in the concept of CVD prevention. 
7.6.2 Implications for the UK discourse on polypharmacy 
Two of the reports (from the King’s Fund and the Royal Pharmaceutical Society) have a strong 
biomedical focus on health, disease and medicines, where patients’ views are pictured as 
centred on the practical aspects of medicines use. Notably, the report from the King’s Fund 
points to the limited knowledge about patients’ views of medicine-taking, and calls for it to be 
determined. This indicates that my findings can add valuable knowledge, by proposing an 
outline of patients’ reasoning around the need for, and effects of, medicines. For example, 
practicalities such as opening packages or understanding instructions did not come across as a 
concern for participants in this study, whereas getting diagnosed with high blood pressure 
represented something that had an impact on many patients’ lives. Perhaps the efforts to reach 
promote optimal use of medicines also need to consider the consequences of suggesting that 
medicines could be needed? 
7.6.3 Implications for scholars researching the use of medicines 
The link between lifestyle, health and disease that is present throughout policy documents on 
CVD prevention also has potential connections to the concept of pharmaceuticalisation. When 
patients see medicines both as a way to manage the diagnosed risk and as a proactive step 
towards health, the medical framing of obesity, smoking and drinking could lead to an ever-
increasing perceived need for medicines. If taking medicines for CVD prevention is not seen 
as necessary ‘labelling’ people, and the straightforward signs of effects from tablets are 
valuable in patients’ sense-making regarding the concept of risk, pharmaceutical intervention 
might outweigh other types of risk reduction (e.g. smoking cessation) that does not produce 
equally clear results. 
Revisiting the theoretical background for this study, my findings resonate with several of the 
dimensions of pharmaceuticalisation suggested by Williams and colleagues (see section 
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1.3.3).[56] The conclusion in this study that medicines are presented to, and perceived by, 
patients to fully solve the issue of CVD risk corresponds to the phenomenon described as 
Selling sickness. Also the aspect called Mediation can be recognised in my findings; the 
newspaper presentations of extended prescribing of statins was dominated by personal accounts 
while still framing CVD in medical context and offering space to people directly promoting 
extended use of pharmaceuticals. The animated and lengthy debate in the daily press of a 
medical issue, where the discussion about prescribing has moved into an arena for issues 
spanning daily life as well as politics and business, supports the idea of a conceptual shift from 
medicalisation to pharmaceuticalisation as an explanatory theory for the power relations 
surrounding the use of medicines. While medicalisation described a situation of diminishing 
people’s own abilities to deal with health matters and instead placing such things under 
professional control, pharmaceuticalisation places that responsibility back with people. 
Potential patients are given the task to monitor their health and make choices about it – albeit 
in a medical framing. 
One major finding in this study – that patients’ understanding of CVD risk management 
prescribing fosters a sense of responsibility which leads them to incorporate medicines into 
their lives as a way to stay or get healthy – also indicates that medical and social arguments are 
re-negotiated in the field of medicines use. People (newspaper readers as well as those that 
participated in my interview study) are active both as patients and as consumers when engaging 
with medicines for the purpose of improving their own lives, as described in the dimensions 
Patients, consumers and the life world and From treatment to enhancement?. 
A possible addition to the concept of pharmaceuticalisation is the role of doctors (here, an NHS 
GP) in establishing trust in the medicines that are suggested and promoted by the surrounding 
social world. This position of mediating between a vast body of medical knowledge and a 
singular individual, and possibly also as a gatekeeper between a patient and a tool for increased 
healthiness, could be a basis for exploring the place of medical professionals in the use of 
medicines in a context influenced by private interests. 
 
7.7 Summary 
In this chapter, findings from my two reviews of literature and the interview study have come 
together in an account of CVD risk management that shows how patients understand the 
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diagnosis of risk factors and the medicines prescribed to prevent disease. A biomedical 
description of health and medicines is present in patients’ reasoning, for example informing 
how CVD risk is pictured. However, the biomedical model is interpreted with an individual 
perspective that forms the basis for patients’ decisions about medicines. 
To situate my findings in relation to the background for the study, I have discussed them in 
relation to recent three reports about different aspects of prescribing, polypharmacy and health 
promotion. The comparison suggests additions to the concept of appropriateness in prescribing, 
and points to the possible effects of considering a patients’ perspective based on experiences 
when prescribing for prevention in primary care. In addition, I have reviewed the suggested 
framework of pharmaceuticalisation in the light of CVD prevention. 
In the next and final chapter, I shall review the trustworthiness of my research using the criteria 
outlined in chapter 4 (see section 4.7 and table 4.4), and ultimately consider how this study has 
created knowledge that adds to the characterisation of the complex phenomenon of 
polypharmacy. 
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Chapter 8 
Conclusions: New perspectives on polypharmacy 
 
8.1 Chapter overview: Summary and critical review of findings 
In this thesis, I have explored patients’ understanding of medicines in CVD risk management. 
This particular way of using medicines was used as a topical and rich example of prescribing, 
with the aim of learning about some of the mechanisms that influence polypharmacy. 
Cardiovascular risk management in primary care is supported by a growing (but challenged) 
body of evidence implemented via clinical guidance that makes an increasing number of people 
eligible for medications. At the same time, increased prescribing is criticised for creating 
problems on both an individual and a systems level. 
In this final chapter, I consider what patients’ understanding of CVD prevention with medicines 
might add to the knowledge about the complex issue of polypharmacy. To demonstrate the 
trustworthiness of my findings, I critically review them in relation to my study design and 
methods. Finally, I conclude with what this study adds, and give some suggestions of what 
could be addressed in further research. 
 
8.2 New perspectives on polypharmacy 
This study adds some knowledge about the biomedical view of polypharmacy, and also some 
things that relate to other views on health and medicines. 
The two reviews of scientific and lay literature showed that patients use experiences and 
personal understanding as well as medical information when making sense of the need for 
medicines. That informed my interview study, in which I sought to clarify how patients balance 
CVD risk with possible benefit and harm from medications when making decisions about their 
own medicine-taking. What I found was an acceptance of medications built on reasoning 
around an individualised interpretation of CVD risk, responsibility for engaging with health 
matters and trust in health care professionals. My study indicates that the main influences on 
patients’ understanding of medicines in CVD risk management are i) the acceptance of a 
biomedical view of what CVD risk is and how it can be managed, ii) the use of tangible signs 
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in evaluation of medicines, and iii) the application of an individual perspective in making sense 
of a strategy that is designed for populations, leading to overestimation of benefit. 
8.2.1 Appropriateness of medicines 
My findings indicate that patients accept a biomedical model of health and illness, where 
disease can be measured with instruments and controlled with medications. Moreover, patients 
seem to take the medical involvement per se as an indicator of need for intervention. The 
absence of symptoms appears to be of less importance – an expert’s biomedical description is 
readily adopted and interpreted as a need for medicines. Patients referred to the body of medical 
science, represented by their own GP, as the guarantor of the need being valid. In relation to 
understanding polypharmacy as an effect of medical progress, these findings point to a view 
that aspects of life which have in some way been characterised as related to disease will 
eventually become reasons for needing medicines. 
Strategies originating from the medical community to counteract problematic polypharmacy 
often mention doctors’ responsibility to listen to patients’ choice about whether to use 
medicines or not. However, I found that when a diagnosis is made and treatment suggested by 
the trusted doctor, patients see it as obvious that medication is necessary and will be beneficial. 
This challenges the principle of informed decision making and undercuts the component of 
rational prescribing that stresses that treatment shall be offered or suggested to patients; once a 
CVD risk diagnosis is mentioned by a doctor it seems to be ‘too late’ since patients interpret it 
as a direct prediction of disease.  
The current biomedical view on polypharmacy uses the achievement of clinical benefit as an 
indicator of appropriateness of prescribed medicines. Patients’ understanding of positive 
effects from their tablets adds dimensions to that understanding of benefit. What I found was 
that the visualised immediate effects from medicines become interpreted as signs of 
improvement of both present and future health. In situations where the treatment provides a 
visible effect (such as anti-hypertensives on blood pressure and statins on cholesterol), 
medicines therefore seem to have the capacity to ‘prove their own necessity’. This view of 
benefit, described by patients in my study, corresponds to both GPs’ targeting of biomarkers 
and the narrative in public campaigns related to cardiovascular health. 
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8.2.2 Medicines’ role in health and everyday life 
Some findings from my study relate to areas that fall outside the biomedical discourse on 
polypharmacy, and thus point to possible new dimensions of the phenomenon. 
An aspect of patients’ understanding of medicines that came through in this study was the 
notion of medicines being not only the necessary response to a diagnosis but also a way to stay 
healthy in a wider sense. The ‘risk management patient’ is not using medicines because of 
illness, but in an effort to maintain and promote health. This suggests a connection to the idea 
of medicines as enhancement, which was previously focused on lifestyle aspects such as 
appearance and sexual performance. Now, also one’s blood pressure seems to be a possible 
area for self-improvement. As long as medicines are communicated as a way to stay healthy, 
and prescribers continue to be a trusted source of information, they may continue to be 
accepted. From this perspective, polypharmacy is to some extent an issue of personal 
inclination; if the patient perceives and trusts the accuracy of a need for medicines, the number 
of tablets may be less important. 
Faced with the asymptomatic diagnosis of ‘being at risk for CVD’, patients complement the 
biomedical view with a personal logic of the benefit from medicines. Here, experiences are a 
valuable source of knowledge about medicines. In line with this reasoning, tangible signs of 
medicines’ effects hold an important position. My findings regarding how effects from 
medicines are interpreted indicate that patients devise a context of experienced and visualised 
results. This context is used in personal sense-making about the medicines, which in turn can 
support further use. 
 
8.3 Critical review 
The collection and handling of research data is a process of selection,[94] and all choices of 
techniques – from sampling and recruitment of research participants to presentation of the 
findings – have implications for what knowledge the study will generate and display. 
Therefore, it is necessary to assess the process as a whole when looking at the usefulness of 
findings. In this section, I discuss the strengths and limitations of my study and how they 
influence the usefulness of the findings. This critical review starts with revisiting the limitations 
of the two literature reviews that informed my empirical study. Then I will apply the criteria 
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for establishing trustworthiness of my interview study and the knowledge it has created, as 
outlined in chapter 4, section 4.7. 
8.3.1. Limitations of the literature reviews 
The review of scientific literature on patients’ expectations was limited in terms of the 
databases searched, and also for being carried out mainly by only one person. However, as it 
was only a starting point for my research and the findings in the review have been confirmed 
during the course of the project, the consequences of this limitation does not appear to be so 
significant. 
With regards to the influence of my strategies for searching, including and analysing articles 
on my findings in the review of how CVD risk and risk management are represented in UK 
newspapers, I suggest two potential limitations which are presented below. 
The first limitation is that my analysis does not allow for assessing the importance of 
newspapers as a source of information about one’s own CVD risk. Focusing the searching and 
reading of newspaper articles on different types of publications, aimed at particular groups of 
people, might have allowed for checking whether segments of the population were reached by 
news reflecting their main risk factors and management strategies for CVD. The strategy that 
I applied gives an overview of the media representation of statins from the point of view of an 
academic or other external analyst, but runs the risk of not reflecting any one particular reader’s 
consumption of news. 
The second limitation is that my aim to capture all news stories in the included publications 
during a specific time period may have missed to represent the development of particular 
themes in the stories over time. This may be important due to the strong, often opposing, 
viewpoints that were put forward in many articles. Focusing the searching and analysis on the 
presentation of a few key issues, such as how the guidelines were described or how different 
stakeholders’ arguments were communicated, could have added aspects to assessing the 
publicly available messages about CVD. With regards to one major theme in the interviews 
being that patients ‘seek stability’ when forming an understanding of CVD risk and medicines 
use, the variability of voices, viewpoints and depth of discussion of the updated guidelines 
comes across as possibly interesting to explore further. 
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8.3.2 Conceptual framing and planning of the empirical study 
The conceptual framing and planning of a study determines if it is designed to produce the 
knowledge that is needed to answer the research questions.[172] At the start of this thesis, I 
suggested that part of the problem with polypharmacy as a phenomenon of modern health care 
lies in the inconsistent knowledge about it. Although specific (medical) aspects of it are 
described, other possible perspectives – for example that of patients – remain uncharacterised. 
Therefore, this study was set up to consider the medical phenomena of polypharmacy and CVD 
risk management from a perspective that acknowledges both the biomedical and social aspects 
of medicines use. 
With this aim, I planned a study that would elicit descriptions of how patients understand their 
own use of medicines in CVD risk management. The study was informed by reviews of 
scientific and lay literature, which meant my search for information was guided by other 
existing bodies of knowledge about different aspects of medicines use. Focusing the literature 
review on patients’ expectations meant that I got an overview of various types of influences on 
how people understand and evaluate medicines. Moreover, it provided me with examples that 
I could use during the interviews to encourage participants to express their own views. The 
analysis of newspaper articles highlighted the potential tension between messages from policy-
makers, information from prescribers and people’s own understanding of health matters, which 
indicated areas to explore in interviews. Although my analysis of data was inductive, the 
various descriptions of medicines in CVD risk management all helped me identify and 
formulate questions and hypotheses that drove the process forward. 
In recruitment and sampling of participants I aimed to include people with different experiences 
of CVD risk and use of medications. The characteristics of all included participants are shown 
in appendix A11. Recruitment was done via GP practices and using search criteria that would 
identify patients from groups of people at high and low risk for CVD. When contacting GP 
practices, I met with difficulties in terms of very few agreeing to help me recruit patients. This 
could be at least partially due to the way that primary care research is organised within the 
NHS, with there being incentives for primary care centres to engage in research funded by 
certain bodies, for example the National Institute for Health Research, NIHR (which was not 
funding this project). However, as the practices that actually took part were situated in different 
parts of Liverpool, it was possible to include patients from areas of different socioeconomic 
status. 
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Patients from both the high risk and the low risk groups responded to the invitation. Based on 
the information people had given in their replies, I applied maximum variation sampling to try 
and collect as many variations as possible of how people of different ages, genders and health 
were making sense of the CVD risk management medicines that had been prescribed to 
them.[96]  
As described in chapter 5, section 5.2, this strategy produced a sample of participants that all 
had received a high blood pressure diagnosis at some point and had all been prescribed 
medication against hypertension, which they had been using for at least a few years. Different 
types of blood pressure medicines and statins were the most frequently mentioned ones in 
participants’ replies to my interview questions about which medicines they used, and a 
multitude of aspects related to blood pressure were thus present in the data. A limitation in the 
sample was that all participants actually used the blood pressure medicines that had been 
prescribed to them – in contrast to what is often reported, no-one had rejected the medicines 
altogether. Another limitation was the lack of participants in the youngest age group (below 41 
years) and of women at high risk of CVD and over the age of 80. This affected my ability to 
achieve a purposive sample with maximum variation, mainly to the effects that the interview 
data lacks views from women at high risk for CVD and/or high age. However, the stories and 
examples that were shared by participants did not seem to be bound to particular backgrounds 
in terms of illness and medicine-taking – participants that look “similar” in terms of sampling 
categories expressed very different thoughts and view during the interviews. 
The presence of personal stories, opinions and thoughts about CVD risk management 
medicines in the group of participants that my recruitment and sampling strategies produced – 
despite the process failing to fill all aspects of the sampling frame – indicates that they were 
valid for this study. Participants’ examples showed many possible understandings and 
meanings of CVD risk and its management, which is what this study set out to look for. In 
describing their own experiences, people concentrated on various aspects and made different 
types of connections which could help me piece together an alternative picture of CVD risk 
built on patients’ views. 
A different recruitment strategy or set of inclusion criteria could have included even more 
perspectives on patients’ understanding of CVD risk – for example particular links to obesity, 
smoking or comorbidities. Concentrating my inclusion to patients of a certain age, gender or 
socioeconomic background could also have allowed me to produce a more detailed account of 
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views held by a specific group of patients. Sampling outside a medical context, like 
approaching people in the community, might have captured more critical voices from people 
that had chosen not to attend health checks or seek help from their GP for health problems, but 
would have diverted the focus of the study from exploring patients’ use of medicines. In terms 
of my aims for this study – to explore a current primary care policy from a patient perspective 
– some diversity among the participants was preferred, since the development of CVD risk 
management means it encompasses many different groups of potential patients. 
8.3.3 Truth value and neutrality 
To consider the truth value of my findings is to question how well they convey participants’ 
understanding of the research topic – whether the different parts of my account truthfully 
represent the ‘voices’ in the data although they have been fitted together with theory and other 
people’s stories. Since I adopted a critical realist perspective in my study, the truth value is not 
a measure of if the findings are true in relation to a particular definition of medicines or CVD 
risk management. Instead, it relates to how all the possible meanings that participants shared 
were incorporated into the knowledge that was created in the study.[172] The question of 
neutrality is about establishing that the findings represent participants’ views rather than mine. 
Several steps throughout the research process help to ensure that the collected data is 
transformed into an account that, although informed by theory and literature, shows the 
knowledge that participants shared. 
An advantage of interviews as a method is that both the researcher and the participants can use 
examples and explanations during the course of the interview to clarify meaning and check the 
understanding of questions and answers. By “using the human as the research instrument” [96] 
I could adapt each interview into an exploration of topics that each participant seemed to find 
important, and thereby gather as much information as possible in areas where people indicated 
that they had a lot to share. For example, I adapted my questions in the interview schedule to 
participants’ own examples from their medical and life history. To encourage participants to 
share stories that would provide rich descriptions, I tried to convey my curiosity about their 
experiences. This was done both by emphasising that the research was about people’s own 
views and by letting my non-verbal communication show that I was interested, surprised or 
impressed by what they told me. 
The recording of interviews and subsequent verbatim transcribing produces ‘proof’ of what 
was said during interviews and thus gives a foundation against which findings can be checked. 
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As described in chapter 4, section 4.6.2 I began analysis by familiarising myself with the data 
though listening to recordings while reading transcripts. This process served as a check that the 
interview had been accurately and coherently transformed from talk to text,[172] and also 
allowed me to mark out where things were said with for example emphasis, hesitation or 
jokiness. Thereby, participants indications of things as important, difficult to describe or used 
as a curious story were carried into the analysis. 
At the early stages of data analysis, the breadth of my interview material became evident and I 
decided to condense it by means of applying a coding frame in order to focus my interpretation 
to a few themes. A drawback of using a structured frame for condensing data (rather than open 
coding) might be that it limits the sensitivity to unexpected findings. However, it can also help 
the researcher to maintain the connection with the research question throughout the data 
extraction process and support the production of a useful account.[94] In my experience, the 
condensation of data was a necessary step to take forward the analysis. By constructing the 
coding frame after a round of open coding, using themes that were prevalent in all interviews, 
I would argue that my approach was useful without constraining the analysis and jeopardising 
its truth value. 
During the steps of data analysis, I kept returning from the condensed dataset to whole 
transcripts so that I could review the context of extracts and thereby code them in a way that 
was truthful to their wider meaning. Thereby, associations were compared not only in terms of 
wording or what topic they were related to, but also in relation to both longer sections of 
transcripts, whole accounts and my field notes from the interview. Keeping the context of 
extracted data close at hand and going back to test my interpretation in the light of a longer 
narrative helped my emerging story to stay aligned with the whole stories that participants had 
shared during the interviews. One feature of my analysis which served as a check that my 
interpretive account had not taken me too far away from participants’ stories was testing the 
thematic structure on new data. The themes, subthemes and categories that were derived from 
the first 14 interviews required only minor adjustments when the last four interviews were 
coded with it, showing that my interpretation had retained a strong relation to individual 
accounts of using medicines in CVD risk management. 
The qualitative analysis of data is undeniably subjective, since it is done by a researcher that 
enters the process with a set of ideas and interests.[94] Thereby, the meaning that I see 
(informed by my reviews of literature and the conceptual framing of my study) quite possibly 
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differs from what a different researcher would find. By including a transparent account of the 
analysis process, I show my active role as a researcher in this particular study; in identifying 
starting points for the analysis, choosing important aspects and presenting the findings.[137] 
Since I demonstrate how the individual stories were brought together and how I moved from a 
descriptive towards an interpretive account (see appendix A10), I also invite the reader of my 
research to review the truth value and neutrality of the process of knowledge creation and the 
findings it produced. 
8.3.4 Consistency and applicability 
The assessment of consistency is the questioning of whether the findings in my study would be 
the same if it was repeated in a similar context – that is, whether they are stable over time and 
between situations. Since this study was done with a critical realist perspective, many different 
types of knowledge about medicines counted as knowledge. However, when knowledge is 
created in conversation between participant and researcher, the interaction shapes what is said 
during interviews and thereby what was registered as information and included in the further 
research process. In reviewing the consistency of my findings I will therefore critically review 
how my position as a researcher in relation to the participants might have influenced what they 
chose to tell me about CVD risk and medicines and how I understood their answers. 
From participants’ point of view, this study was first presented in a predominantly medical 
context: the invitation letter came from their GP practices, the information leaflet and reply slip 
were centred on health conditions and medicines, and I presented myself as a health care 
professional. By starting off from a point associated with a biomedical perspective I ran the 
risk of framing CVD risk management as an exclusively medical issue towards the participants, 
thereby encouraging answers describing a ‘correct’ way of using medicines [169] or even 
signalling that people who had rejected medicines were less welcome to participate. Despite 
these challenges, as a group of people that are at risk for CVD the participants in this study 
represent a variety of ages and life situations (see appendix A11 for a list of participants’ 
characteristics). 
However, during interviews I emphasised that I was interested to hear about people’s own 
experiences, thoughts and views, and not primarily in checking which particular medicines 
they used or not. Some confirmation that the conversations reached beyond standardised 
statements was given when participants described their elaborate views on medicines and 
health and also pointed out that they had not discussed the medicines like this with their doctor. 
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My positionality – my relation to the field I am researching – also has the potential to shape 
the analysis that I present. Being a pharmacist with a background in drug epidemiology and 
health policy work, my views on actors, relations and responsibilities in the field of prescribing 
and use of medicines are shaped by both academic education and professional experience. The 
former has provided me with an understanding of the physiological mechanisms for relations 
between for example blood pressure and heart attacks and the statistical rationale for 
controlling biomarkers in populations with the aim to reduce morbidity, mortality and health 
care costs. The latter has shown the importance of political, social and organisational aspects 
around health care. For example, my professional understanding of health care as a system of 
professionals in an organisational context allowed for the conclusion that GPs are key actors 
in the future of risk management prescribing. Moreover, it has highlighted the double role of 
prescribers as they simultaneously treat individual patients and deliver evidence-based care to 
populations. 
Finally, I turn to the applicability of the findings in this study on other areas of health care and 
use of medicines. It is done by considering some aspects of the study design as well as the 
character of my findings.  
Taking an inductive approach in my analysis of the interview data, which started with open 
coding, permitted my interpretation to include what the participants themselves associated with 
their diagnoses and medicines. Potentially, this could make the findings more applicable to 
other areas, as people might have included experiences related to various medicines in our 
conversations, thereby sharing more of a “generic” view of medications. On the other hand, it 
is possible that a deductive analysis approach could have supported the applicability of 
findings, by actively searching for data that would be relevant also to other diagnoses. 
However, the two provisional themes used in the condensation of interviews into a dataset 
(‘blood pressure’ and ‘medicines’ effects’) were linked to statements about CVD risk diagnoses 
specifically, but also to broader ideas about health promotion and prevention of disease. Since 
both themes contained descriptions of how individuals perceive benefit from risk management 
medicines, how medical information might be interpreted and what roles people see for GPs, 
policy-makers and the pharmaceutical industry, the further analysis produced an account that 
is useful in a broader examination of polypharmacy in primary care. 
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8.4 Suggestions for further research 
This study has explored a particular aspect of prescribing in a particular context. However, 
many more factors influence how medicines are used, and aspects that were present in this 
study but not fully explored could add valuable knowledge about polypharmacy and patients’ 
views on medicines. 
One perspective is the relation between cultural factors such as social class or ethnicity and the 
understanding of medicines in CVD prevention. The prevalence of CVD varies between groups 
of different socioeconomic status and ethnical origin,[196-198] but the interplay between risk 
factors, lifestyle and life situation can be ambiguous. The strong focus on individual 
responsibility in relation to health and medicines that I found in this study might not appear, or 
appear in a different way, in different populations. Since my analysis omitted social structures 
as an explanatory factor, further research could test or expand the conclusions in a more socially 
diverse sample of patients. 
This study was initially planned to compare how patients and health care professionals 
balanced possible benefit and harm from medicines. Since it instead came to be an exploration 
of different aspects of patients’ views, the professional angle remains to be explored. The 
scoping interviews with four GPs in Liverpool present many potential starting points in 
themselves (see appendix A1), and they become even more interesting when related to my 
findings about patients’ reasoning. One question to address is how health care practitioners see 
risk management with medicines in relation to other interventions, and how they negotiate 
between population and individual effects when delivering evidence based care. 
A recent critical examination of the NHS Health Check programme questions its effects in 
terms of directing resources, predicting disease and improving outcomes for patients.[79] 
Valuable knowledge about structural features that contribute to prescribing and polypharmacy 
could come from investigating professionals’ views on their role in implementing prevention 
policies that involve medicines. As a complement to my research on patients’ understanding 
of medicines for CVD risk management, and in the light of the criticism, such investigations 
of the relations between policy and practices could add valuable knowledge about the role of 
medicines in modern health care. 
One subject that this study has touched upon is how people engage with scientific knowledge: 
how patients interpret medical information and incorporate it into personal decisions and 
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actions regarding medicines. My findings in this area resonate with descriptions of how people 
interact with the institutions of science and technology that modern society is built around [41], 
some of which I will mention here since they could point to further research. 
The incorporation of both ideas and products of biomedical science into daily life represent 
what Giddens [199] calls the linking of local practices with global relations. In the context of 
my study, this description refers to how the local, everyday use of tablets in the absence of 
illness symptoms becomes linked to an outcome that is globalised in the sense of time (benefit 
will be achieved at an unknown point of time in the future) and place (benefit will be achieved 
by a few patients within a treated cohort). The linking is made possible by means of acceptance 
of a system of knowledge that is trusted, although not fully understood. Trust is maintained 
through individuals’ interaction with the system at so-called access points; encounters with 
professional representatives or tokens that inspire trustworthiness. Apart from recognising their 
GP’s advice as important, participants in this study used the visual indications of medicines’ 
effects as an access point – they had seen that the tablets worked, and thus accepted the context 
of risk, medicines and health. 
Regarding the concept of risk, Beck [200] discusses how it is central to modern society. 
Signifying a danger that is defined by the knowledge about it, risk becomes possible only in 
systems of expert knowledge. Furthermore, risk represents a revealed uncertainty – something 
that has become a threat precisely because it has been identified. However, although scientific 
objectivity rules the calculation of average effects of different risks, the definitions of what is 
actually a harmful outcome or dangerous level is ultimately socially negotiated.[201] Experts’ 
definition of risk, however, has only a limited meaning for individuals since average effects 
and measurements are not applicable to specific cases. Giddens suggests that the concept of 
risk indicates a multitude of possible futures, thereby implying responsibility on making 
choices in managing it.[202] My findings have several connections with this discourse of risk, 
for example patients’ interpretation of the population-based prevention strategies and the 
understanding of a risk score as a defined condition. 
Within the scope of this study, I have merely established that these theories describe my 
findings – or that my findings constitute an example of some of the phenomena central to the 
theories. Further research could make use of this connection, either by using the empirical 
findings to test and expand the theory or by strengthening the theoretical interpretation of my 
data for the purpose of suggesting implications. Questions to address could be how people 
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judge what health information to trust, and which aspects of prescribing that might threaten the 
trust that currently seems to exist. 
 
8.5 Conclusions 
This study shows patients’ understanding of the use of medicines in prevention of CVD. It has 
pointed to a strong influence of a biomedical description of health on people’s views, but also 
highlighted how an individual perspective dominates patients’ decisions and actions. Central 
influences on patients’ views are a simplified representation of CVD risk something that will 
have particular consequences for the individual, anticipation of defined effects from medicines, 
and a personalised understanding of health information, which leads to individual 
responsibility for engaging with risk management. 
My findings indicate how policies based on biomedical evidence might be perceived by the 
people whose health they are aiming to promote. Insights regarding communication around 
health risks and patients’ formation of expectations of benefit from medicines contribute 
knowledge about a central part of modern health care. A partly new role for medicines in 
personal and professional health promotion has been presented in this thesis, together with a 
description of responsible patients who expect personal effects from their medications. 
This exploration of polypharmacy has shown that the rationale behind extended prescribing 
needs to be examined with patients’ views in mind, and offers a theoretically and empirically 
grounded account of central aspects to address. 
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Scoping interviews with GPs 
The initial plan for the empirical part of this research was to compare patients’ and GPs’ 
views on the use of multiple medicines in risk management prescribing, and an exploratory 
study was designed in the first year of the project. Since I met with difficulties in recruiting 
GPs to interview, and the two literature studies that ran alongside the empirical study (see 
chapters 2 and 3) indicated a number of aspects to investigate within patients’ understanding 
of CVD risk management, I decided to focus the project on patients only. However, the few 
completed interviews with practitioners were valuable as background material by being first-
hand descriptions of how CVD risk management is applied in UK primary care today. Main 
topics in the GP interviews also served as statements against which patients’ understanding 
could be compared and contrasted, and thus helped the analysis of empirical data. Here, I 
summarise the aspects that informed the analysis of my interviews with patients. 
Four GPs in Liverpool were interviewed at the start of the empirical study; two men and two 
women at three practices situated in different parts of the city. In the interviews, I asked about 
their own experiences and practices in prescribing for the long-term management of CVD 
risk conditions – how they made decisions, discussed with colleagues and interacted with 
their patients. The GPs’ descriptions entailed both examples of their own professional 
practices and the overall strategies they and their colleagues used in order to provide as good 
care as possible within their capacity. After addressing their own reasoning and prescribing, I 
specifically asked about their opinions on the current strategies in place for CVD risk 
management and how they negotiated the treatment of individual patients with overall NHS 
policies. 
One major topic in the interviews was the use of evidence in practice. All four GPs expressed 
their trust in available guidelines. They mentioned that national prescribing guidelines 
covered clinical as well as economic aspects, and therefore supported rational prescribing. 
Having guidelines at hand meant medicines were not used too early or too freely. Risk 
stratification tools were described as helpful in assessing which patients would benefit from 
treatment. The documentation was also useful in explaining to patients why they should 
consider treatment; the GPs’ experience was that most patients understood and accepted the 
evidence if it was presented to them. 
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The GPs described their strategies for motivating patients to use medicines to manage CVD 
risk. As this often entailed “starting someone that feels perfectly well on tablets for 
something you think is a problem”, the application of evidence-based medicine to patients 
sometimes required some argumentation. All found it useful to refer to the evidence in 
guidelines, and felt that it supported patients’ understanding of the possible benefits or simply 
their acceptance of the medicines when side effects occurred. Three of the GPs focused on 
the connection between biomarkers and disease endpoints such as heart attacks and strokes, 
whereas one concluded that the patients just needed to know that having low blood pressure 
and cholesterol was good, and having high was bad. In cases where patients chose not to use 
medicines, it could be convenient to stress the relation between biomarkers and outcomes: 
“whether their blood pressure is 150 over 90 or 135 over 70 means nothing on a day to day 
basis, but knowing that by having it at 130 over 70 might stop them having a stroke… there’s 
a gain there”. 
All the GPs mentioned the media as influential on their patients’ opinions about medicines; 
both newspapers and information distributed online. With regards to CDV risk management, 
this sometimes resulted in patients’ preferring non-pharmacological interventions over taking 
tablets. Weight management, smoking cessation support and advice for physical activity was 
available to their patients and promoted as an addition to medicines. Here, the impact of 
socioeconomic circumstances was cited; reaching well-informed and health-conscious 
patients in affluent areas was contrasted with providing care for patients who “are sat at home 
smoking and drinking, with lots of social problems as a consequence”. Despite the difference 
in level of deprivation between the areas where they worked, all the GPs saw primary care as 
the foremost stakeholder in improving people’s health. 
A recurring theme was the GPs’ reliance on the evidence that is included in clinical 
guidelines for CVD risk management. In terms of how decisions and recommendations were 
made, their descriptions suggested that the evidence is applied to individuals, rather being 
used as a resource for responding to individual needs. One GP expressed the consideration of 
benefit and cost-effectiveness it like this: “If you’d do it for the NHS, then you do it for each 
patient too.” Benefits with early detection and active management were expressed on both 
micro and macro levels; they included influencing individual’s risk for disease as well 
minimising the number of unplanned hospital admissions so that the practice’s performance 
compared well in benchmarking of outcomes.
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Published review and synthesis of scientific literature 
A paper based on my review and synthesis of literature on patients’ expectations of medicines 
was published in Health Expectations; see overleaf. 
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Abstract
Background An increasing part of prescribing of medicines is done
for the purpose of managing risk for disease and is motivated by
clinical and economic beneﬁt on a long-term, population level.
This makes beneﬁt from medicines less tangible for individuals.
Sociology of pharmaceuticals includes personal and social perspec-
tives in the study of how medicines are used. We use two charac-
terizations of patients’ expectations of medicines to start forming a
description of how individuals conceptualize beneﬁts from risk
management medicines.
Search strategy and synthesis We reviewed the literature on
patients’ expectations with a focus on the inﬂuences on expecta-
tions regarding medicines prescribed for long-term conditions.
Searches in Medline and Scopus identiﬁed 20 studies for inclusion,
describing qualitative aspects of beliefs, views, thoughts and expec-
tations regarding medicines.
Results A qualitative synthesis using a constant comparative
thematic analysis identiﬁed four themes describing inﬂuences on
expectations: a need to achieve a speciﬁc outcome; the develop-
ment of experiences and evaluation over time; negative values such
as dependency and social stigma; and personalized meaning of the
necessity and usefulness of medicines.
Conclusions The ﬁndings in this synthesis resonate with previous
research into expectations of medicines for prevention and treatment
of diﬀerent conditions. However, a gap in the knowledge regarding
patients’ conceptualization of future beneﬁts with medicines is iden-
tiﬁed. The study highlights suggestions for further empirical work to
develop a deeper understanding of the role of patients’ expectations
in prescribing for long-term risk management.
Background
Prescribing of medicines is one of the most
common interventions in medical health care in
the UK. Most prescriptions are issued in pri-
mary care and the annual cost for these exceeds
£8 billion.1 Best practice for identifying persons
at risk for disease, controlling symptoms,
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preventing acute events and managing sequelae
is outlined in treatment guidelines. Early detec-
tion and treatment can be crucial in certain
conditions. However, lowered thresholds for
diagnosis of conditions associated with risk for
future disease and the subsequent increase in
treatment of such conditions introduce medi-
cine-taking to a large number of patients for
whom the individual beneﬁts are less obvious.2,3
Examples of this are medicines that target ele-
vated blood pressure or cholesterol, which are
among the most commonly prescribed in the
UK today.4
Awareness that the rising rates of prescribing
for management of risk are accompanied by
growing health-care costs, widespread poly-
pharmacy and more medication errors has led
to eﬀorts to improve the quality and safety in
prescribing.5 The format of guidelines,6 style of
medical practice7 and eﬀectiveness of interven-
tions directed towards key patient groups8 are
areas that have been targeted – all of which are
concerned with the prescriber or the system in
which doctors and patients interact. These
medicines management strategies tend to men-
tion patients’ views as important to consider,9
but retain a theoretical focus that limits the
understanding to one based on medical deﬁni-
tions of health, illness and medicines.
Patients’ usage of medicines can be seen as
taking place at an intersection of medical science
and daily lives. A vast body of knowledge in
medical sociology describes many aspects of the
interaction between people and medicines. The-
ory spans from individuals’ compliance with
medical instructions10,11 via characterizations of
the role of medicines in daily life12,13 to consider-
ations of the whole-systems inﬂuences from
patients, medical professionals, health-care
organization and governance.14–17
Treatment for the purpose of management
of risk for disease often targets asymptomatic
conditions that require long-term commitment
by patients for potential beneﬁcial eﬀects to be
demonstrable. One factor contributing to such
commitment could be patients’ expectations of
future beneﬁts or risk limitation arising from
the prescribed medicines. In a theoretical
description of the inﬂuences on patients’ expec-
tations on medicines, Thompson and Sunol
emphasize the combination of cognitive and
aﬀective components and outline a range of
personal and social factors that interplay with
the information provided in a health-care con-
text.18 These include needs, values, experiences
and emotions, as well as social norms, condi-
tions and restrictions. Four types of expecta-
tions are identiﬁed: Ideal, predicted, normative
Box 1 Classiﬁcation of patients’ expectations suggested by Thompson and Sunol18
Type of expectations Characteristics
Ideal expectations Desired or preferred outcome based on idealistic beliefs regarding what a medicine can provide
Predicted expectations Anticipated, realistic outcome based on personal or vicarious experience and other sources
of knowledge
Normative expectations What the patient thinks should or ought to happen, based on evaluation of what is deserved or
socially endorsed
Unformed expectations Inability or unwillingness to formulate what is expected due to fear, social norms or lack
of knowledge
Health-care context-speciﬁc features that inﬂuence expectations
Long-term relation between patient and doctor
Patient’s emotional state may be shaped by illness experience and coping strategies
Patient’s knowledge about the condition and the effects of medicines may be very limited at the outset of a treatment,
but increases over time
Patients tend to use a subjective rather than objective set of notions when evaluating effects and services
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and unformed (see Box 1). Patients’ expecta-
tions regarding medicines for a number of
long-term conditions are described by Pound
et al19 in a meta-ethnography of lay experi-
ences of medicine-taking. The authors mention
a number of tangible eﬀects that are used by
patients while evaluating medicines by means
of balancing of risks and beneﬁts. The latter is
composed of hopes for what medicines shall
do: relieve or control symptoms, avoid relapse
or hospitalization, slow or halt disease progres-
sion, prevent future illness or bring normality.
Guided by these descriptions, we want to
contribute new knowledge regarding patients’
expectations of medicines prescribed for the
purpose of management of risk. An empirical
study is in progress. In the review and synthesis
of literature reported here, we draw on qualita-
tive work on long-term medicine-taking to start
building an understanding of patients’ expecta-
tions that is not limited to a medical deﬁnition
of what medicines can and will do. Our
research questions were ‘What are the inﬂu-
ences on patients’ expectations regarding pre-
scribed medicines?’ and ‘What beneﬁts do
patients expect from medicines prescribed for
long-term prevention of disease?’
Methods
Search strategy
The database searches were set up to explore
possible inﬂuences on patients’ expectations of
medicines. We used broad search terms to cap-
ture multiple aspects of our research questions.
The database searches were then done by UD
in two stages. The ﬁrst step explored inﬂuences
on patients’ general expectations related to
prescribed medicines. To ﬁnd out speciﬁcally
about treatments for the management of risk
for future disease, the second step focused on
patients’ ideas about beneﬁts with medicines
prescribed for preventive purposes. Search
terms are outlined in Box 2. Searches were per-
formed in Medline and Scopus during August
and September 2013 for publications from all
available years.
Selection of publications
The ﬁrst step in the selection was scanning of
article titles. Abstracts and full-text articles
were then checked by UD for descriptions of
patients’ accounts of using medicines and
descriptions of inﬂuences on expectations. Due
to the exploratory nature of this review, quality
of the reported study was not used as a crite-
rion for inclusion or exclusion. Instead, a care-
ful examination of the applicability of the
reported ﬁndings to the area of long-term
treatments was undertaken at the selection and
synthesis stages. This assessment was done by
UD with support from JR and TW. Articles
were included in the review if they explicitly
addressed qualitative aspects of patients’ expec-
tations, beliefs, views or thoughts about medi-
cines prescribed for treatment or prevention of
long-term conditions and were written in Eng-
lish. Publications retrieved in the searches but
excluded during the review process described
practices or behaviours rather than views, pro-
fessionals’ expectations rather than patients’,
evaluations of speciﬁc interventions or solely
Box 2 Search terms
Research question Search terms Hits
What are the inﬂuences on patients’
expectations regarding prescribed
medicines?
expect*AND inﬂuence* AND patient* AND prescribing OR prescription 614
expect*AND patient* AND primary care AND prescribing OR prescription 135
inﬂuence* AND qualitative research AND prescribing OR prescription 427
What beneﬁts do patients expect from
medicines prescribed for long-term
prevention of disease?
beneﬁt* AND expect*AND qualitative research AND
prescribing OR prescription
225
beneﬁt*AND expect* AND medicine* AND patient* AND prevent* 122
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quantitative aspects of patients’ expectations.
Articles about end-of-life care or medicines
used for lifestyle or aesthetic purposes (obesity,
facial acne, hair loss) were also excluded, on
the basis that expectations related to these
types of treatments are likely to be inﬂuenced
by emotional factors that lie outside the scope
of this research.
Extraction and synthesis of data
Data extraction and synthesis was done by
open coding of reported inﬂuences on
patients’ expectations in the selected literature
followed by a constant comparative thematic
analysis20 and synthesis.21 Included articles
were read closely to pick up data that was
related to our research questions, and descrip-
tive codes were allocated to pieces of text.
The coding process was informed by, but not
limited to, the aspects of patients’ expectations
on medicines discussed by Thompson and
Sunol and Pound et al.18,19 Codes were grouped
together into categories that were adjusted as
the analysis proceeded. By comparing extracts
with the whole data set, including examination
of cases that contradicted or deviated from
the rest, the analytical categories were aggre-
gated into themes that captured both general
and speciﬁc aspects and similarities as well as
diﬀerences in the dataset. The synthesis
allows for themes to be formulated at a level
‘beyond’ description of the diﬀerent types of
data in separate studies so that new interpre-
tations and explanations can be suggested.
The extracted data together with contextual
characteristics for the included studies are
summarized in Table 1.
UD undertook the searches and selection of
publications and the initial open coding and syn-
thesis. Discussion between UD and JR strength-
ened the interpretive validity by identifying
areas of dissonance or uncertainty and reﬁning
the developing categories. All three authors par-
ticipated in ﬁnalizing the themes. The criteria
for trustworthiness proposed by Lincoln and
Guba were used as a framework for the critical
assessment of the emerging analysis.22
Findings
Combinations of the search terms in titles or
abstracts yielded 1428 unique records. After
scanning of article titles, 92 abstracts were
reviewed and 27 full-text articles assessed for
inclusion. Reference lists in the reviewed papers
were scanned for useful sources, which
returned 23 more publications. The ﬁnal syn-
thesis included 20 publications, 12 of which
were identiﬁed via databases and eight from
the scanning of references. The selection pro-
cess is outlined in Fig. 1.
Four themes were identiﬁed from our synthe-
sis of the literature, see Table 2. Inﬂuences on
patients’ expectations on medicines range from
being highly speciﬁc and related to short-term
targets that medicines are hoped to help achieve
to general views on whether medicines are useful
at all. Practical experiences, personal beliefs and
other people’s opinions are inﬂuential as expec-
tations are formed and develop over time.
A need to achieve a speciﬁc outcome
Expectations can be determined by the need to
bring about a speciﬁc change. Medicines as an
instrumental way to relieve both speciﬁc and
wide-ranging aspects of symptomatic illness are
elicited by patients with depression needing to
get better quickly after ‘hitting rock bottom’23
and epilepsy, where the medicines control sei-
zures as well as reduce worry.10 Preventive
medications are also seen as providing very spe-
ciﬁc beneﬁts such as ‘stopping a heart attack’
or ‘curing the bones’.24,29 These anticipations
resemble a combination of the ideal and pre-
dicted expectations described by Thompson
and Sunol.18 More general descriptions of med-
icines as eﬀective tools to care for oneself
beyond what can be obtained with diet and
exercise are shared in interviews with patients
suﬀering from heart failure and osteoporo-
sis.25,27 In terms of expressing expectations, it
has been suggested that this is predominantly
done by patients looking for speciﬁc outcomes,
especially in relation to a condition that greatly
impacts on their daily lives.24
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Table 1 The dataset
Authors (year) Content
Schoﬁeld et al. (2011)23 Context Semi-structured interviews with 61 patients recruited from GP practices in three areas
in the UK. Eligible patients invited via a letter from their GP. All participants had been
prescribed antidepressants against depression and/or anxiety for at least a year.
Purposive sampling is used to reﬂect the population of users of antidepressants in
terms of age, sex, ethnicity and socio-economic background. Most participants had
experienced several episodes of depression at the time of the interview.
Findings • At the time of initiation of treatment, medicines were seen as a short-term measure
to get better at a time when they really needed it.
• Many participants had reservations against antidepressants when ﬁrst consulting
their GP, due to concerns about using medicines in the long-term, fear of addiction
and negative views held by themselves or others.
• Using and experimenting with medicines over time makes patients experts on their
own conditions and treatments. This expertise gives the patient more control over
decisions regarding management of their illness.
Conrad (1985)10 Context In-depth interviews with 80 people with epilepsy about the meanings of medications in
everyday life and why medicines are taken or not, carried out as a part of a larger
project about living with epilepsy. All participants were or had been using medications
against the condition. Recruitment was done via community channels. Participants are
described as between 14 and 54 years old, mostly lower middle class and coming
from urban areas in the United States. Interviews were held independent of medical
and institutional settings.
Findings • Peoples’ practices regarding medicines are related to aspects of control in two
directions: taking control over symptoms or worries about the disease, or being
controlled by a disease that forces usage of medicines.
• A continuous evaluation of the medicines is undertaken, and patients may stop
taking them if no speciﬁc effect is perceived.
• The author refers to a general view in society that it is better to try to achieve
health goals without medicines, and reports reﬂections of this view in the
participants’ accounts.
Dolovich
et al. (2008)24
Context The study aims to investigate expectations and inﬂuences thereon to ﬁnd out if
expectations have an impact on how medicines are used. Purposive sampling and
recruitment through community and health-care channels in Canada were used.
The 18 participants represent different ages, living conditions and types of medicines
used. Semi-structured interviews were conducted around the medicines the participant
considered most important and analysed using grounded theory.
Findings • Expectations are most clearly expressed by patients who want a clearly deﬁned
outcome in a condition that affects their daily life.
• Participants are realistic in what they want medicines to achieve and use different
sources of information to adapt and confirm their expectations.
• The number of medications used every day was described as an issue; either as
burdensome for an individual or in general terms.
Unson et al. (2003)29 Context With a stated aim to increase adherence, patients’ beliefs about osteoporosis (OP)
medication and medicines in general are assessed. Focus groups based on ethnicity
was recruited via senior centres and housing estates in deprived areas in the
United States. A convenience sample of 55 women aged 60 years or older
participated. Most participants were on prescribed medication, but not for OP.
Authors suggest that what is handled as a dichotomous question (treatment or not)
in medicine is a more complex decision for patients, where heuristics, moral aspects
and power relations are at play.
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Table 1 Continued
Authors (year) Content
Findings • Side-effects are considered serious and on a short-term basis; ‘they can be worse
than the disease itself’ and ‘25% protection without side-effects is better than
50% with’.
• Participants use both their own experiences and those shared by others in decisions
about medication.
• Participants expressed scepticism regarding prescribers’ knowledge about how
medicines affect speciﬁc patients and saw prescribing partly as doctors’
experimentation.
Granger et al. (2013) Context Mixed methods study aiming at exploring theoretical linkages between symptom
experience over time and the meaning of medication adherence. Ten patients with
chronic heart failure completed questionnaires measuring beliefs, behaviours,
symptoms and satisfaction and were interviewed about the meaning associated with
medicines. Patients were recruited by research nurses during an admission to a US
university hospital with exacerbation of their condition.
Findings • Experience of symptoms inﬂuences the meaning attributed to medicines.
• Medicines are described in positive ways as tools to care for oneself, but also with
negative notions of being inevitable if wanting to avoid death.
• Patients were questioning how a large number of medicines everyday can be helpful.
Mazor et al. (2010)25 Context Telephone interviews with women ≥65 years that fulﬁlled WHO criteria for osteoporosis
recruited from a multispecialty practice in Massachusetts, United States. History of
dispensed prescriptions was used to classify participants into three groups of equal
sizes: not using medication, started but discontinued medication and currently on
medication. The study links core beliefs about medicines to patients’ views on
perceived need, safety and efﬁcacy of a medication.
Findings • The need and usefulness of medication is described as related to age, but with
different conclusions: old age and brittle bones make medicines necessary,
or offset the eﬃcacy of medicines.
• Patients that make use of peers’ knowledge or experience of the medication are
sceptical to treatment.
• Connects participants’ views on medicines with their core beliefs about health
and illness.
Nair et al. (2007)26 Context Semi-structured interviews seeking to investigate patients’ experiences with
risk–beneﬁt assessment when making decisions about treatment for type II diabetes.
The 18 Canadian patients used different types of treatment and were recruited
through community and health-care channels. Both purposeful and theoretical
sampling was used to ensure inclusion of patients that found treatment easy
as well as difﬁcult. The interpretation of the interviews was validated in a focus group
session towards the end of the analysis process.
Findings • Avoidance of medication may be based on the impression that one is already taking
too many medicines.
• Duration of illness and experimentation with medicines inﬂuences the understanding
of the effects of disease and the treatment.
• Patients develop a personalized understanding of the value of a treatment, and this
forms a basis for the decision on whether to use a medicine.
Smith et al. (2000)35 Context Experiences, concerns and willingness to participate in decision making about
medicines were explored and compared between patients with the three conditions.
Group interviews were arranged via voluntary organizations for each condition
in the UK.
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Table 1 Continued
Authors (year) Content
Findings • Patients with schizophrenia had experienced medicines as a way for doctors to
modify their behaviour in order to be acceptable in society.
• Patients wishing to leave decisions about medicines to doctors still wanted to be
informed about positive and negative effects so that they could monitor
their treatment.
• Information about medicines is used to participate in decisions and
challenge doctors.
Cranney et al. (1998)30 Context In an investigation of barriers to implementation of guidelines for hypertension
treatment, UK healthy elderly patients’ and GPs’ perceptions of risks and beneﬁts
were addressed. Participants recruited via a GP practice (75 patients) and on a
training course (121 GPs). Attitudes to risk with untreated hypertension and ideas
about beneﬁt from prescribed medicine were assessed with questionnaires
accompanied by visual aids during semi-structured interviews.
Findings • Most patients overestimate both the risk with untreated hypertension and the
beneﬁt from preventive treatment and accepted treatment based on trusting
their doctor.
• When provided with information about the clinically proven relative risk reduction,
fewer patients accept treatment and more patients mention the risk of side-effects.
• Communicated ideas about beneﬁt with treatment are rather vague and based on
conceptions of prevention being necessary or helpful in general.
Leaman and
Jackson (2002)31
Context Questionnaire completed by 216 patients from a single GP practice in the UK.
A random sample of patients, stratiﬁed for age and gender, were asked to state the
level of beneﬁt requested for acceptance of a ﬁrst, second and third medicine for
treatment of hypertension. Beneﬁt was represented with ﬁxed levels of NNT(5).
Hypothetical scenarios explaining the consequences of a myocardial infarction and
some practical aspects of the treatment accompanied the questionnaire,
and respondents were asked to answer with only these aspects in mind.
Findings • Patients request a much higher level of beneﬁt than what has been clinically proven.
• Authors mention patients’ lack of rationality in making decisions about medicines,
leaving decisions to doctors and altered circumstances when facing a real rather
than a hypothetical situation as explanations for why so many patients are on
treatment for hypertension despite the results in the study.
Fuller et al. (2004)32 Context Older people’s attitudes to stroke prevention were examined by presenting probabilities
of risks and beneﬁts with warfarin treatment. People aged 66–97 years answered
questionnaires about hypothetical scenarios of risk reduction and practical aspects
of treatment. The 81 participants were recruited via an elderly medicine outpatient
clinic at a large university hospital in the UK.
Findings • Participants expressed wishes for a guaranteed number of years of disease-free
survival in order to engage with medicine-taking.
• Experiences of disease in the family and personal health beliefs are inﬂuential on
the acceptance of treatment.
Hux and Naylor (1995)33 Context Data on beneﬁt of lipid-lowering medication from a large clinical study were presented
in different formats (relative and absolute risk reduction, NNT, average and stratiﬁed
survival) to 100 participants aged 35–65 recruited from an outpatient setting in
Canada. Treatments were presented as free of charge, without side-effects and
suggested by a doctor in hypothetical scenarios. Participants’ preferences and their
stated certainty about the decision were recorded to investigate how the format of
beneﬁt data inﬂuences decisions about treatment.
Findings • Relative risk reduction generated the highest acceptance for treatment, followed by
absolute risk reduction.
• Stratiﬁed survival data were preferred over average numbers.
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Table 1 Continued
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Arkell et al. (2013)34 Context Experiences, attitudes and expectations about information given prior to starting
anti-TNF therapy were assessed in focus group interviews with ten rheumatoid
arthritis (RA) patients in the UK. All participants were currently on treatment and
purposively sampled to represent different ages, disease duration and activity and
anti-TNF agent used. Data were analysed with a phenomenological approach.
Findings • Patients described a willingness to face increased cancer risk due to treatment
if sustained relief from RA symptoms could be achieved.
• Fear of disease symptoms and long-term effects inﬂuenced the desire to start and
stay on anti-TNF medication; side-effects were considered secondary.
Gale et al. (2012)36 Context Meta-ethnography of qualitative literature on usage of medication for prevention of
cardiovascular disease, seeking to explore variations in behaviour and implications
for practice.
Findings • The context for patients’ decisions about medicines goes beyond the clinical
setting – social interactions in the personal community, other people’s experiences
and various sources of information are inﬂuential.
• Doctors are trusted sources for information about medicines; information
from academia, pharmaceutical companies and media is less trusted.
Sale et al. (2011)28 Context A phenomenological study conducted to investigate patients’ experiences with the
decision to take OP medication after sustaining a fracture. Participants aged over
65 years who had had a fracture in the last ﬁve years and were at high risk for
having another one were recruited via an OP screening programme in Canada.
Two-thirds of the 21 patients were currently taking OP medication. Cost for
medication was covered by a local drug plan for all participants.
Findings • A decision to use or not to use medicines is often not permanent; patients
report they have changed their mind about medicines or might do it later.
• The decision to start OP medication is often based on trusting the prescriber’s
recommendation.
• Discussing the decision about medicines with friends or family or searching
information elsewhere often resulted in not accepting treatment.
Adams et al. (1997)37 Context Attitudes of patients with asthma to prophylactic medication are explored with a
patient-centred perspective. In-depth interviews were carried out with 30 participants
recruited from a GP practice in Wales. Participants represented different ages,
social backgrounds and duration of asthma.
Findings • Using medication every day is closely linked to the idea of having a disease.
• Those patients that accepted the treatment as part of living with asthma still
disliked using medicines every day.
• Negative views on steroids, associated with illicit use, were overcome by the fact
that they are needed by the patient and prescribed by a professional.
Stack et al. (2008)38 Context Patients’ beliefs about multiple medicines are addressed in interviews with 19 patients
diagnosed with cardiovascular disease and type II diabetes. Authors acknowledge that
usage of many medicines is associated with poor adherence and self-management in
patients. Recruitment was done via two urban GP practices in the UK.
Findings • Diabetes medicines are seen as necessary, whereas medicines for the management
of cardiovascular risk, especially lipid-lowering agents, are given lower status.
• The patients that describe a perceived risk for cardiovascular events have
experienced heart attacks or strokes among family or friends.
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The need for conﬁrmation of a medicine’s
eﬀect by symptom relief or some other immedi-
ately observable beneﬁt is an often mentioned
theme in relation to patients’ expectations on
medicines. Correspondingly, a lack of salient
eﬀect from the medicines may lead to loss of
perceived meaning with the therapy in patients’
views. This phenomenon points to the link
between medicine-taking and relief of symp-
toms being an important motivator for
patients.10,19,26,27
Patients’ expectation that medicines will
obtain certain eﬀects also seems to apply to
outcomes deﬁned by someone other than the
patient; both as a general ‘they should do what
the doctor says need to be done’24 and more
speciﬁcally mentioned by people with schizo-
phrenia saying that medicines are used by doc-
tors to control patients’ behaviour and make it
acceptable to society.35
In relation to expectations on medicines for
risk reduction, several studies report that
patients overestimate the possible beneﬁts with
preventive treatments: The requested reduction
of risk for cardiovascular events and stroke in
return for the eﬀort of taking medicines every
day is much higher than clinically available,
and when provided with information about the
likely level of beneﬁt, patients tend to decline
treatment referring to potential side-eﬀects.30,31
In interviews with elderly patients about
their willingness to use anticoagulants to pre-
vent stroke, patients discussed the decision in
terms of gambling and trade-oﬀs and expressed
Table 1 Continued
Authors (year) Content
Marshall et al. (2006)39 Context Relations between level of cardiovascular risk, acceptance of treatment and
demographic characteristics were investigated quantitatively. Patients without
diagnosed cardiovascular disease from GP practices in the UK were invited to
participate in coronary risk screening and a research study. Preferences regarding
treatment in hypothetical scenarios were recorded from the 181 participants before
the screening, and a second interview was conducted afterwards to see whether
patients changed their minds when told about their own risk.
Findings • Patients’ preferences are stable over time but vary between individuals.
• A difference in acceptance of treatment between patients from different social classes
is suggested to be related to ideas about moral obligation to use medicines.
Figure 1 PRISMA diagram of search
results and selection of publications.
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wishes for a guaranteed number of disease-free
survival years.32 The format of risk and beneﬁt
information when suggesting treatment for
the management of risk seems inﬂuential on
patients’ decisions about treatment: Relative
risk reduction yields much higher acceptance
than number needed to treat (NNT) and dis-
ease-free survival stratiﬁed between groups of
patients gave more positive responses than
when presented in a summarized way.33 The
representation of beneﬁts by absolute or rela-
tive risk reduction might be interpreted by
patients as giving everyone a reduced risk,
whereas with NNT, one single person gets the
whole beneﬁt of survival, making it less appeal-
ing. An expressed desire for a guaranteed num-
ber of years and the gambling and trade-oﬀ
language used by patients in discussions of the
decision to accept or decline treatment also
suggest that beneﬁt is being conceptualized as
an entity.
Experiences and evaluation develop over time
The expectations placed on medicines seem to
be inﬂuenced by previous experiences of illness
and medicine usage.10,26 Predicted expecta-
tions18 dominate. These are weighted together
in a continuous evaluation of whether and how
to use the prescribed medicines and longer
duration of illness seems to open up for a more
nuanced description of expectations. A cyclical
trial and evaluation, where patients balance
their view on long-term medicine-taking with
important experiences of improvement and
worsening of their condition, make patients
experts on their own treatment.23 This evalua-
tion includes factors from the medical realm
such as information about the condition, possi-
ble consequences and prescribed medicines as
well as factors from other parts of life. In com-
parison with medical professionals’ evaluation
of medicines’ appropriateness, patients use a
Table 2 Codes and themes
Theme Examples of codes
1. A need to achieve a
speciﬁc outcome
Medicines relieve symptoms, help avoid hospitalization, control disease or
improve the conditions of daily life10,23–25
Conﬁrmation of effects is sought, and lack of identiﬁable effects can lead to the
medicine being seen as not useful10,24,26,27
Medicines offer something beyond what is achieved by diet and exercise25,28
A medicine prescribed for prevention ‘stops a heart attack’, ‘cures the bones’ or
‘does the job the doctor says need to be done’24,29
Beneﬁts with preventive treatments are overestimated30,31
Patients wish for guarantees of survival30–33
2. Experiences and evaluation
develop over time
Duration of illness inﬂuences understanding of disease and treatment effects26,34
Past bad experiences of side-effects triggers a conscious evaluation of risks and
beneﬁts when new treatments are suggested26
Patients are seeking to conﬁrm and adjust expectations26,28
One’s own experiences and those of other people are used in decisions
about medicines24,25,28,29,34–36
Risks and beneﬁts are balanced by patients in a different way than
by doctors26,29–32
3. Negative values – dependency,
criticism and social stigma
Fear of getting addicted, associations with illicit substance use23,37
Hesitancy to be dependent on medicines for a normal life10,37
The number of medicines used by one person can be seen as too high26,27
4. A personalized meaning
of medicines; their necessity
and usefulness
Medicines for different conditions are seen as being of different value38
Patients with the same condition express diametrically different views about the
treatment: necessary or of very limited value; as something that helps to live
normally or the only way to avoid death; as a choice based on experience or a
resignation in lack of other options23,25,37
Core health beliefs and notions of responsibility and morality inﬂuence decisions24–26,39
ª 2015 John Wiley & Sons Ltd
Health Expectations
Patients’ expectations of medicines, U Dohnhammar, J Reeve and T Walley10
shorter time-scale when determining whether a
medicine has beneﬁcial eﬀects. Their accep-
tance of risks or symptoms in relation to side-
eﬀects and the number of aspects weighted into
decisions also make patients’ decision making
diﬀerent from that stipulated by a biomedical
model of health and illness.29,34
Aside from patients’ own experiences, infor-
mation from surrounding people is reported by
several authors as inﬂuential on expectations.
Doctors’ advice30,35 is balanced with personal
and vicarious experiences,25 whereas academics
and pharmaceutical industry are seen as less
reliable sources.36 Development of trust in a
prescriber seems to inﬂuence patients’ decision
to accept treatment, suggesting that it leads to
expectations of beneﬁcial eﬀects,28,36 while
patients that retain a more critical stance
compare prescribing to experimentation and
question the doctor’s knowledge about how a
speciﬁc patient’s body works.29 Consulting
peers seems to be associated with patients
being reluctant to accept treatment.28,29
Patients’ balancing of perceived beneﬁcial
and harmful eﬀects changes over time.26,28
Even patients that want their doctors to make
decisions about treatments state a desire to
be informed about the anticipated eﬀects to
participate actively in evaluation of the eﬀects.
Information for this purpose is also sought
from public sources and the health-care system
to conﬁrm and adapt expectations.24
Negative values – dependency, criticism and
social stigma
The third theme encompasses negative aspects
of medicines that are not derived from personal
experience but instead related to general, socie-
tal views. It contains aspects of normative and
unformed expectations.18 Certain types of med-
icines are described by patients as associated
with addiction, dependency and illicit substance
usage. Patients with asthma describe negative
associations evoked by illegitimate use of ste-
roids by bodybuilders and depressed patients
hold initial reservations about treatment due to
fear of addiction and social stigma. Patients
describe both their own views, those of family
members and reports available in the public
realm as negatively inﬂuencing usage of
medicines.23,37
The number of medicines used by one person
is also reported as something that may be val-
ued negatively and evoke criticism from others.
Patients question the helpfulness of taking a
large number of medicines every day27 and
may decline new suggested therapies on the
basis that they are already using too many
medicines.26
A personalized meaning of medicines; views on
their necessity and usefulness
The fourth theme is built up by codes related
to the utility of medicines in patients’ lives,
beyond that of providing immediate eﬀects.
This encompasses longer periods of time and
wider aspects of living with illness. A recurring
feature in the data set was the widely contrast-
ing views patients share in relation to medi-
cines’ usefulness and necessity. This theme
displays a combination of the four types of
expectations described in Box 1.
When diagnosed with a chronic condition
such as asthma or epilepsy medicines can play
the role of either aids to obtain normality, by
giving the patient control over symptoms, or
obstacles cutting one oﬀ from normality by
their association with social stigma and having
an illness. However, such negative notions can
be overcome by acquiring knowledge about a
condition: Steroids form an essential part of the
management of asthma, and medication against
depression or epilepsy becomes accepted as a
way to get on with life.10,23,37
A number of authors address the question
about whether medicines are seen as necessary
for life, health, etc. or if usage is optional, sub-
ject to personal inclination and should be
balanced with life style changes to help manage
the condition. Patients with multiple conditions
may regard some medications more necessary
than others, or some as being essential and
other optional.38 In interviews with elderly
women about osteoporosis medication, some
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participants stated that the medication was an
inevitable, normative way to treat a condition
associated with old age and therefore it would
be eﬀective, whereas others claimed that the
natural ageing of the bones would limit the
eﬀectiveness of medication. In more general
terms, prescription medication was described
both as a way to obtain something beyond
what diet and exercise could bring and as a
‘last resort’ that would only be used if those
failed.25
In several studies, medicines are described as
a commitment and ‘part of life’ by patients
with chronic conditions. However, this can
have both positive and negative connotations.
Heart failure patients interviewed about their
associations with medicines report taking them
without knowing what beneﬁts they will bring
but ‘because I don’t ever get better’ or ‘other-
wise I will die’. On the other hand, the medi-
cines also allow patients to ‘complete things
during the day’ and ‘enjoy doing more
things’.27 Similarly, depressed patients des-
cribed the decision to use medicines in the
long-term as a conclusion based on experience,
or as resigning to them being the only way to
get by.23
One way to reconcile the opposing views
expressed by patients living with the same
chronic condition is the conclusion that expec-
tations on medicines are inﬂuenced by deeply
held personal views. This is described in terms
of core beliefs about health and illness and
feelings of responsibility or obligation to use
medicines when diagnosed with a condi-
tion.26,28,39 Links between acceptance of treat-
ment and demographic characteristics such as
level of education or social class have been
addressed and discussed by a few authors, but
with inconclusive results.31,39
Discussion
Our analysis identiﬁed four themes regarding
inﬂuences on patients’ expectations of medi-
cines: a need to achieve a speciﬁc outcome; the
development of experiences and evaluation
over time; fear of dependency and social
stigma; and personalized meaning of the use-
fulness and necessity of medicines. The desire
for observable short-term eﬀects, usage of
experiences and knowledge in a process of
evaluation and notions of meaning linked to
personal and societal values show that expecta-
tions on medicines are multidimensional and
dynamic. A low acceptance for side-eﬀects, fear
of dependency on medicines that do not have
addictive properties and criticism against using
a high number of medicines every day are
inﬂuential factors that fall outside the biomedi-
cal model of health and illness.
In the speciﬁc case of expectations of beneﬁt
from medicines that are prescribed to manage
asymptomatic risk conditions, our ﬁndings
highlight a number of issues for consideration.
Patients’ desire for tangible beneﬁts and spe-
ciﬁc outcomes in theme 1 and the role of
experiencing ill health and medication eﬀects
in theme 2 point to a potential lack of mean-
ingful ways to relate to and engage with medi-
cine-taking when the reason for treatment is a
risk identiﬁed by one’s doctor. An implication
of this may be that patients interpret a deci-
sion about using such medicines as a dichoto-
mous choice rather than as a way to inﬂuence
the likelihood of outcomes. Another aspect is
the perceived need for and acceptance of treat-
ments for a growing number of conditions
related to risk for future disease. Themes 3
and 4 point to possible issues regarding
patients’ acceptance of the concept of risk
reduction by means of treating cohorts to
decrease the number of acute events in a pop-
ulation. Prescribing of several medications to
manage, for example, blood pressure may be
considered medically appropriate if there is
evidence for possible beneﬁt from all of them.
However, patients’ views that it renders a
number of daily tablets that is ‘too high’ or
that higher blood pressure is part of ageing
challenge the notion of beneﬁt. In a wider
sense, the increased availability and prescrib-
ing of medicines that target risk for future dis-
ease might inﬂuence personal and societal
values held about using medicines for preven-
tive purposes.
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Inﬂuences identiﬁed in our analysis mirror
the ideal, predicted, normative and unformed
expectations described by Thompson and
Sunol18 (see Box 1) and show how patients
engage in practical evaluation of medicines as
described by Pound et al.19 By combining one
review and 17 primary data collections from
several clinical ﬁelds that assess diﬀerent quali-
tative aspects of medicine-taking, we broaden
the description of inﬂuences on patients’ expec-
tations on medicines. Our synthesis progress
the understanding of patients’ expectations by
highlighting the importance of evaluation of
medicines from an individual perspective. This
ﬁnding is important for the further develop-
ment of a theoretical description of medicines
used for the purpose of risk management.
Codes and themes also resonate with an
investigation of the impact of long-term medi-
cine-taking on quality of life published just after
the searches for this analysis were undertaken.40
There, the authors identify wishes for tangible
eﬀects, usage of diﬀerent sources of information
to conﬁrm expectations, trusting or challenging
recommendations from one’s doctor, fear of
dependency and complex decision making
regarding the usage of a necessary but disliked
medicine. Our study adds weight to the ﬁndings
of Krska and colleagues by identifying these
themes across a range of data sets.
Methodological limitations of the presented
synthesis stem from the fact that although all
the three authors were active in the decisions
about searches and extraction as well as the
coding and formulation of themes, the practi-
cal work was done mainly by one researcher.
During the database searches, it became clear
that ‘expectations’ is used liberally in the litera-
ture and it was diﬃcult to specify narrow
search terms that captured exactly what we
were looking for. For this reason, it became
apparent that searching reference lists of the
included articles was also an important way to
identify publications. Other limitations are due
to the diverse nature of the primary data in
the included publications, which is derived
from narratives, interview material and data
collected via questionnaires and describe both
personal experiences and statements about
hypothetical scenarios. Although the connec-
tion between using medicines and living with a
long-term medical condition has been high-
lighted,10,37 only a few of the included publica-
tions discuss this issue in relation to their
ﬁndings. This makes it diﬃcult to determine
whether the data represent speciﬁc expectations
on medicines or thoughts about health, illness
and care in general. An example of this is the
discussion of a relation between readiness to
make a decision about starting treatment and
acceptance of it in a couple of the included
publications, where the decision-making pro-
cess may be hampered by a patient’s ambiva-
lence vis-a-vis the diagnosis or the prescriber in
clinical cases, and by diﬃculty to relate to the
task in a hypothetical situation.
Assessment of truth value, applicability, con-
sistency and neutrality helps determine the use-
fulness of ﬁndings in qualitative research.22
The recursion of codes and themes between
this synthesis and other investigations of quali-
tative aspects of patients’ views on medicines is
an indication of good truth value and consis-
tency of the results. However, the neutrality
may be compromised by the fact that most of
the included publications, although researching
qualitative aspects of expectations, adopt at
medical model where the aim to increase
adherence to treatment becomes evident in the
conclusions. Applicability of ﬁndings may dif-
fer between clinical ﬁelds. With regard to long-
term management of risk, the reviewed litera-
ture contains descriptions of some elements
that relate to patients’ decisions to accept or
decline medicines. However, gaps remain in the
theoretical understanding of how beneﬁts with
such medications are conceptualized, and how
this may interrelate to prescribing for such pur-
poses. This gap will be addressed in new empir-
ical research. We are currently undertaking a
study exploring patients’ expectations on risk
management medicines in an area where pre-
scribing is high due to health policies’ focus on
early intervention, cardiovascular disease.
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Conclusions
Unwanted eﬀects of the increasing prescribing
of medicines in the UK are the growing bur-
dens of medication-related problems, waste
and costs for patients and the NHS. In addi-
tion to interventions framed as medicines
management, addressing the social aspects of
health, illness and medicines could oﬀer a way
to understand and address more aspects of the
increasing levels of prescribing in primary care
in the UK.
The stochastic nature of usage of medicines
for the purpose of risk management, where
time to beneﬁcial outcome and distribution of
beneﬁt in a group of treated individuals are
impossible to predict, makes patients’ concep-
tualization of beneﬁts an interesting and
important but also under-researched element of
prescribing. Whereas medical and economic
arguments for risk management medications
can be gathered on a population level, ﬁndings
in this qualitative synthesis suggest that indi-
vidual patients are inﬂuenced by many more
types of knowledge and values in a continuous,
personal evaluation of whether to start and
continue using medicines.
A deeper exploration of how patients con-
ceptualize beneﬁts with medicines prescribed to
manage risk is the objective of our next study,
involving interviews with patients at diﬀerent
levels of risk for cardiovascular disease. Build-
ing on this review, the aim will then be to
develop a fuller theoretical understanding of
how this topic can contribute to improved
usage of medicines.
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Invitation letter   (Practice notepaper) 
 
Dear ___________________ 
 
[Name of practice] is taking part in a local research study where researchers are trying to 
find out more about experiences of using multiple medicines. We are doing this so we can 
provide care and support for those that do so. To find out more about how it is to use 
medicines, the researchers need to talk to as many people as possible so that they can hear 
a wide range of views. 
 
I am writing to you to invite you to take part in the research study. Along with this letter is a 
leaflet that tells you why it is being done and what will be involved for you if you decide to 
take part. This is to help you decide whether or not you wish to take part in the research. If 
you want to take part, you just need to return the questionnaire on the next page and send it 
back to the researchers. You may then be contacted by Ulrica Dohnhammar, a research 
student at the University of Liverpool, who will interview all participants in the study. 
 
Please take as much time as you like to read the leaflet and discuss it with your family, 
friends or your GP here at the practice. This letter also includes a copy of the consent form 
that tells you what the researchers will ask your permission to do with the information that 
participants share with them. If you have questions or need more information about the study 
and how you can take part, please don’t hesitate to ask Ulrica. Her contact details are: 
 
Ulrica Dohnhammar 
Department of Health Services Research 
Waterhouse Buildings 
1-5 Brownlow Street 
Liverpool L69 3GL 
 
telephone: 0151 795 5325 
e-mail: ulrica.dohnhammar@liverpool.ac.uk 
 
If you would like to take part in the study, please fill in the short questionnaire and send it 
back to Ulrica in the stamped addressed envelope enclosed. 
 
[Signature]
Appendix 5 
 
201 
 
 
 
 
Balancing Benefits and Risks with 
Multiple Medicines 
a research study 
 
 
Patient Information Leaflet 
 
 
 
Balancing Benefits and Risks with 
Multiple Medicines 
You are being invited to take part in a research study. 
It is important for you to understand why the 
research is being undertaken and what it will involve 
before you decide whether to participate. Please take 
time to read the following information carefully and 
feel free to discuss it with anyone you wish. 
We are very happy to answer any questions if 
anything is unclear or you need more information. 
You do not have to accept this invitation and should 
only take part if you would like to. 
Thank you for taking the time to read this. 
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1. What is the purpose of the study? 
A lot of people are taking many medicines every day 
to treat health problems and prevent future disease. 
Beside the good effects of the medicines, doing this 
can bring difficulties: Medicines may interfere with 
each other, and the risk for side effects increases. 
Besides how the medicines affect your body, they 
may also influence how you can live your daily life. 
By including these perspectives in the research we 
want to learn about how people take positive and 
negative aspects of health into account when 
deciding how to use medicines. 
We are interested to hear your thoughts about using 
your medicines – how you expect them to help you, 
what worries you might have about your health and 
medicines and how you have tackled difficulties 
related to this. In a similar way, we will ask GPs 
about how they include balancing of positive and 
negative effects when prescribing medicines. 
 
 
2. Why have I been invited to take part? 
We want to talk to adults who are prescribed 
medicines that prevent heart problems. The GP 
practice that you are registered with has agreed to 
help us invite people among their patients to the 
study. 
Only persons who understand verbal or written 
explanations in English will be eligible to take part. 
 
3. Do I have to take part? 
It is entirely up to you if you want to take part. 
Whether or not you decide to join the study, this will 
not affect any of your medical care. 
 
4. What will happen if I do join the study? 
If you decide to take part in the study, please fill in 
the questionnaire that you got together with this 
leaflet. Send them through the post to us, using the 
stamped addressed envelope. 
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A researcher will then contact you to arrange for an 
interview. The interview will take place in a location 
that is convenient for you. 
During the interview we want to hear about your 
views on positive and negative effects of using your 
medicines. We will ask about your experiences and 
how taking multiple medicines fits in with your life. 
The interview is expected to last for about an hour. 
None of the information that you share with us will 
be passed to your doctor or pharmacist. 
Before the interview starts, we will ask you to sign a 
form stating your informed consent to participate in 
the study. 
With your permission, we would like to record the 
interview so that we don’t have to take notes but can 
focus on listening to what you are telling us. The 
recording will be typed up to make a transcript of 
the interview. This transcript will be anonymised so 
that no personal details which could identify you are 
left. 
Analysis of the transcripts will produce the results 
from the study. 
All the information you give us will be in the 
strictest confidence. 
 
5. What are the downsides of taking part? 
We are asking you to set aside time to fill in the 
questionnaire and to meet us for an interview of 
about one hour. In finding a time and place for the 
interview we will be as flexible as possible so that the 
arrangement suits you, but we understand that it 
might not be practical for you. 
During the interview, we will ask you about positive 
and negative experiences that you have had from 
your health condition and your medicines. Some 
people find this upsetting to talk about. 
If you do become upset or unwell, we will ask your 
permission to get in touch with your GP so that they 
can provide you with the necessary help and 
support. 
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6. What are the benefits in taking part? 
By taking part, you can help us find out more about 
how people balance positive and negative effects 
with medicines when deciding how to use them. 
Hearing and analysing many peoples’ experiences 
gives the research team an opportunity to identify 
issues that need to be addressed, and suggest ways 
for improvement so that more people can use 
medicines in a way that is meaningful to them. 
Although the findings may not help you directly, 
other people who have taken part in similar studies 
have found it interesting and enjoyable to share 
their views on health and medicines. 
 
7. What if I am unhappy or there is a problem? 
If you have any concerns or problems with the study, 
please contact the project lead, Ulrica Dohnhammar, 
to discuss them. Her contact details are at the back 
of this leaflet. If you require a formal response to 
your concern, we would ask you to write to us 
clearly stating the issues you wish to  
raise. We will respond to this letter within two 
weeks. 
If you remain unhappy or have a complaint which 
you feel cannot be made directly to the research 
team, then you should contact the University of 
Liverpool Research Governance Officer on 
01510794 8290 or ethics@liverpool.ac.uk. When 
contacting them, please provide the name of the 
study and the researcher so that they can be 
identified, and the details of the complaint you wish 
to make. 
 
8. Will details about me and my participation in 
the study be confidential? 
All information given for the study will be in the 
strictest confidence and handled in accordance with 
the Data Protection Act (1988). 
Researchers on the study have no access to any of 
your personal details until you have sent us the 
questionnaire as a confirmation of your wish to take 
part. 
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If you decide to join the study your personal details 
given on the questionnaire will be stored securely, 
accessible only to the research team. They will be 
destroyed within three years of the end of the study. 
All data from the interviews will be anonymised 
before being stored securely. Only members of the 
research team will know who the data is from. Only 
anonymised data will be used in the analysis stages of 
the study. 
 
9. What will happen to the results of the study? 
The results of the study will be based on our analysis 
of the anonymised data from all the interviews. The 
findings will be published so that as many as 
possible can benefit from them. We will therefore 
present the study and its findings at conferences and 
in academic journals. 
Since this study is part of doctoral research training, 
the findings will also be included in the final thesis 
presented to the University of Liverpool. 
A summary of the results will be sent to everyone 
who takes part in the study. We will also send 
reports to the University of Liverpool and to the 
Research Ethics Committee. 
No report will include any identifiable information 
or personal details about anybody that has taken 
part in the study. The final report may contain quotes 
from interviews so that we can give examples of 
what people told us. These quotes will also be 
anonymised, so that nobody reading the report can 
know what you have said during your interview. 
 
10. What happens if I want to leave the study? 
You are free to leave the study at any time, and 
without giving an explanation. If you decide to leave 
the study after we have interviewed you, you can ask 
for the data to be destroyed. 
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11. Who is organising and funding the study? 
Ulrica Dohnhammar, who is a health professional 
and research student, is leading the study. She is 
responsible for all aspects of the coordination and 
management of the research. 
If you decide you want to join the study you may be 
contacted by her. 
Other members of the research team are Dr Joanne 
Reeve, a GP and Senior Clinical Research Fellow at 
the University of Liverpool and Tom Walley, 
Professor of Clinical Pharmacology at the University 
of Liverpool. 
The study has been approved by the National 
Research Ethics Service Committee North West, 
Haydock (Ref: 13/NW/0387). The University of 
Liverpool is funding the research. 
 
12. Who can I contact if I want more 
information? 
If you have any questions, need any more 
information or would just like an informal chat about 
the study, please contact: 
Ulrica Dohnhammar 
Health Services Research, University of Liverpool 
Waterhouse Buildings Block B 
1-5 Brownlow Street 
Liverpool L69 3GL 
Telephone 0151 795 5325 
ulrica.dohnhammar@liverpool.ac.uk 
 
 
Thank you for reading this leaflet. 
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Consent form 
Balancing benefits and risks with multiple medicine
 
Researcher: Ulrica Dohnhammar, University of Liverpool 
Chief Investigator: Dr. Joanne Reeve, University of Liverpool 
 
1. I confirm that I have read and understood the information leaflet dated 1 July 2013 for 
the above study. I have had time to consider the information, ask questions and have 
them answered satisfactorily. 
 
2. I understand that my participation is voluntarily and that I am free to withdraw at any 
time without giving any reason. 
 
3. I understand that the information I share with the researcher will be recorded and that 
the recording will be transcribed to produce a full account of the interview. 
 
4. I understand that anonymised quotes may be used in reporting of the study, and I 
agree to this. 
 
5. I understand that the recording of my interview will be saved for up to three years 
after the study has finished, and will then be destroyed. 
 
6. I give permission for the transcript of my interview to be kept for ten years in 
anonymised form, and potentially used in future research. 
 
7. I agree to take part in the above study. 
 
 
_____________________ _______________ _____________________ 
Name of participant Date Signature 
 
_____________________ _______________ _____________________ 
Member of the research team  Date Signature 
taking consent 
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Questionnaire for the study “Balancing benefits and risks with multiple medicines” 
By filling in and returning this questionnaire to the research team, you declare your interest to participate 
in the study. 
 
1. Please provide your contact details so that the researchers can get back to you: 
 
Name:  ___________________________________ Telephone: ______________________ 
Address:  _________________________________ Postcode: ______________________ 
 
2. Please tick the boxes that best describe you: 
Age: 18 - 40 41 - 60  61 - 80  81 or over 
 
Gender: Female  Male 
 
Number of medicines that I take on a daily basis: 
 No medicines  1-5 medicines More than 5 medicines 
 
If I think about my ability to do daily tasks such as walking about or doing housework… 
I can do what I want 
I need some help with it 
I need help with most things 
 
Thinking about my emotional well-being I would say that… 
I mostly feel good  
I feel a bit anxious or depressed sometimes 
I feel anxious or depressed most of the time 
Please continue on the next page 
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3. Please describe your current health: 
 
What health problems do you have? 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
 
 
If you have heart problems, for how long have you had them? 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
 
 
 
Thank you! Please send this questionnaire back to the research team: 
Ulrica Dohnhammar 
Department of Health Services Research 
Waterhouse Buildings 
1-5 Brownlow Street 
Liverpool L69 3GL 
 
An addressed and stamped envelope is enclosed.
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Sampling framework 
 
Sampling of patients was done in two steps. 
Step 1: n (expected) ≈ 300. Identification of eligible patients by searches in practice databases for 
individuals matching the inclusion criteria. 
Step 2: Purposive sampling among patients that have expressed their interest to participate in the study, n 
≈ 30. Distributed as evenly as possible over the following categories: 
Parameter Indicator 
Age 18-40 years 
41-60 years 
61-80 years 
+ 81 years 
Gender Female 
Male 
Disease status Recent diagnosis Single condition 
Long-standing health conditions Multiple conditions 
Health status Good on both indicators 
Mixed 
Bad on both indicators 
Prescribing status No medicines 
1-5 medicines 
more than 5  
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Interview schedule; original and final versions 
 
This is the first version of the schedule for the semi-structured interviews with patients. 
 
Questions and prompts Aspect to be explored 
I’m interested to hear about your experiences of 
taking several medicines every day. Could I start by 
asking you what different medicines you take? 
How are the medicines described?  
How do they fit in with daily 
activities? 
 Which are they? 
 What are they for? 
 Do you take them all at the same time or 
are they spread out over the day? 
How long have you been taking this one? Was the condition diagnosed in 
conjunction with screening or an 
acute event? 
Is treatment described as the only 
option to deal with the condition, or 
as one method among others? 
 Did anything happen that made you go to 
your doctor? 
 Have you had to change anything about 
how you live your life? 
Can you tell me a about this one (choose one that is 
recently started or was started in relation to an event 
of some kind) – what was it for again? 
Have the anticipated benefits and 
risks been discussed explicitly? 
Has this been followed up? 
 Did you and your doctor discuss the idea 
behind using this medicine before you 
started it? 
 Do you remember what you were told 
about the medicine? 
 How have you been since you started 
taking it? 
 Have you talked to your doctor about how 
it goes? 
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Question and prompts (continued) Aspect to be explored (continued) 
When it was suggested that you start with this 
medicine, did your conversation with your doctor 
cover what you wanted to know or did you talk to 
other people as well? 
Are popular or scientific media 
used as resources? What 
impressions or conclusions seem to 
come from that?  
Does peer groups or patient groups 
influence the individual’s 
perception of what the medicine 
can or will do for them? 
 How much did you want to know? 
 Did you read about it on the internet? 
 Did you ask family members, friends, 
social groups, other patients at the surgery? 
 Did you ask the chemist, read the package 
leaflet, look in a BNF book? 
If you compare living with your (condition) and 
living with taking the medicines every day, would 
you say it is “worth the effort” to take the medicines? 
Is a conscious balancing of benefits 
and risks done? Which factors are 
taken into account on each side? 
 Do you feel or think that the medicines are 
helping you? 
 Is it a large number of pills to take every 
day? 
 Has your opinion changed over time? 
In the research project we are investigating how 
people deal with taking many medicines every day, 
and particularly how they go about balancing the 
pros and cons with their health conditions and 
medicines. Is this something that you can relate to 
from how you handle your medicines? 
Are benefits and risks described in 
similar terms? Does there seem to 
be an active participation in the 
decision to use medicines? If so, 
how does it manifest itself? 
Is there anything you would change about your 
medicines if you could? 
Open question to capture any 
opinions evoked by the topic of the 
interview. 
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This is the final version of the interview schedule. Updates were informed by practical 
experiences, such as adaptation to how people tended to start describing the medicines they 
were taking and my increasing confidence in conducting interviews. It was also influenced by 
the emerging analysis: my questions got a more pronounced focus on the concept of risk and 
the personal understanding of how the medicines are beneficial. Additions are marked in 
italics. 
Question and prompts  Aspect to be explored 
I’m interested to hear about your experiences of 
taking several medicines every day. Could I start by 
asking you what different medicines you take? 
How are the medicines described? 
How do they fit into daily 
activities? 
 Which are they? 
 What are they for? 
How long have you been taking this one? Was the condition diagnosed in 
conjunction with screening or an 
acute event? Is treatment described 
as the only option to deal with the 
condition, or as one method among 
others? How was the link between 
the medicine’s effect and the risk 
for future events described by the 
doctor? 
 Did anything happen that made you go to 
your doctor? 
 Have you had to change anything about 
how you live your life? 
 Why did your doctor say you needed this 
one? 
Did you want to know about the medicine before 
starting to take it? How did you go about? 
Have the anticipated benefits and 
risks been discussed explicitly? 
Has this been followed up? 
 What did your doctor say about it? 
 Did you read about it on the internet or in 
the papers? 
 Did you ask family members, friends, other 
patients at the surgery? 
 Did you ask the chemist, read the package 
leaflet, look in a BNF book? 
What is it like to be at risk for heart problems? How is the risk condition described 
in ‘own words’? Are people 
responsible for engaging with 
treatment of risk?? 
 Personal feeling/knowledge vs. medical 
information? 
 Accept/question/doubt the condition? 
 Do you have to treat it? 
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Question and prompts (continued) Aspect to be explored (continued) 
What good do you think or feel the medicine is doing 
for you? 
How are possible benefits from 
medicines described in ‘own 
words’, and how are they related to 
risks?  How are you feeling now – has anything 
changed? 
 Do you think the medicine is helping you? 
 Is there anything particular that has 
influenced how you think about the 
medicines? 
 How did your doctor choose which 
medicine you needed? 
 
Do you feel that you are balancing pros and cons 
with the medicines? 
Is a conscious balancing of benefits 
and risks done? Which factors are 
taken into account on each side? 
 Is it a large number of pills to take every 
day? 
 Has your opinion changed over time? 
 Is it worth the effort to take medicines? 
 Which things are you taking into account? 
What effect are you looking for? What would tell you 
that the medicines are working? 
Returning to the question about 
benefit, with a focus on the 
personal experience and how it 
informs thoughts about future 
outcomes. 
 Feeling good 
 Test results 
 How do present effects link to future 
outcomes? 
 
Is there anything you would change about your 
medicines if you could? 
Open question to capture any 
opinions evoked by the topic of the 
interview. 
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Description of the analytical process 
In this appendix, I give my account of my data analysis; how I created new knowledge about 
medicines in CVD risk management by combining the research participants’ stories into one 
theoretical description. For the purpose of transparency (and thereby trustworthiness of my 
analysis) I display the intermittent products of analytical steps: from the initial inductive open 
coding via data condensation and iterations of coding and critical review, to the formulation of 
a final, interpretive framework. 
 
Inductive open coding 
The initial open coding for any data that said something about the research question and how 
participants made sense of CVD risk and risk management (see chapter 4, section 4.6.2) 
generated a diverse collection of descriptive categories, which are shown in a slightly 
condensed form in figure A10.a. 
Category Illustrative data – quotes, field notes, analytical comments 
Measuring and 
visualising – 
technological 
references 
“You can do the Q test yourself, it’s on the internet.”; “Nowadays the doctor 
doesn’t just test your cholesterol before giving you statins, they do many 
more tests.” 
Risk calculations are described as accessible, normalised. 
“It is strange that the doctor trusts blood pressure readings, because they can 
vary so much.” 
“Measuring the pressure once at the surgery is a bit nonsensical.” 
“Why is your first blood pressure reading high when you measure it at home, 
where there are no white coats around?” 
Sense-making around the processes of assessing blood pressure. 
Blood pressure seems different from other conditions – even people that come 
across as being used to sorting health matters out for themselves and tell me 
that they ‘know their bodies’ indicate that the blood pressure is somehow 
located closer to the medical context or professionals than to their own life. 
Health “There’s nothing the doctors can do for me at this age anyway.” 
People focus on doing something about conditions – indicates activity, 
agency, direction, responsibility. 
(continues overleaf) 
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“Some people use medicines as a way to get away with eating fatty things – 
that’s awful.” 
There is a ‘right way’ to be healthy – eat well and exercise. Same as the 
public health message! (interview with Joyce) 
“We are lucky to be healthy at this age, with the help from medicines.” 
Using medicines is not a sign of ill health but a way of being healthy. 
Knowledge about one’s body is achieved through medical facts, not 
experience?(interview with Fred) 
Is it the experience of ill health that makes people balance things? If so, 
treatment suggested to people at low risk might be accepted with less 
criticism? 
“Other than my heart being partly dead, I‘m in perfect health.” 
There is a division between medical conditions and health. 
Decision-
making 
“I would question the doctor, if there was a problem to talk about” So being 
treated for risk is not something that is seen as questionable? 
“We don’t use medicines because we want to, but because we have to.” 
Who determines the necessity? (interview with Rose) 
It is the doctor’s job to judge whether treatment is needed – they’ve got the 
education, and medicines are serious things so their knowledge is necessary. 
Risk “High blood pressure bothers me, it’s a condition that could shorten my life.”  
“It is just high blood pressure; could have been something that affected my 
ability to move about and live my life.” 
The concept of risk does not seem relevant to him – things do not exist until 
they happen! (interview with Tobias) 
Medicines in 
general 
“Medicines are becoming more and more sophisticated.” 
“Other people take medicines just because the doctor says so.” 
“All the way from when we were cave men and romans, people have wanted 
to take medicines and potions.” 
“Other people want quick fixes for their health.” 
Examples of how others want quick fixes, but no-one saying they would want 
one, even though many seem afraid of what their high blood pressure will 
lead to. 
Medical 
information 
 “You shouldn’t trust the newspapers, discuss it with you doctor instead.” 
“I read all the leaflets and mark up important parts.” 
“I never read the leaflets, it scares you too much.” 
(continues overleaf) 
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“Sometimes you get to know too much about the tablets; you can start 
believing that you’ll get all the side-effects.” 
Is information from doctors not scrutinised in the same way? 
No-one mentions guidelines – doctors and pharma are present but not the 
actor between them. 
Blood pressure If it is found out you have it, you take tablets for life. 
“Everybody knows that having high blood pressure is a bad thing.” 
Guidelines (and related information, such as the media discussion) define the 
concept of blood pressure. 
How come that blood pressure seems to be so accessible in language (people 
talk easily about their own)? It is hidden inside the body, only detectable with 
doctors’ equipment! Who has the ownership and responsibility for it? Is it – 
and the decisions about it – handed over to the professional in the clinic? 
Contradictions One patient saying both “I don’t believe the risk calculations are true for me” 
(challenging biomedical model) and “Obviously it is better to lower my blood 
pressure to a normal level, so I take the medicines” (accepting biomedical 
model) 
Where does the motivation come from; why does he accept medicines despite 
not seeming to believe the rationale? (interview with Nathan) 
 
Figure A10.a Early categories of descriptive and interpretive labels. Extracts from field notes and my 
analytical comments are indicated in italics. 
 
From this broad material, it became evident that I needed to condense the data before any 
further analysis would be meaningful. The focus on a few aspects would help me in two ways. 
Firstly, it would keep the analysis centred on my research question and thereby contribute new 
knowledge regarding the research problem I set out to address. Secondly, it would use the 
potential of the qualitative methods to produce an interpretive account rather than a descriptive 
one, and thereby contribute to the theoretical understanding of patients’ views of medicines. 
As described in chapter 4, section 4.6.3, I constructed a coding frame by combining my 
research question with provisional themes from the open coding. 
 
Constructing a coding frame 
Initially, I built the coding frame around the provisional theme of ‘blood pressure’. The first 
14 interview transcripts were coded line by line in their entirety with this frame. However, it 
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was difficult to apply it in consistent way. If I took an inclusive stance, the participants’ 
statements about medicines, CVD risk and risk management quickly became too diverse and 
wide-ranging to be captured within it. 
If I took a stricter approach to the coding, it appeared I had to leave too much interesting 
information outside. For example, information about CVD risk was entwined with information 
about medicines; they seemed to define each other and it was difficult to separate 
understandings of the condition from understandings of medicines’ effects. 
Since the coding process felt ambiguous at this stage, I kept a record of the interesting but ‘left 
over’ data. After a while the list was so rich that I started to look for additional provisional 
themes that could expand the analysis and gather more of the information that participants had 
indicated as important. 
Most of the extracts described some aspect of the medicines people were taking; how they 
worked (or not) and what they did to help with the CVD risk that had been diagnosed. As 
patients’ understanding of the prescribing of medicines was a core topic for my study, I decided 
to use ‘medicines’ effects’ as a second provisional theme. The final version of the coding frame, 
with which I again coded the first 14 transcripts, is shown in chapter 4, section 4.6.3. 
 
Categorising data 
The coding generated a dataset centred on the main issues for the study (a diagnosis closely 
related to prevention policies and patients’ views, and experiences and expectations of 
medicines), yet encompassing multiple angles so that the advantages of the interview method 
were used (capturing new and multiple explanations based within and outside the biomedical 
model). 
To start forming an interpretive account of my data, I reviewed the coded extracts using the 
constant comparative technique (see section 4.6.5). Early categories were formed around 
reactions to and understanding of the blood pressure diagnosis, which types of knowledge that 
people use when making decisions and how treatments are evaluated. The first structure of 22 
categories related to 9 themes is shown in figure A10.b. At this stage, some data extracts was 
allocated to a theme but not yet placed in a category. 
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Theme Categories 
Early reactions Finding out 
Contextualising Causes 
 Consequences 
 Cohort features 
 Explanations 
 Un-allocated 
Disease or not Hidden 
 It is a disease 
 It is not a disease 
 Levels 
Knowledge types and sources Heuristics 
 Internalised biomedical view 
Reasoning Early reactions 
 Long-term evaluation 
 Un-allocated 
What to do Interaction between person and medicines 
 What the doctor says 
 Personal belief 
Effects At present 
 On outcome 
Long-term evaluation  
Questioning   
 
Figure A10.b The first category structure. 
To examine my emerging findings, I started writing an account of them. As discussed in chapter 
4, section 4.6.6 the writing tests the explanatory strength of the structure and content of the 
analysis. The writing highlighted many reasons for reviewing and questioning the first thematic 
structure, as it pointed to areas where data was too diverse within categories or where data 
about a particular phenomenon had ended up in multiple places. 
One example was my problem with allocating data extracts that alluded to cohort features – 
were they about the risk or the medicines? Questions like this were resolved by going back to 
the transcripts and critically reviewing quotes in their full context. Reminding myself of the 
circumstances around data extracts helped me to find new possible thematic associations and 
move data around accordingly. As long as the category structure did not harbour all the 
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descriptions in a straightforward way, without overlaps or ambiguities, I kept reviewing the 
relations between the data extracts and my emerging interpretation. The writing and re-
structuring of data in categories were parallel processes that informed each other. 
An issue that took long to resolve, was my initial consideration of whether participants regarded 
hypertension as a disease or not. The various coded descriptions of reasons for the blood 
pressure to be high, how it affected daily life, what it might lead to in the long term and what 
could be done about it both suggested and denied that it was a disease; see figure A10.c. 
It is a disease 
“It is a health related medical condition” – setting high blood pressure apart from other less 
serious conditions 
“it could shorten my life” – tangible consequences, disrupting biography 
“the sensible side kicks in and you do something about it” – needs to be addressed; indication for 
medicines 
It is not a disease 
“I would be a very bad patient” – having high blood pressure does not make him a patient at 
present 
“perhaps it is only natural to have higher blood pressure as you get older” – i.e. it is not an 
indicator of something being wrong 
“My blood pressure varies a hell of a lot during the day and maybe they just caught me at the 
wrong moment or the right moment I don’t know but there we are” – there is an element of chance 
in the process of determining whether the blood pressure is high; not a clear boundary between 
well and ill 
 
Figure A10.c. Contrasting data regarding whether high blood pressure is a disease or not. My 
analytical notes are displayed in italics. 
However, these categories later dissolved as my questioning of how it could make sense led 
towards other, more meaningful and explanatory associations between the data extracts. A 
tangible example was how participants emphasised the need for some intervention towards 
high blood pressure, no matter whether their descriptions indicated that it was a disease or not. 
This finding drew my attention to another important division among participants’ stories about 
CVD risk and medicines; that between control and uncertainty. Many patients stressed that 
once the medicines showed that the blood pressure or cholesterol was stable, the ‘problem’ was 
resolved. Their examples indicated that conditions associated with CVD risk are only a 
problem when they are not kept under control. 
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To further explore the notion of certainty and uncertainty as a defining factor, I critically 
reviewed the data in all categories to really separate out understandings of ‘the risk condition’ 
itself, and the managed risk. These two themes became the starting point for a re-structuring of 
my analytical structure. After further testing of my emerging ‘researchers’ story’ by means of 
writing and critically reviewing, adjusting and condensing the data and categories, I had 
generated an explanatory structure for influences on patients’ understanding of medicines in 
CVD risk management. Four subthemes show patients’ reasoning around the concept of being 
at risk, and two outline how they ascertain control over the risk. The final thematic structure is 
shown in table 5.2 (page 87). 
A final round of coding of the last four interviews required no further adjustments, and so I 
considered the analysis finished and proceeded to write the final version of my account, which 
is presented in chapters 5 and 6.
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Participants’ characteristics 
To provide some context for the quotes that accompany my findings, I present the 
characteristics of each participant in the study in table A11.1 (see overleaf). 
 
Comments regarding how the information was collected and is displayed 
Participants are displayed in the order in which the interviews were done. The information in 
the table corresponds to categories in the sampling frame which I used to ensure that I included 
participants with as many different experiences and life situations as possible. 
Most categories (age, gender, number of medicines, physical and mental wellbeing, self-
reported health status) were included in the questionnaire that patients sent back to me to 
declare their interest in participating in the study (see appendix A7). The ‘risk level’ category 
corresponds to my sampling for patients at both high and low risk. It was not in the 
questionnaire, but assigned by me based on what diagnoses and events people told me about. 
Participants’ descriptions of their current health status are displayed in their own wording, as 
it was written in the free text sections of the questionnaire. 
The statement to capture self-reported physical wellbeing was formulated as ‘If I think about 
my ability to do daily tasks such as walking about or doing housework…’ followed by the 
alternatives ‘I can do what I want’ (displayed in the table as A), ‘I need some help with it’ (B) 
and ‘I need help with most things’ (C). 
Similarly, the statement regarding mental wellbeing was formulated as ‘Thinking about my 
emotional wellbeing I would say that…’ followed by ‘I mostly feel good’ (displayed in the 
table as a), ‘I feel a bit anxious or depressed sometimes’ (b) and ‘I feel anxious or depressed 
most of the time’ (c). 
I have also included extracts from my field notes from each interview, showing the context I 
perceived around the interview. This indicates my impression of each participant and my own 
frame of mind from each interview – something that shaped the conversations as they took 
place and also supported (by means of challenging or confirming what was said) my later 
analysis. 
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Table A11.1 Participants’ characteristics 
Name 
(pseudonym) 
Age 
group 
Current self-reported  
health status 
No. of 
meds 
Wellbeing Risk level 
My reflections during the interview Physical Mental High Low 
Holly 41-60 Hypertension, 
psoriasis arthritis, 
kidney disease, 
frequent urinary tract 
infections, asthma. 
>5 B a  X I get the feeling it’s not the first time she has been 
interviewed about using medicines. This might have to 
do with how she tells me things; unbroken narratives 
that have clear beginnings and ends. She seems to 
know what she thinks and feel confident that it’s her 
way of dealing with things. 
Richard 61-80 High blood pressure,  
slowly worsening 
arthritis, poor memory. 
I’m quite fit and active 
(for my age). 
1-5 A a  X This participant wants to know if any medications that 
will improve memory are being developed. He seems 
happy to talk to me – it’s a day out. 
Albert 61-80 Slightly elevated blood 
pressure, cholesterol 
elevated, ulcer control 
has been needed. 
1-5 A a  X This man emphasises his scientific outlook on health – 
he sounds genuinely factual when he describes his 
thoughts. He apologises for not having particularly 
strong views about taking medicines. 
Anthony 61-80 Arthritis, COPD and 
cardiac. 
Heart problems: 8 
years approx. 
>5 B b X  He seems excited to be in the study, but a little 
nervous. But he is open – starts talking about his health 
before I ask any questions. He seems to have thought 
about and pondered over medicines before. 
(continues overleaf) 
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Nathan 41-60 Hypertension, high 
cholesterol, otherwise 
fit. 
1-5 A a  X He is interested in knowing how my research is going 
to be used and how it fits in with the health care 
system. He describes his own reasoning about health 
and medicines – spanning medicalisation, 
pharmaceutical industry’s influence over prescribing 
and mechanisms of action for medicines. I get a weak 
feeling that he is testing an idea about a possible link 
between a chest problem and a drug with me, but I do 
not elaborate on it. 
Gerald 80+ Breathing, walking, 
heart, cancer 
(melanoma spots & 
lung). 
Heart problems: 
Seventies?* 
>5 A a X  This man lives in sheltered accommodation. He has 
hearing problems and says he will forget what we 
talked about the minute I walk out the door. Difficult 
to get a conversation going, as he does not elaborate on 
his views about medicines. 
Rose 61-80 None that I am aware 
of. 
1-5 A a  X One of the ‘worried well’ that has taken time to think 
about her tablets. I get the sense that she wants to help 
me with the research as best she can. During the 
conversation she gets interested in the idea that people 
can have so different views of medicines – she will 
talk with her friends about it later. 
Alfred 61-80 Hypertension. 1-5 A a  X A relaxed but professional conversation. I get the 
feeling that he wants to hear my opinion on his 
problems with side effects, but avoid saying anything 
about them. 
(continues overleaf) 
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Norman 61-80 Angina, high blood 
pressure, arthritis 
(ankles, knees, wrists). 
Heart problems: 
approx. 4 years 
1-5 A a X  He seems disillusioned due to getting older, and often 
mentions his drinking. Does not speak so easily about 
health matters; he uses short statements when he 
replies to my questions. 
Paul 61-80 High blood pressure, 
enlarged prostate, 
urticaria currently 
under investigation 
1-5 A a  X This participant is a very serious person who wants to 
do the right thing. He seems to like being interviewed, 
and says he is surprised over how much he had to say.  
Joyce 61-80 Osteoarthritis, 
scoliosis, high blood 
pressure, breast cancer 
(past), DVT (past) 
>5 A a  X She has strong personal views about what is the right 
thing to do regarding health and medicines, but also 
says it is an individual decision for people to make. 
Shares her views, but also lets me know when she has 
nothing more to say. 
Judy 61-80 Slightly elevated BP. 
Otherwise in good 
health 
1-5 A a  X A reflecting, professional person with a background in 
nursing. She seems to be interested in the questions I 
ask and really thinks about the answers, giving me her 
personal and professional view. The interview is split 
between her account of using medicines and a 
conversation about balancing personal decisions and 
official information about health-related behaviour. 
Michelle 41-60 Poli arthritis, high 
blood pressure, 
depression. 
>5 B/C c  X A person interested in research! She wants to know 
how my study will be used and what it can lead to. 
Tells me straightforwardly why she wanted to 
participate, and shares a strong story about what 
medicines can do for you and to you, and how difficult 
life can be. 
(continues overleaf) 
 226 
  
Fred 61-80 Heart problems: 
I had a treble bypass 
17 years ago. I have a 
pace-maker in 6 
months ago. 
1-5 B a X  This man does not worry too much about health, but 
wants his body to function so he can keep up his daily 
activities. He seems a little nervous to talk to me, but 
wants to do a good job with the interview. Gives me 
vivid descriptions of his heart operations. 
James 61-80 I have type 2 diabetes 
& high blood pressure, 
also I have had my 
prostate removed, 
prostate cancer, back 
problems. 2 fractures 
of the spine and a 
degenerative disc. 
Heart problems: N/A. I 
take tablets for my 
blood pressure, all 
under control. 
>5 B b  X As I step into the house I realise that he has probably 
recently lost his wife and this catches me a little off 
guard. He has been her carer for some years and that 
has had a large impact on his life. This man is an 
original scouser with strong connections to his family 
and neighbourhood, and he describes health as 
entwined with work and responsibilities.  
Samuel 61-80 Type 2/depression/loss 
of memory. 
>5 B c  X A participant who offers me his own views on the 
NHS and health policies, in addition to answering my 
questions. Neither the memory loss nor the depression 
that he stated in the questionnaire was noticeable. Says 
he has not discussed his medicines with anyone before 
this interview. 
(continues overleaf) 
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Stephen 61-80 COPD**, Raynaud’s 
disease, mucous 
membrane, cervical 
spondylosis. 
>5 B b  X This participant expresses his anxiety over ill health 
and reliance on medicines, and he worries about side 
effects. He asks for my opinion as a pharmacist, and I 
have to be upfront with the fact that I can’t give advice 
since I’m not licenced to practice in the UK. Instead, 
we agree that he can go and talk to his local pharmacist 
about it. 
Tobias 80+ Heart problem since 
2003. Anterioseptal 
myocardial infarction, 
severe LVSD***, mild 
to moderate aortic 
stenosis, 
dyslipidaemia, 
CKD3****, macular 
degeneration. 
>5 A a X  He starts by explaining how his severe heart condition 
restricts his mobility – he basically cannot leave 
Liverpool. Despite this he sees himself as in perfect 
health and has a serene outlook on life, which he 
shares with great confidence. 
 
* not clear whether this means his seventies or the 1970’s 
** chronic obstructive pulmonary disease 
*** left ventricular systolic dysfunction 
**** chronic kidney disease stage 3 
 
